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SUMMARY 
Aberrations in signaling networks have long been studied for their contribution to tissue 
degeneration and cancer. Chemical modulation of such pathways provides an excellent 
opportunity to fine-tune their activity, owing to the rapid and dose-dependent effects of small 
molecules. The results of the presented thesis demonstrate the application of small molecules in: 
(i) studying one of the key pathways in cancer and development–TGF/Smad signaling; and (ii) 
modulation of cellular fate towards stemness via targeting self-renewal- and pluripotency-
associated signaling molecules.  
In the first chapter, I describe the use of newly-synthesized molecules derived from the 
indirubin family of natural compounds in the regulation of R-Smad signaling, with a focus on 
TGF-related Smad2/3. Using a large screen encompassing cell lines of various cancerous- and 
non-cancerous tissue origins, I show that indirubin derivatives (IRDs) collectively, and the IRD 
E738 analogue specifically, interfere with TGF/Smad signaling via a profound reduction in 
steady-state R-Smad levels. My analyses illustrate that this effect is not only due to reduced R-
Smad gene transcription by E738, but also a result of protein degradation, demonstrating that the 
IRD modulates the TGF/Smad pathway through different mechanisms. Further investigation by 
transient over-expression of wild-type-, truncated-, and phosphorylation-defective mutant forms 
of Smad2 and Smad3 reveals the significance of the "linker domain", in particular its 
phosphorylation status, in the small molecule's regulation of basal Smad stability. Given the role 
of Smad linker phosphorylation–referred to as "phospho-Smad signaling"–in the malignant switch 
of TGF in some tumor types, the potential connection between E738's regulation of steady-state 
Smad2/3 stability and the phospho-Smad pathway is explored. Using patient-derived 
cholangiocarcinoma (CCA) cell lines, I show that IRD E738 inhibits oncogenic phospho-Smad 
isoforms (linker region sites), while maintaining those associated with a cytostatic phenotype (C-
terminally phosphorylated sites). This effect reflects the molecule's inhibitory activity on kinases 
(e.g., GSK3 and CDKs) involved in the phosphorylation of Smad2/3 linker region.  
The results of the second chapter outline a combined chemical and genetic approach for 
enhancing the generation and maintenance of human iPSCs. Using a cell-based high-throughput 
screen, a series of OCT4-inducing compounds (O4Is) are identified, including imidazopyridine 
analogues, with the lead compound termed O4I3, as well as 4-(tert-Butyl)-N-(2,3-dimethylphenyl) 
thiazol-2-amine, herein O4I4. The small molecules either alone or in combination are shown to 
activate pluripotency-associated signaling, and to increase the reprogramming efficiency of 
human fibroblasts into iPSCs when combined with ectopic expression of the master pluripotency 
transcription factors: OCT4, SOX2, KLF4, and MYC (known as "OSKM"). Transcriptomic 
analyses (DNA microarray/RNA-sequencing) and ATAC-sequencing revealed previously 
unrecognized, targetable molecular events in the path towards pluripotency. Indeed, O4I3 lifts an 
epigenetic barrier of reprogramming through inhibiting the histone demethylase enzyme, KDM5A, 
thus allowing the enrichment of H3K4Me3 at the OCT4 promoter. Additionally, applying a 
combination of O4I3 and O4I4 to OSKM-based reprogramming reveals the involvement of bone 
morphogenetic protein (BMP)/Smad signaling upstream of high mobility group A1 (HMGA1) in 
O4I3/4-mediated induction of endogenous OCT4, which in turn initiates the reprogramming 
process.  
Altogether, the results of both chapters demonstrate the potential use of new classes of small 
molecules in targeting signaling networks associated with cancer and somatic cell 
reprogramming. 
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 ZUSAMMENFASSUNG 
Schon lange werden Veränderungen in Signalnetzwerken hinsichtlich ihres Beitrags zu 
Gewebsdegeneration und Krebs untersucht. Dank der schnellen und dosisabhängigen Wirkung 
kleiner Moleküle (Small Molecules) liefert eine chemische Modulation solcher Signalwege eine 
hervorragende Möglichkeit deren Aktivität genau einzustellen. Die Ergebnisse der vorliegenden 
Arbeit zeigen die Anwendung kleiner Moleküle: (i) bei der Untersuchung eines Schlüssel-
Signalwegs bei Krebs und der Entwicklung - der TGF/Smad-Signalweg; und (ii) bei der 
Modulation des Zellschicksals: Ausbildung von Stammzelleigenschaften durch Angriff auf 
Signalmoleküle, die eine Rolle bei  Selbsterneuerung und Pluripotenz spielen. 
Im ersten Teil beschreibe ich die Anwendung neu-synthetisierter Moleküle, die sich von der 
Naturstoff-Familie der Indirubine ableiten, bei der Regulation der R-Smad-Signalisierung mit 
Fokus auf TGF-assoziiertes Smad2/3. Mittels eines umfangreichen Screenings, welches 
verschiedene aus Tumor- und Nicht-Tumor-Gewebe stammende Zelllinien umfasst, zeige ich, 
dass Indirubin-Derivate (IRDs) insgesamt, und besonders das IRD-E738-Analogon, den 
TGF/Smad-Signalweg über eine erhebliche Reduktion des Steady-State-Levels von R-Smad 
beeinflussen. Meine Untersuchungen verdeutlichen, dass dieser Effekt nicht nur auf eine 
verringerte R-Smad-Gentranskription durch E738 zurückzuführen ist, sondern auch Folge von 
Proteinabbau ist. Dies zeigt, dass IRDs den TGF/Smad-Signalweg über verschiedene 
Mechanismen modulieren. Weitere Untersuchungen mittels transienter Überexpression von 
Wildtyp-Smad2 und -Smad3 sowie der durch Mutation entweder verkürzten oder nicht-
phosphorylierbaren Formen offenbaren die Bedeutung der „Linker-Domäne“, insbesondere deren 
Phosphorylierungsstatus, in der Regulation der basalen Smad-Stabilität durch kleine Moleküle. 
Angesichts der Rolle, welche die Linker-Phosphorylierung - bezeichnet als „Phospho-Smad-
Signalisierung“ - beim Umschalten der TGF-Funktion in die maligne Form in einigen Tumorarten 
spielt, wird die mögliche Verbindung zwischen der Regulation der Steady-State-Stabilität von 
Smad2/3 durch E738 und dem Phospho-Smad-Signalweg untersucht. Durch Verwendung von 
Cholangiokarzinom-(CAA-)Zelllinien, die von Patienten stammen, zeige ich, dass das IRD E738 
onkogene Phospho-Smad-Isoformen (Phosphorylierung in der Linker-Region) hemmt, während 
es jene erhält, die zum zytostatischen Phänotyp (Phosphorylierung im c-terminalen Bereich) 
gehören. Diese Wirkung spiegelt die inhibitorische Aktivität des Moleküls auf Kinasen (z. B. GSK3 
und CDKs) wider, welche an der Phosphorylierung der Linker-Region von R-Smad2/3 beteiligt 
sind. 
Die Ergebnisse des zweiten Teils geben einen Überblick über eine gleichzeitig chemische und 
genetische Vorgehensweise, die dazu dient, die Bildung und Aufrechterhaltung humaner iPSCs 
zu steigern. Mittels eines zellbasierten Hochdurchsatz-Screenings konnten eine Reihe OCT4-
induzierender Verbindungen (O4Is) identifiziert werden. Dazu gehören Imidazopyridin-Analoga, 
darunter die Leitsubstanz O4I3, sowie 4-(tert-Butyl)-N-(2,3-dimethylphenyl)thiazol-2-amin, 
bezeichnet als O4I4. Die kleinen Moleküle Aktivieren entweder alleine oder in Kombination 
pluripotenz-assoziierte Signalwege und erhöhen die Effizienz bei der Reprogrammierung 
humaner Fibroblasten zu iPSCs, wenn sie mit einer ektopischen Expression der Haupt-
Pluripotenz-TranskriptionsfAktoren OCT4, SOX2, KLF4 und MYC (bekannt als „OSKM“) 
kombiniert werden. Transkriptomanalysen (DNA-Microarray/RNA-Sequenzierung) und ATAC-
Sequenzierung offenbarten bisher unerkannte, als Angriffsziel geeignete molekulare Ereignisse 
auf dem Weg zur Pluripotenz. So beseitigt O4I3 eine epigenetische Reprogrammierungsbarriere 
durch Hemmung der Histon-Demethylase KDM5A, so dass die Anreicherung von H3K4Me3 am 
OCT4-Promotor ermöglicht wird. Zusätzlich wird durch die Anwendung einer Kombination von 
O4I3 und O4I4 bei der OSKM-basierten Reprogrammierung eine Beteiligung des BMP/Smad-
Signalwegs, welcher HMGA1 (high mobility group A1) vorgeschaltet ist, bei der O4I3/4-
vermittelten Induktion von endogenem OCT4 gezeigt, was wiederum den 
Reprogrammierungsprozess initiiert. 
Insgesamt zeigen die Ergebnisse beider Teile eine mögliche Verwendung von neuen Klassen 
kleiner Moleküle für den Angriff auf Signalnetzwerke auf, die in Verbindung mit Krebs und der 
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1.1. TGF/BMP signaling 
1.1.1. TGF/BMP signaling–the core pathway 
Identification of the key players of transforming growth factor  (TGF)/bone morphogenetic protein 
(BMP) signaling dates back to more than a decade ago. With increasing number of studies, the concept 
of the signaling pathway and its medical relevance has been enriched throughout the years, but also 
has raised new questions on the topic, in particular the impact of the cellular context on the responses 
to TGF/BMP signaling.   
The TGF superfamily of ligands includes more than 30 related cytokines with a key role in cellular 
development and tissue homeostasis. This consists of 3 TGF isoforms, 4 activin proteins, nodal, 10 
BMPs, and 11 growth and differentiation factors (GDFs), all sharing a so-called "cysteine knot" in their 
mature form (recently reviewed in [1]).  
 
Figure 1. Schematic illustration of the principles of TGF/BMP signaling. The simplest way for 
understanding the basics of the pathway is to divide it into the following sequential steps; (i) receptor-
mediated C-terminal phosphorylation of the regulatory Smads (R-Smads), Smad2/3 and Smad1/5/8 in 
case of TGF- and BMP receptors, respectively, (ii) complex formation with the common Smad, Smad4, 




and (iii) translocation of the trimeric structure to the nucleus where it directly acts as a transcription factor 
in cooperation with other DNA binding partners. 
The signaling pathway is triggered when the ligands bind to preformed dimeric receptor structures, 
referred to as activin receptor like kinases (ALKs). Upon ligand binding, type I and type II dimers bridge 
in order to form the heterotetrameric active receptor complex in which the constitutively active type II 
receptor phosphorylates and activates type I receptor at its intracellular serine/threonine (S/T) kinase 
domain. Activated type I receptor then activates receptor-regulated Smads (R-Smads) by means of 
phosphorylating two seine residues at their C-termini, which enables heteromerization with the common 
Smad (Co-Smad), Smad4, as well as with other R-Smads (basics of TGF signaling is reviewed in 
[2]). The trimeric structure containing 2 R-Smads and 1 Smad4 molecule is thought to be the principle 
functional unit of the TGF/BMP pathway, which shuttles to the nucleus where together with other DNA 
binding partners regulates the transcription of various target genes involved in cellular proliferation, 
differentiation, death, and migration (Figure 1).  
1.1.2. TGF/BMP signaling–the key players (Smads) 
Depending on the ligand initiating the pathway, R-Smads fall into 2 groups, which have been 
traditionally divided into TGF/activin/nodal-activated Smad2/3 and BMP/GDF/AMH-activated 
Smad1/5/8. However, this classification does not precisely reflect the reality. The pathway is split only 
downstream of type I receptors meaning that ALK4/5/7 specifically phosphorylate Smad2/3 and 
ALK1/2/3/6 are specifically responsible for phosphorylation of Smad1/5/8 [2].  
Aside from R-Smads and Co-Smads, inhibitory Smads (I-Smads) i.e., Smad6 and Smad7, form a 
distinct subfamily of Smad proteins, known to terminate the signaling through distinct and diverse 
mechanisms. The latter include: (i) Competitive inhibition of R-Smad binding; I-Smads have been initially 
found to interact with TGF/BMP type I receptors, prompting the idea of a direct inhibitory mechanism, 
(ii) recruitment of E3 ligases to the active receptor complex, which leads to receptor ubiquitination and 
subsequent proteasomal degradation, (iii) interacting with protein phosphatase 1 (PP1), which targets 
them to active receptors, leading to receptor inactivation through dephosphorylation, and (iv) binding to 
Smad binding elements (SBEs) and inactivating Smad-dependent promoter activation, implicating a 
nuclear role for I-Smads [2].     
R-Smads and Smad4 share two highly conserved domains known as Mad homology 1 (MH1) and 
MH2 at their amino- and carboxy-terminal sequences, respectively. The MH1 domain contains nuclear 
localization signals as well as a -hairpin structure, which is critical for DNA binding ability. The MH2 
domain, on the other hand, has a series of hydrophobic surface patches, enabling the protein for various 
interactions with activated type I receptors, Smad4, and DNA binding partners, to name a few. MH1 and 
MH2 domains are coupled via a less conserved proline-rich linker region [3]. Although R-Smad 
activation is initiated by receptor-mediated phosphorylation of the SXS motif in the MH2 domain, it is 




increasingly apparent that the linker region plays a critical role in Smad activity and stability, through 
integration with signaling molecules stemming from other pathways [4]. 
1.1.3. TGF/BMP signaling–noncanonical (non-Smad) pathways 
Beyond the Smad-dependent, canonical TGF signaling, the activated receptor complexes also 
signal through other transducers, for example, the mitogen-activated protein kinases (MAPKs), including 
the extracellular signal-regulated kinases (Erks), c-Jun amino terminal kinase (JNK), p38 MAPK, as well 
as the IκB kinase (IKK), phosphatidylinositol-3 kinase (PI3K)/Akt, and Rho family GTPases, which in the 
context of TGFβ family signaling are collectively referred to as non-Smad (noncanonical) signaling 
pathways (thoroughly reviewed by Zhang et al. in [5]). These receptor-activated non-Smad 
transducers exert their effects either as isolated pathways or hand in hand with Smads, as they 
converge onto Smads through post-translational modifications in the linker region. 
1.1.3.1. Non-Smad pathways–activation of Erk MAPK 
The role of Erk MAPKs in TGFβ signaling has been frequently reported, even before the discovery 
of Smads. The primary evidence came from the studies showing a rapid activation of Ras (as early as 
5-10 min comparable to the kinetics shown by mitogenic growth factors) upon TGFβ stimulation in 
normal epithelial- as well as colon cancer cells [6-8]. Mechanistically, upon ligand binding the 
constitutively active type II receptor phosphorylates type I receptor at its S/T residues and induce 
tyrosine phosphorylation of both type I and II, as well as ShcA. These phosphorylated tyrosines recruit 
Grb2/Sos, which then activates Erk1/2 through the Ras-Raf-MEK1/2 axis [9]. This leads to the 
phosphorylation of several target genes, among others, members of the AP-1 family, including p53 and 
other transcription factors, which interact and cooperate with Smads to regulate gene expression [10].  
A key biological function of Erk in the context of TGFβ signaling is the epithelial-to-mesenchymal 
transition (EMT) [11, 12], a normal event in embryonic development, which is pathologically associated 
with tumor invasion and fibrosis [13]. Similar to TGFβ, BMPs can also induce EMT, cell migration, and 
invasion in an Erk-dependent manner. In this regard, Erk activity has been shown to contribute to BMP7-
induced morphologic conversion in prostate cancer cells [14], as well as BMP2-mediated motility and 
invasiveness in lung [15] and gastric cancer cells [16]. Additionally, Erk activity has been shown to be 
essential in BMP-induced cell differentiation through the regulation of BMP target genes, such as 
alkaline phosphatase (AP), collagen I, fibronectin, osteopontin, osteocalcin, and Runx2 [17, 18].    
Importantly, Erk modulates the activity of R-Smads including Smad1, Smad2, and Smad3 by direct 
phosphorylation [19-21]. Although in cell culture systems, Erk-mediated phosphorylation of Smads is 
normally known to inhibit Smad transcriptional activity [21], some studies have reported the opposite 
[22], which may be in part due to a different cell type and/or the examined response. The former 
regulation has been used to explain how oncogenic Ras overrides TGFβ-induced anti-mitogenic 
responses in cancer cells [20]. Oncogenically-activated Ras acting via Erk, phosphorylates Smad2 and 
Smad3 at specific residues in the linker region, which are distinct from those of the TGFβ receptor I 




(TGFβRI). This, in turn, inhibits Smad2/3 nuclear accumulation and transcriptional activity. Accordingly, 
mutation of these phosphorylation sites in Smad3 produces a Ras-resistant form, which can recover 
TGFβ's growth inhibitory effects in Ras-hyperactive cancer cells [20]. 
1.1.3.2. Non-Smad pathways–activation of TGFβ-activated kinase 1 (TAK1) and downstream 
JNK- and p38 MAPKs, as well as IKK 
In response to cytokines, p38 and JNK MAPKs are activated through the action of MAPK kinases 
(MKKs), MKK4 and MKK3/6 [23]. Like cytokines, TGFβ can induce the activation of JNK via MKK4 and 
p38 via MKK3/6 [5]. In contrast to the activation of R-Smads and Erk, which occurs through sequential 
phosphorylation, regulation of this branch of non-Smad signaling relies on a more elaborate mechanism, 
involving the ubiquitin-proteasome pathway. Ligand-bound TGFβ receptors interact with the RING-
domain E3 ligase, tumor necrosis factor receptor-associated factor 6 (TRAF6) to induce K63-linked 
polyubiquitination of itself; polyubiquitinated TRAF6 then associates with and activates TAK1 (also 
known as MAPKKK7), and finally its downstream kinases, JNK and p38 [24, 25]. In addition, other 
MAPKs such as MEKK1, MEKK4, MLK2, MLK3, and ASK1 have been also reported in the TGFβ-
activated JNK and p38 signaling [5]. Although being independent from the activation of R-Smads, 
regulation of JNK/p38 MAPKs by TGFβ receptors involves the inhibitory Smads, Smad6 and Smad7. 
Smad6 inhibits TGFβ-activated MAPKs by recruiting the deubiquitinating enzyme A20 to TRAF6 [26], 
whereas Smad7 promotes TGFβ-activated MAPKs, as it interacts with Smurf2 and routes TGFβ 
receptors to caveolin-1-containing lipid rafts wherein TRAF6 is localized [27].     
One of the important outcomes of JNK- and p38 MAPK activation is apoptosis; this is particularly 
relevant to BMP's roles in development, as well as TGFβ's roles in tumor suppression [5]. In light of this, 
JNK- and p38 MAPK have been shown to cooperate with Smad signaling in inducing apoptosis, as 
Smad3 is known to play an essential role in TGFβ-mediated pro-apoptotic effects (examples are; [28, 
29]. In addition to apoptosis, TGFβ-activated JNK- and p38 MAPKs also contribute to the induction of 
EMT [5]. In this regard, blocking p38 MAPK activity using small molecule inhibitors or by expressing a 
dominant-negative MKK3 mutant [30, 31] as well as silencing TRAF6 expression [25] has been shown 
to block TGFβ-induced EMT and cancer cell invasion. Additionally, TGFβRI can recruit TRAF4, aside 
from TRAF6, and TAK1 for the Smad-independent activation of JNK- and p38 MAPK, which appears to 
be an obligatory step in cellular migration and metastatic dissemination in response to TGFβ [32]. 
TGFβ- and BMP pathways may crosstalk with nuclear factor-B (NF-B) signaling mainly because 
of TAK1's role in activating IKKs, which in turn activates NF-B [33]. The cellular cues that lead to either 
the pro-apoptotic response of TGFβ or the pro-survival effects of NF-B, both through activating TAK1, 
are yet to be fully determined. Similar to Erk1/2, JNK- and p38 MAPKs directly regulate R-Smad activity 
via phosphorylating the protein at specific residues in the linker region, which overlap with those 
phosphorylated by Erk MAPK. 
      




1.1.4. TGF/BMP signaling–regulatory mechanisms 
As abovementioned, the critical regulatory steps in R-Smad activity are mediated by C-tail 
phosphorylation and subsequent nucleoplasmic shuttling (also see Figure 1). However, activated R-
Smads are prone to a variety of post-translational modifications (e.g., phosphorylation), which enable 
the peak transcriptional action, on the one hand, and recognition by the ubiquitin-proteasome pathway 
(UPP), hence destruction, on the other hand (summarized in [34]). This concept although paradoxical 
presents an opportunity to reveal how the cellular responses to TGF and BMP signals are coupled to 
the turnover of their central mediators, Smads, and more importantly how R-Smads get to act before 
their disposal.  
1.1.4.1. Controlling TGF/BMP signaling by phosphorylation: Smad action turnover switch    
A series of phosphorylation steps drives the process of Smad signaling, starting with receptor S/T 
kinases. The receptor-induced R-Smad phosphorylation is reversed by the action of tail phosphatases 
(e.g., PPM1A), limiting the general pool of activated R-Smads (reviewed in [35]). R-Smad molecules 
engaged in transcription of the target genes rapidly undergo a second step of phosphorylation events; 
these are mediated by nuclear cyclin-dependent kinases (CDKs) 8 and CDK9, priming R-Smads for 
further phosphorylation by glycogen synthase kinase 3 (GSK3). CDK8/9 are components of 
transcriptional mediator and elongation complexes and GSK3 is a Wnt- and phosphoinositide 3 kinase 
(PI3K) downstream molecule. These phosphorylations–clustered in the interdomain linker region–not 
only promote R-Smad transcriptional action through recruiting DNA binding factors like Yes-associated 
protein (YAP, in case of Smad1/5) and Pin1 (in case of Smad2/3), but also add binding sites for the E3 
ubiquitin ligases, Smad-specific E3 ubiquitin protein ligase (Smurf) 1/2 and neural precursor cell 
expressed developmentally downregulated protein 4-like (NEDD4L), targeting R-Smads for 
polyubiquitination and proteasome-mediated degradation (summarized in Figure 2). Degradation of 
agonist-activated R-Smads occurs simultaneous to dephosphorylation of the linker by small C-terminal 
domain (SCD) phosphatases, allowing repeated rounds of signaling. If R-Smads are not 
dephosphorylated, they will be further phosphorylated by GSK3, which marks them for proteasomal 
degradation, depleting the pool of TGF/BMP signal transducers. In this manner, the delivery of TGF 
and BMP signals is coupled to the turnover of R-Smad messenger molecules. 
In a different context, mitogens and stress signals acting through MAPKs and the cell cycle acting 
through cell division-related CDKs (e.g., CDK4) phosphorylate R-Smads at sites similar to those 
phosphorylated by CDK8/9. MAPK- and/or CDK-primed linker modifications can be followed by GSK3-
mediated phosphorylation (Figure 2). This not only marks R-Smads for degradation as aforementioned, 
but also creates entry points for cooperation between the TGF/BMP pathway with other pathways 
including MAPK- and Wnt signaling [19, 36-38].  
 





Figure 2. Schematic illustration of "R-Smad signaling cycle" shows the connection between R-
Smad transcriptional activity and R-Smad turnover, which is mediated via sequential 
phosphorylation steps, as indicated. On the right, sequence alignments of the linker domain of human 
(h) Smad2/3 and Smad1/5 as well as those of drosophila (d) are shown with the phosphorylation residues 
and the involved kinases highlighted. The responsible ubiquitin E3 ligases and the regions mediating the 
binding of the ligases to R-Smads are indicated. R-Smad sequence alignment illustration is taken from 
[39].    
Binding of the R-Smad partner transcription factors, like YAP and Pin1, as well as E3 ubiquitin ligases 
(Smurf1/2 and NEDD4L) involves WW domains on such proteins; these are 38- to 40 amino acid 
sequences–characterized by a pair of highly conserved tryptophan residues–that typically interact with 
proline-rich regions (PPXY where X is either serine or threonine or "PY box") or in case of Pin1 with 
phospho-SP motifs (Figure 2). The PY box is located next to the phosphorylated regions in the linker 
domain of Smad [35].  
Taken together, the Smad action turnover switch is controlled by a specific phospho-serine 
code, which is written by nuclear- and cytoplasmic kinases, CDK8/9, MAPKs, and GSK3. The 
tandem WW domains in R-Smad binding partners are the readers of this code that dictate Smad 
transcriptional action, on the one hand, and its elimination, on the other hand. In the BMP 
pathway, CDK8/9 phosphorylate Smad1/5, creating docking sites for interacting with WW domain 
of YAP. Subsequent phosphorylation by GSK3 switches off YAP binding and turns on binding 
to WW domains of Smurf1. In a similar way, TGF-activated Smad2/3 are first phosphorylated by 
CDK8/9, which adds binding sites for Pin1 and GSK3 in order to enhance NEDD4L binding [39]. 
 
 




1.1.4.2. Controlling TGF/BMP signaling-basics of ubiquitination/deubiquitination and its role in 
the pathway 
As previously described, Smurf1/2 and other HECT domain E3 ligases carry WW domains, which 
recognize and bind to PY-rich motifs in the linker region of R-Smads and I-Smads, targeting either their 
own degradation or that of the binding partners. If bound to I-Smads, Smurfs are recruited to the active 
receptor complex, promoting its destruction through the UPP, as aforementioned. TGF or BMP-
activated R-Smads, exploit Smurfs for the elimination of the transcriptional corepressor, SnoN (also 
referred to as Ski-like), which further enhances the transcriptional function of Smad complexes 
(reviewed in [40]). Additionally, Smurf1 interacts with and causes the degradation of receptor-activated 
R-Smads of the BMP pathway–Smad1/5–as well as the membrane localization of the inhibitory Smad, 
Smad7, and hence influences the output of TGF signaling [41, 42]. R-Smads of the TGF pathway–
Smad2/3–are known to be targeted by Smurf2 [43] and the other member of the HECT domain E3 
ligases, NEDD4L [44]. Importantly, Smurf2 has been shown to bind to Smad3 without ubiquitinating the 
protein [43], whereas NEDD4L represents the major ubiquitin ligase responsible for degradation of both 
Smad2 and Smad3. The latter is known to also cause the degradation of the common mediator, Smad4, 
thereby affecting both TGF- and BMP responses [45]. These examples demonstrate that 
polyubiquitination is an important regulatory mechanism through which the TGF/BMP pathway is 
controlled; it has to be noted that these ubiquitin ligases not only target R-Smads but also its negative 
regulators (e.g., Smad7 and SnoN), as stated above, therefore they are able to both enhance and 
terminate the signaling.  
In addition to the HECT domain enzymes, members of the RING-finger family of E3 ligases are also 
able to mediate the proteasomal degradation of Smads and/or their partners. Binding of TGF-induced 
R-Smads to the E3 ligase Arkadia (also known as RNF111) causes the degradation of SnoN and Ski, 
and hence enhances Smad transcriptional responses [46]. Another example of the positive regulation 
of TGF signaling by ubiquitination is the interaction of Smad3 and anaphase-promoting complex (APC), 
which results in the ubiquitin-dependent degradation of the corepressor, SnoN [47]. The E3 ligase, SCF 
has been shown to mediate the TGF-dependent degradation of Smad3 [48] and Smad4 [49], thus 
inhibiting the TGF responses. In the BMP pathway, the U-box-dependent E3 ligase, STUB1 (also 
known as CHIP) promotes the degradation of Smad1/5, thereby terminating Smad signaling [50]. 
Polyubiquitination has been long studied in the regulation of TGF/BMP signaling and is mostly 
coupled to proteasomal degradation of activated R-Smads, although in many cases–as the above 
examples show–appears to be a positive regulator of the TGF and BMP signal transducers. In this 
regard, monoubiquitination represents an equally important mechanism in controlling both Smad4 and 
R-Smads' functions, without promoting their degradation [40]. Monoubiquitination came to our 
understanding of TGF/BMP signaling after unraveling the important role of deubiquitinases (DUBs; 
also known as deubiquitinating enzymes) in the regulation of the pathway; this suggests the existence 




of parallel and continuous rounds of mono-, poly-, and de-ubiquitination in the fine tuning of TGF/BMP 
signal transduction.  
Ubiquitination–derived from the word "ubiquitin", a 76 amino acid protein–involves consecutive action 
of three catalytic enzymes: (i) a ubiquitin-activating enzyme (E1); (ii) a ubiquitin-conjugating enzyme 
(E2); and (iii) a ubiquitin ligase (E3). Initially, E1 attaches the C-terminal glycine residue of ubiquitin to 
a cysteine residue within its active site via a thioester bond. The activated ubiquitin is then transferred 
to the cysteine residue of the second enzyme involved, E2. Ubiquitin-loaded E2 is then paired with 
specific E3 ligases, which catalyze the ligation of ubiquitin to a lysine residue of the target protein, that 
can be ubiquitin itself (reviewed in [51]). Compared with other post-translational modifications, 
ubiquitination presents a particularly diverse process; the attachment of ubiquitin to target proteins 
manifests as monoubiquitination (if ubiquitin is linked as a monomer to a single lysine residue), 
multiubiquitination (if ubiquitin is linked as a monomer to multiple lysine residues) and polyubiquitination 
(if several ubiquitin molecules are added serially to the same lysine residue), with each of these types 
having distinct cellular functions [51]. Monoubiquitination is normally involved in protein transport, DNA 
repair, and endocytosis, whereas multiubiquitination often acts on the latter [51]. These examples 
demonstrate that monoubiquitination is mostly a regulatory mechanism of protein function rather than a 
signal which dictates protein degradation. Polyubiquitination–normally associated to protein destruction 
through the 26S proteasome–further adds to the diversity of ubiquitination, as it is subclassified 
depending on any of the seven lysine residues of ubiquitin (K6, K11, K27, K29, K33, K48, and K63) 
attached to the first ubiquitin molecule. Importantly, a single ubiquitin chain may contain mixed linkages 
and/or multiple branches. Additionally, ubiquitin can be conjugated with ubiquitin-like modifiers (e.g., 
SUMO) or small molecules (e.g., phosphate) [51]. These various ways by which ubiquitin chains are 
assembled provide countless means in regulating biological processes. In light of this, K48-linked 
polyubiquitination is thought to be majorly involved in proteasome-mediated degradation of the target 
proteins, while K63-linked polyubiquitin chains are known to rather influence cellular functions such as 
endocytosis and DNA repair [51]. In this respect, K63-linked polyubiquitination and monoubiquitination 
are comparable to protein phosphorylation, meaning that they can modulate protein activity, its 
subcellular localization, as well as its interaction with other proteins without the need for changing the 
total amount of protein levels. It is, however, worth mentioning the emerging evidence, showing that 
monoubiquitin(s) of substrates could be marked for protein degradation either through the UPP or 
autophagy [51].   
With respect to the TGF- and BMP pathways, monoubiquitination has been shown to modulate 
Smad activity without promoting its degradation (reviewed in [52]). An early example of such regulatory 
mechanism is the RING ubiquitin ligase, TRIMM33 (tripartite motif containing 33; also referred to as 
TIF1 or ectodermin), which monoubiquitinates Smad4 in its MH2 domain (K519), and hence inhibits 
both TGF- and BMP signals presumably by promoting Smad4 nuclear exclusion as well as disrupting 
its complex assembly with R-Smads [53]. TRIMM33 also mediates some Smad4-independent 




responses, as it competes with Smad4 for binding to C-terminally phosphorylated Smad2/3. By doing 
so, TRIM33 forms a complex with activated R-Smads, binds to the promoter of nodal target genes 
(marked with H3K9 trimethylation and H3K18 acetylation), and displaces the chromatin-compacting 
factor chromobox homologue 3 (CBX3) [54]. During differentiation of embryonic stem cells, the latter 
process is a prerequisite step for the transcriptional activation of nodal target genes by the Smad 
complex [54]. It remains to be investigated, however, how general the involvement of TRIM33 is in the 
regulation of Smad signaling, and whether it activates or represses the target genes. Another example 
of Smad activity modulation by mono- and multiubiquitination is the inhibition of Smad3 signaling by the 
HECT-domain E3 ligase, Smurf2. The use of mice strains harboring a target-disrupted Smurf2 allele 
has shown enhanced TGF responses in the absence of the E3 ligase. However, this effect was found 
to be independent of Smurf2-mediated polyubiquitination, and to be rather associated with Smad3 
multiple monoubiquitination at lysine residues in the MH2 domain (K333 and K378), which blocks the 
formation of Smad3 homo- and heteromeric complexes [55].    
The level of ubiquitinated proteins is rapidly readjusted by the action of deubiquitinating enzymes 
(DUBs), which remove ubiquitin chains from the target proteins (regulation of TGF signaling by 
deubiquitination has been summarized in two excellent reviews; [56, 57]). The catalytic activity of 
DUBs cleaves the isopeptide bond between the glycine residue of ubiquitin and the lysine on the target 
protein. Human genome encodes more than 100 DUBs, which are classified in 6 groups based on their 
catalytic features; (i) ubiquitin-specific proteases (USPs), (ii) ubiquitin C-terminal hydrolyses (UCHs), 
(iii) ovarian tumor proteases (OTUs), (iv) Josephins, (v) MINDYs (motif-interacting with ubiquitin-
containing novel DUB family), and (vi) JAB1/MPN/ MOV34 metalloenzymes (JAMM/MPN+). The latter 
family are zinc metalloproteases, whereas USPs, UCHs, OTUs, Josephins, and MINDYs contain 
cysteine peptidase activity. The USP subfamily represents the most abundant group of DUBs 
(approximately 55%) and has been largely implicated in the regulation of TGF and BMP pathways. 
Deubiquitinating enzymes act on different components of the TGF/BMP pathway; from receptors to 
Smads. USP family members, USP4, USP11, and USP15 display highly conserved structural domains 
and protein sequences and have been all mentioned in the deubiquitination of either TGF- and/or BMP 
receptors [56]. USP4 is known to relocate in the plasma membrane upon Akt-mediated phosphorylation 
where it binds to ALK5, deubiquitinates the protein, and hence protects it from degradation, leading to 
enhanced TGF responses [58]. In this manner, USP4 depletion was shown to inhibit TGF-induced 
epithelial-to-mesenchymal transition (EMT) and Akt-induced breast cancer cell migration [58]. In fact, 
there is a dynamic balance between polyubiquitination and deubiquitination in controlling the fate of the 
TGFR1, ALK5. This is achieved by the action of Smad7, on the one hand, which recruits Smurf1/2 and 
WWP1 to the receptor, and the deubiquitinase activity of USP4 and USP11, on the other hand [59]. As 
a proof of concept, in cells overexpressing Smad7, the interaction between ALK5 and USP11 is not 
promoted upon TGF stimulation, suggesting a competition between the two protein in binding to the 
receptor complex. Similar to USP4, USP11 depletion has been associated with reduced TGF-related 




transcriptional activity and EMT [59]. USP15 enhances both TGF and BMP pathways using a 
comparable mechanism, which counteracts the process of Smad6/7-Smurf-mediated ALK5 receptor 
ubiquitination [60]. USP15 amplification has been associated with several cancers, such as 
glioblastoma, ovarian, as well as breast and has been correlated with high activity of TGF signaling 
[60]. These findings highlight the importance of DUB inhibition, by genetic- as well as chemical means, 
in the regulation of signal transduction pathways, and hence in controlling diseases (e.g., cancer) which 
involve such pathways. 
A more recent example from the regulation of TGF signaling by the USP family of DUBs is USP2a, 
which has been initially identified as a p53 negative regulator through stabilizing MDM2 [61]. In the TGF 
pathway, USP2a was found to support metastasis by removing K33-linked ubiquitin chains from 
TGFRI, leading to enhanced Smad2 recruitment, and thus TGF responses [62]. Additionally, TGFRII 
phosphorylates USP2a; such phosphorylation promotes the dissociation USP2a and Smad2 from the 
receptor complex, releasing Smad2 into the cytoplasm [62]. As aforementioned, several USPs (e.g., 
USP4, USP11, and USP15) are known to deubiquitinate TGFRI through complex formation with 
Smad7. This concept of multiple DUBs acting upon the same substrate–TGFRI–poses interesting 
questions; do these DUBs work together in controlling TGF signaling? or are these enzymes able to 
act independently and in the absence of one another? The evidence from different lines of studies 
suggests that both possibilities are likely. On the one hand, USP4 phosphorylation at S445 has been 
shown to trigger heteromeric complexes with USP11, USP15, and USP19, implicating that these DUBs 
could act as a complex [58]. On the other hand, mice knock-out experiments demonstrate that upon 
USP15 depletion, TGF signaling is still normally regulated [63], suggesting that in the prolonged 
absence of one of the enzymes, the others could compensate for its loss.    
In addition to receptor deubiquitination, USP15 has been shown to reverse monoubiquitination of 
Smad3 [64], providing an additional layer of control in the regulation of TGF  signaling by the ubiquitin 
system. Consistent with receptor deubiquitination, USP15 was found to reverse monoubiquitination of 
R-Smads involved in both TGF- and BMP pathways [64], whereas its family members–USP4 and 
USP11–are thought to be limited to TGF signaling. Restoring TGF signaling through reversible 
monoubiquitination has been also shown in case USP9x (also known as FAM), which deubiquitinates 
monoubiquitinated Smad4 (at K519) [65]. Importantly, USP9x knockdown was found to negatively 
influence the TGF-induced p21 transcription, and to be required for TGF-mediated growth arrest and 
cellular migration [65].  
Among other members of the USP family of DUBs, CYLD has been reported to inhibit TGF signaling 
through specifically reversing K63-linked ubiquitination of Akt [66] and Smad7 [67]. The former results 
in inhibition of Akt, subsequent activation of GSK3, which in turn promotes CHIP-mediated degradation 
of Smad3, thereby inhibiting TGF signaling and fibrotic responses [66]. With regards to Smad7, data 
obtained from CYLD-knockout mice experiments showed that the enzyme targets K63-ubiquitination 




sites (K360 and K374) of Smad7, which are important ubiquitination sites required for the activation of 
transforming growth factor -activated kinase 1 (TAK1) and p38 MAPK. In light of this, Smad7 
knockdown and/or p38 MAPK inhibition in primary T cells was found to impair differentiation of regulatory 
T cells (Tregs), highlighting the significance of TGF signaling in the development of Tregs which is 
mediated through K63-linked polyubiquitination of Smad7 [67].  
Other families of DUBs have been also shown to regulate the TGF/BMP pathway both positively 
and negatively. From the OTU family, OTUB1 is known to impact TGF signaling via interaction with 
active Smad2/3 [68]. What appears to be special with regards to this deubiquitinating enzyme is that 
unlike other DUBs, it acts only upon TGF exposure, reversing the polyubiquitination of C-terminally 
phosphorylated Smad2/3, and hence enhancing TGF-mediated gene transcription and cellular 
migration [68]. The mode of action of OTUB1 highlights the dynamic interplay between phosphorylation 
and ubiquitination in controlling TGF signaling. Although being known to cleave K48-linked ubiquitin 
chains, OTUB1 has been shown to stabilize the active Smad2/3 complex in a noncanonical manner and 
independently of its catalytic activity and through inhibition of ubiquitin transfer from E2 to E3 [56]. TGF 
activity can also be sustained by the UCH family member, UCH37 (also known as UCHL5), which acts 
through targeting the type I receptor, ALK5. Accordingly, UCH37 knockdown has been shown to 
decrease TGF-induced transcriptional responses and lateral cell migration during the early phase of 
TGF signaling activation [69, 70]. The zinc metalloprotease DUBs, AMSH [71] and AMSH-LP [72] exert 
a positive feedback on the TGF- and BMP signals via sequestering Smad6 and Smad7, respectively.  
Several DUBs have been reported to have a role in the modulation of non-Smad TGF signaling. 
Among the USP family members, USP4, which is thought to be a positive regulator of TGF signaling 
as aforementioned, has been reported to suppress the noncanonical TGF pathway through 
deubiquitinating TAK1, thus inhibiting the activation of TNF-induced NF-B [73]. The negative 
regulation of TAK1 could also be achieved by the action of USP18 during the process of T helper 17 
(Th17) cell differentiation. In this regard, USP18 knockout mice was found to be defective in the 
generation of Th17 and resistant to autoimmune encephalomyelitis, majorly through restricting IL2 
expression [74]. Focusing on the TRAF6-TAK1-p38 MAPK axis, A20 from the OTU family of DUBs has 
been reported to inhibit the pathway by deubiquitinating TRAF6. Accordingly, knockdown of either A20 
or Smad6, which acts as a transporter of A20 to direct the enzyme to TRAF6, results in increased 
apoptosis, and maintains the phosphorylation of TAK1 and p38/JNK MAPK. This indicates that the A20-
Smad6 axis is essential in the modulation of TGF-induced TRAF6-TAK1-p38 MAPK signaling and 
shows a new role for Smad6–not Smad7–in controlling the noncanonical TGF pathway [26]. The 
abovementioned examples shed light on the involvement of deubiquitinating enzymes not only in the 
regulation of canonical TGF signaling but also in that of the noncanonical pathways. 
The regulation of TGF/BMP signaling by ubiquitination and deubiquitination has been mostly 
focused on the receptor-activated R-Smad pool, which is followed by multiple sequential 




phosphorylations in the linker region, marking activated R-Smads for degradation (see Figure 2). 
Although this regulatory cycle holds true, the small constant pool of Smurfs and other E3 ligases as well 
as deubiquitinating enzymes implicates that they may have some effect on steady-state Smad stability 
(reviewed in [40]). In light of this, Smurf1 has been shown to bind to the PY motifs of Smad1 and 
Smad5, promoting their degradation [41]. Additionally, Smurf2 is known to control baseline properties 
of Smad1 and Smad2 through ubiquitination [75]. Although not being a target of Smurf2, basal Smad3 
has been reported to be stabilized by a proteasome inhibitor [76]. One of the E3 ligases that can 
ubiquitinate Smad3 at steady state is CHIP [77], which was also found to contribute to the ubiquitination 
of nonactivated Smad1 [50]. Similar to the regulation of receptor-activated R-Smad levels, steady-state 
R-Smad stability appears to be finetuned by a continuous interplay between phosphorylation and 
ubiquitination. A clear example of such regulatory mechanism is the role of the scaffolding protein, Axin 
and its associated kinase, GSK3 in basal Smad3 turnover. Mechanistically, Axin facilitates GSK3-
mediated phosphorylation of Smad3 at a conserved threonine residue in the MH1 domain (T66), which 
triggers Smad3 ubiquitination and degradation in the absence of TGF stimulation, and hence 
desensitizing cells to TGF [78]. Other kinases have also been reported to control baseline activity of 
R-Smads in different contexts. In this regard, activated Erk1 has shown to positively regulate Smad2 
signaling by phosphorylating Smad2. Importantly, the Erk-mediated elevation of Smad2 protein levels 
was found to occur as a result of increased half-life of the protein [21].  
1.1.5. TGF signaling–tumor suppressor vs. tumor promoter 
The suitability of the TGF pathway as a target in cancer therapy can only be evaluated by a deep 
understanding of its dual role in tumorigenesis, i.e., how tumor cells in contribution with stroma evolve 
to evade the tumor-suppressive functions of this signaling, and more dramatically hijack the signal to 
their advantage, turning it into a tumor-promoting response. As aforementioned, TGF- and BMP 
responses are greatly influenced by the cellular context as well as by integration with other signaling 
pathways. In cancer, this pleotropic reaction to the pathway, makes TGF a powerful tumor suppressor 
in the context of early stage tumors, but an enhancer of invasion and metastasis in the context of more 
advanced cancer (summarized in two excellent reviews; by Massague J. in [35], by Seoane J. and 
Gomis R. in [79]). This dichotomy although paradoxical, has its own logic. TGF's cytostatic effects are 
important in normal tissue homeostasis. As cells acquire mutations and reach a pre-malignant state, 
TGF triggers apoptotic cell death. In some cancer types, this can select for mutations, which eliminate 
the TGF pathway (e.g., inactivating mutations in TGFR2 and Smad4 in gastrointestinal- and 
pancreatic tumors). Upon TGF signaling elimination, tumor cells can create a TGF-rich 
microenvironment, which favors cancer progression through effects on the stroma. Certain tumor types, 
such as breast, melanoma, and glioma are even more skillful in using the remaining signaling capacity 
to their benefit, leading to a diverse set of tumorigenic features ranging from immune evasion to tumor 
growth, migration, invasion, and metastasis.  




1.1.5.1. TGF/BMP signaling in cancer–the cytostatic and apoptogenic program 
TGF's signaling mediators, R-Smads, regulate the expression of hundreds of genes including those 
that are involved in cell cycle progression (reviewed in [79]). TGF inhibits G1 to S phase transition 
through either the induction of CDK inhibitors or the suppression of c-Myc expression. In epithelial cells, 
TGF induces the expression of p15 and p21, thereby inhibiting the formation of cyclin D/CDK4/6 and 
cyclinE- and A/CDK2 complexes, respectively. Smad co-transcription factors, FoxO and Sp1, associate 
with the Smad3-Smad4 complex in order to target the promoters of CDKN2B and CDKN1A, coding for 
p15 and p21, respectively. c-Myc, a key transcriptional modulator of cell growth and division, is 
downregulated by TGF in mammary epithelial cells through the action of Smad3-Smad4 complex in 
combination with several other transcription factors, such as E2F4, E2F5, and CCAAT/enhancer binding 
protein β (C/EBPβ).  
In addition to the regulation of cell cycle, TGF can induce apoptosis via various mechanisms,  
including an increase in the expression of death-associated protein kinase (DAPK) and GADD45, the 
activation of death receptor, FAS, as well as facilitating the binding of Bim to Bcl-2 and Bcl-xL (reviewed 
in [79]). The pro-apoptotic effects of Bim could be also promoted through Smad3-dependent 
transcription of the MAPK phosphatase, MKP2. Moreover, TGF can block the expression of pro-
survival signaling molecules, such as survivin and Akt (reviewed in [79]). As previously described, 
noncanonical (non-Smad) TGF signaling can induce apoptosis through the TRAF6-TAK1-JNK/p38 
MPAK axis in some cell types, an effect which can be facilitated by Smad7. Additionally, some of the 
TGF's pro-apoptotic responses could be linked to the tumor-suppressor, p53, involving Smad7, p38 
MAPK, and the DNA-damage sensitive kinase, ATM [80]. Interestingly, TGF-mediated apoptosis can 
also occur as a result of oxidative stress through the inhibition of anti-oxidant genes or the induction of 
NADPH oxidase (Nox) activity; this leads to mitochondria-dependent apoptosis, at least in part due to 
the regulation of various Bcl-2 family members [81]. 
TGF-mediated tumor suppression does not always occur through direct growth-inhibitory effects on 
target cells and may be exerted via indirect effects on the tumor microenvironment. TGF limits the 
production of paracrine factors in stromal fibroblasts and inflammatory cells. In this regard, inactivation 
of TGFRII in mouse fibroblasts has been shown to result in intraepithelial neoplasia in prostate and 
invasive squamous cell carcinoma of the forestomach, possibly through the activation of hepatocyte 
growth factor (HGF) signaling [82].         
1.1.5.2. TGF/BMP signaling in cancer–from evading TGF's tumor suppression to cancer 
progression 
During the tumorigenic path, cancer cells tend to escape the action of tumor suppressors, such as 
p53 and APC and/or to activate oncogenes for example, KRAS and HER2. If a stem or progenitor cell 
with such oncogenic mutations is exposed to TGF, it will become liable to undergo apoptosis. 




Therefore, this cell must acquire additional alterations which, among other events, disable the tumor-
suppressive responses to TGF in order to advance on the oncogenic track. One way to tumor evolution 
are genetic variations in the core components of TGF-Smad signal transduction through the 
accumulation of somatic mutations and epigenetic silencing. A prominent example of such alterations 
are colorectal cancers, which consistently incur replication errors in the TGFRII gene, TGFBR2 
(reviewed in [83]). Additionally, in gastrointestinal tumors, methylation status of TGFBR2 is known to 
be correlated with its decreased expression levels. In the BMP pathway, mutations in the BMPR1A, 
coding for the BMP type I receptor (ALK3) cause juvenile polyposis, which predisposes patients to 
intestinal polyposis and cancer (reviewed in [84]). 
Mutations of R-Smads, in particular Smad3, are infrequent in cancer and have been reported only in 
limited number of cases [85]. For example, Smad3 loss of expression has been described in gastric 
cancer and T cell lymphoblastic leukemia, and loss of heterozygosity of the 18q21 chromosomal region 
containing Smad2 and Smad4 has been reported in pancreatic- and colon tumors [86]. Unlike R-Smads, 
Smad4 (deleted in pancreatic carcinoma locus 4; DPC4) mutations are a common genetic alteration in 
cancer, and in pancreatic cancer occur as frequent as mutations in the KRAS, TP53, and CDKN2A [83, 
87]. Smad4 mutations are also recurrent in colorectal tumors, and have been observed in esophageal 
and other cancers, with different incidence rates [88, 89]. The disruption of TGF signaling can also 
occur at the level of singling’s negative modulators, including inhibitory Smads, and transcriptional 
corepressors. In support of this, increased expression of Smad7 and Smad6 has been shown to blunt 
TGF  signaling, and hence prevents its anti-tumoral effects in endometrial carcinomas and thyroid 
follicular cancers (in case of Smad7), as well as pancreatic- and breast tumors (in case of Smad6) [90-
93]. Moreover, Smad7 over-expression in immune cells has been linked to chronic inflammation in the 
colonic mucosa, similar to the role of Smad4 mutations in the stromal cell proliferation and submucosal 
invasion [79]. In addition to I-Smads, deletions and amplifications of SKI and SKIL (the gene coding for 
SnoN) have been observed in gastrointestinal tumors [94]. 
Once cancer cells are released from TGF-mediated tumor suppression, they will use the remaining 
ability of the pathway to support tumor cell growth, migration and invasion. Additionally, TGF has 
pleotropic effects on the immune system through inhibiting most components of both adaptive- (e.g., T 
cells) and innate (e.g., macrophages and natural killer (NK) cells) immune system directly and indirectly 
[95]. In this context, TGF stands out as a physiological immunosuppressor; the immunosuppressive 
effects of this growth factor allow tumor cells to escape the anti-cancer immune response, and hence 
TGF represents an appealing therapeutic target with regards to cancer immunomodulation. In light of 
this, the inhibitory effect of TGF on NK cells is one way through which cancer cells create a permissive 
stroma, which promotes tumor progression [79]. As an example, TGF regulates the anti-cancer effects 
of tamoxifen in vivo via controlling the population of NK cells; in this regard the tamoxifen-resistant breast 
cancer cell line, LCC2 is sensitized to tamoxifen treatment upon TGF  inhibition [96]. Moreover, this 
cytokine can inhibit tumor cell death via regulating gene expression in monocytes and macrophages 




[79]. In monocytes, TGF induces the production of pro-inflammatory molecules, including interleukin 1 
and 6 (IL1 and IL6), while blocking oxygen-free radical production [97]. In macrophages, TGF 
suppresses the expression of chemokines, including macrophage inflammatory protein 1α and 2 (MIP-
1α and MIP-2) and the chemokine CXCL1 factor, the cytokine granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukins IL-1β, IL-8, and IL-10, altogether preventing early 
premature immune response [98]. 
Similar to TGF's anti-cancer responses, pro-cancer effects of this cytokine rely on the tumor 
microenvironment; in this context the tumor alters the host immune response to TGF in order to favor 
tumor initiation and progression. Tumor microenvironment consists of various cell types, including 
fibroblasts, endothelial- and immune cells, as well as extracellular matrix proteins [99]. TGF is produced 
in these tumor-adjacent cells and activates stromal signals; the outcome of these signals depends on 
whether the epithelial tumor cell retains a functional TGF signaling or not, as described above. For 
example, in certain tumor types (e.g., colorectal- pancreatic- and prostate cancers) increased levels of 
TGF are associated with poor prognosis and relapse due to the activated TGF signaling in tumor-
adjacent cells, not in the malignant epithelial tissue [79]. Things are more devious in breast cancer, 
gliomas, and melanomas, as they have an intact Smad machinery, thus they are able to respond to 
stroma-derived TGF, resulting in Smad-dependent gene transcription, which in such context is 
profitable for metastasis [35]. Examples of this pro-metastatic program include the Smad-dependent 
expression of angiopoietin-like 4, which promotes extravasation of circulating tumor cells in breast 
cancer, induction of parathyroid hormone-like hormone, IL11, connective tissue growth factor (CTGF), 
and NOTCH ligand, JAGGED1, which allows cancer cells for osteolytic metastasis in breast carcinoma 
and melanoma (reviewed in [35]).  
During EMT, as the abbreviation describes, cells lose their epithelial features and acquire 
mesenchymal properties, including down-regulation of adherent junctions and associated proteins (e.g., 
E-cadherin), elevated matrix metalloproteinases (MMPs), as well as an architectural rearrangement of 
the cytoskeleton, which altogether result in cell motility and invasiveness (reviewed in [100]). EMT has 
a central role in various events during embryonic development in which cells originate far from their final 
destination, such as gastrulation and formation of neural crest and structures of the heart. In cancer, the 
EMT program helps tumor cells to disseminate and release to the surrounding environment. In addition, 
EMT has been associated with chemo-resistance in breast- and pancreatic cancer. Importantly, tumor 
cells often return to an epithelial phenotype through a reversed phenomenon, referred to as 
mesenchymal-to-epithelial transition (MET); MET-related transcription factors (e.g., Prrx1) uncouple 
stemness and EMT, and are required by tumor cells to colonize at distant sites and form metastases 
[100]. TGF regulates a set of transcription factors, including Snail (Snail1), Slug (Snail2), TWIST, Par6, 
and the zinc finger E-box binding homeobox proteins, ZEB1 and ZEB2 [101]. Moreover, in certain 
contexts, Smad-mediated complexes may have an indirect role in controlling the expression of Snail1/2 
via high mobility group A2 (HMGA2). Through its role in inducing EMT, TGF can support the generation 




of fibroblasts from epithelial cells, as well as from endothelial cells via a closely-related process, referred 
to as endothelial-to-mesenchymal transition (EndMT) [79]. EndMT has been reported to be an essential 
source of cancer-associated fibroblasts (CAFs) in a pancreatic mouse model, and myofibroblast 
accumulation has been repeatedly described in the pathogenesis of solid tumors [102, 103]. Although 
TGF-induced EMT is generally thought to be pro-tumorigenic, in TGF-sensitive pancreatic ductal 
adenocarcinoma (PDA) cells, EMT can become pro-apoptotic through the action of Sox4. In these cells, 
Smad4 is necessary for EMT induction but not for the expression of Sox4, therefore the Smad4 status 
of the cell defines whether TGF-induced EMT favors tumor progression or a pro-apoptotic response 
[104]. Taking all these findings into consideration illustrates that there is a strong interplay between 
TGF and EMT induction, and that the overall response is highly subject to cell type- and context-
specific factors.  
One of the biological functions of TGF is enhancing the tumor initiating qualities of cancer stem 
cells (CSCs), which becomes particularly significant in the process of metastatic colonization when cells 
are prone to severe conditions, and eventually only a few can succeed in forming secondary tumors at 
distant regions. If these cells do not have tumor-initiating properties, metastasis may not cause clinical 
symptoms (the role of CSCs in metastasis has been summarized by Trumpp A. et al. in [105]). In 
light of this, TGF has shown to promote the CSC potential in glioblastoma, and to cooperate with Wnt 
signaling in order to activate mesenchymal status of CSC in association with EMT [106]. TGF supports 
a CD44high/Id1high glioma-initiating cell population, which is responsible for tumor initiation, relapse, and 
chemo-resistance [106]. Additionally, TGF helps the self-renewal traits of glioblastoma stem cells 
through the Smad-dependent induction of Sox2, growth factor beta polypeptide (PDGFB), and leukemia 
inhibitory factor (LIF) [107, 108]. LIF is a cytokine with an essential role in embryonic stem cells; it can 
be secreted by cancer cells in some glioblastoma to promote self-renewal of cancer-initiating cells, and 
hence tumor relapse [108]. TGF can also induce the expression of the CSC marker, CD133 in hepatic 
epithelial cells, which is associated with a more aggressive and resistant phenotype [109]. In chronic 
myeloid leukemia (CML), TGF has a critical role in maintaining CML stem cells through the TGF-β–
FOXO–BCL6 axis in cooperation with nutrient signaling [110]. As described above, TGF's effects on 
EMT and tumor-initiating properties occur concomitantly under certain circumstances, and both events 
(EMT- and stem cell-like markers) are observed in circulating tumor cells from patients with metastasis. 
An example is the induction of stem cell traits by enforced expression of EMT-related transcription 
factors, such as TWIST in breast cancer cells [111]. In this context, the role of other TGF family 
members has to be carefully taken into consideration, as they can suppress self-renewal and enhance 
cancer cell differentiation. For example, lung-derived BMP ligands have been shown to impose 
metastatic dormancy in breast cancer cells, and that the BMP antagonist, Coco supports metastatic 
reactivation [112]. 
 




1.2. Indirubin and indirubin derivatives (IRDs) 
The successful isolation and identification of Qinghaosu (青蒿素) as an anti-malarial agent from more 
than 500 recipes of traditional Chinese medicine (TCM) has promised clinical application of TCM-
derived active ingredients against a variety of diseases, ranging from infections to metabolic disorders 
and cancer. Indirubins represent the active ingredient of a Chinese herbal prescription named Dangui 
Luhui Wan, which has been traditionally used in TCM for the treatment of various chronic diseases. Its 
anti-tumor effect was first reported in 1970s in a clinical trial involving 22 patients with CML. 
Mechanistically, the cytotoxic effects of indirubins have been mainly attributed to their inhibitory function 
against a number of membrane-bound- nuclear- and cytoplasmic protein kinases, such as CDKs, GSK3, 
as well as receptor tyrosine kinases (RTKs). Recent discoveries are increasingly adding new molecular 
targets to indirubins' biological profile. However, the clinical application of indirubin and IRDs is largely 
hampered due to the limited pharmacokinetic properties. Therefore, a lot of effort has been directed to 
the chemical modification of indirubin's backbone, leading to the synthesis of a number of different 
derivatives with new biological activities, which influence various cellular signaling networks associated 
with cancer and other diseases (we have recently discussed the impact of indirubins on cancer-
associated signaling networks in [113]). 
  
Figure 3. Chemical structures of indirubin, indigo (2,2'-bisindole indirubin), and isoindigo (3,3'-
bisindole indirubin).   
1.2.1. Indirubins–towards better bioavailibilty: chemical modification and pharamceutical 
formulation 
The synthesis of indirubin was first described by Baeyer in 1881 using isatin and indoxyl in MeOH 
under basic condition. Since the indoxyl moiety is not stable and spontaneously converts to indigo upon 
exposure to air, Russell and Kaupp replaced this chemical with the more stable indoxyl acetate in 1969. 
This method under mild basic condition is suitable for the synthesis of most indirubin derivatives. 
However, 7-aza indoxyl acetate is not stable and degrades under this condition. The synthesis of aza-
indirubins is therefore preferentially conducted in acetic acid with 10% concentrated HCl, as developed 
and reported by Martinet and Dornier (reviewed in [114]). 




Indirubin, indigo, and isoindigo are three isoforms of the small family of bis-indole alkaloids, which 
share the bis-indole’s backbone (see Figure 3). Similar to its isoforms, indirubin and many of its 
derivatives have a poor solubility in water and in major organic solvents because of the stable intra- and 
inter-molecular hydrogen bonds between 1-NH and 2-CO and between 1’-NH and 2-CO, respectively 
(Figure 4) [114]. Studying the co-crystal structure of indirubin-3'-oxime and indirubin-5-sulfonate in 
complex with the ATP-binding pocket of CDK2 has unveiled potential positions on the bis-indole moiety 
of indirubin for chemical modifications, which allow improved pharmacokinetics with minimal negative 
effects on bioactivity–i.e., using 5- and/or 3'-positions facing the ribose/triphosphate canal of the ATP-
binding pocket of the kinase, as well as 5'-position, which is free and open to the solvent (Figure 5) 
[115-117]. The modification at 3’-position is possibly the most successful approach in order to introduce 
substituents with basic functional groups for improvement of solubility and biological activity. In view of 
this, we and others have synthesized the water-soluble indirubin derivatives using the 3'-position. In 
addition, 5- and 5’-positions could also be used for the synthesis of IRDs, however with more 
complicated protocols [114]. 
 
Figure 4. Inter- and intra-molecular hydrogen bonds cause indirubins' poor water solubility. 
 
Figure 5. Demonstration of possible positions for chemical modification of the indirubin 
backbone. A color code has been used to indicate the suitability of each position, with green being 
representative of full accessibility, orange representative of limited accessibility, and red presenting 
unsuitable positions.  




As mentioned above, the bioavailability of indirubins suffers from the poor water solubility of the 
molecule; an early finding in support of this idea is the study on the interaction of indirubin and p-
glycoprotein, showing the low binding affinity when the pH is in the range of 2 to 11 [118]. Although 
chemical modifications in the aforementioned positions have led to the synthesis of more water-soluble 
derivatives, low pharmaceutical activity of those analogues (e.g., inidirubin-5-sulfonate) due to the extra 
hydrophilic property limits the use of IRDs in pre-clinical and clinical models [118]. Alternatively, 
pharmaceutical formulation presents an opportunity to enhance solubility and bioactivity. In this regard, 
both self-micro-emulsifying and self-nanoemulsifying drug delivery systems (SMEDDS and SNEDDS, 
respectively) have shown promising results [119, 120]. Using SMEDDS, 50 ng/mL indirubin was 
detected in the plasma after oral administration, whereas a significantly higher plasma concentration 
(1800 ng/mL or ~10 µM) was achieved using SNEDDS. Given that the reported IC50 values of indirubin 
and indirubin derivatives in cellular assays are normally below 10 µM, SNEDDS provides a suitable 
approach for the clinical application of indirubins. 
1.2.2. Indirubins–molecular mode of action 
1.2.2.1. molecular targets–cyclin dependent kinases  
Indirubins were primarily found to have a high inhibitory activity towards cyclin-dependent kinases 
with IC50 values down to the nano molar range (5-100 nM). As previously mentioned, CDKs are 
serine/threonine protein kinases with a major role in the regulation of R-Smad activity and stability. 
Outside the context of TGF/Smad signaling, CDKs together with their binding partners, cyclins, 
regulate the progression of cell cycle. There are three main transition steps at which the cell cycle 
regulators including CDKs/cyclins decide on passing of cells through the next phase; G1/S, G2/M and 
during mitosis (M) phase. The first checkpoint, G1/S is mostly regulated by CDK4,6/cyclin D and 
CDK2/cyclin E complexes, which are responsible for phosphorylation, and hence inactivation of 
retinoblastoma protein (Rb). CDK2/cyclin A is essential for the S phase progression and is accompanied 
by the action of CDK1/cyclin B and CDK2/cyclin B complexes at the G2/M transition, preparing cells for 
mitotic division [113].  
With regards to CDKs, indirubin and its analogues have been shown to bind to and inhibit 
CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 complexes [113]. Crystal structure 
studies of CDK2 in complex with indirubin derivatives have revealed that indirubin occupies the ATP 
binding pocket of the CDK’s catalytic subunit via hydrophobic interactions and hydrogen bonds [115]. 
The more water-soluble derivatives, indirubin-3’-monoxime and indirubin-5-sulfonate have been 
demonstrated higher affinity for CDKs and potent inhibition of the enzymes. While the sulfonate 
analogue fails to be up-taken by tumor cells, the oxime analogue (3IO) is cell-permeable and has 
demonstrated high efficacy in several malignancy models, making it the most widely-studied derivative 
of indirubins (reviewed in [121]. In this regard, Hoessel et al. showed that the kinase inhibitory activity 
of indirubin-3’-oxime causes reduced phosphorylation of Rb, and subsequently induces G1- and G2/M 




cell cycle arrest in the human leukemia cell line, Jurkat [115]. Moreover, the compound has shown anti-
proliferative effects in the breast cancerous cell line, MCF-7 by inducing a G2/M cell cycle arrest through 
inhibiting CDK1 [122]. Furthermore, it was found to increase the expression of the CDK inhibitor, p27, 
and to reduce that of CDK2 and cyclin E, resulting in a G0/G1 arrest in human neuroblastoma cell lines 
[123].  
1.2.2.2. molecular targets–glycogen synthase kinase 3 
The indirubin-mediated CDK inhibition mostly occurs in combination with the inhibition of glycogen 
synthase kinase 3β. GSK3β is a multifaceted serine/threonine kinase, and a key player of the canonical 
Wnt signaling pathway, which controls several physiological processes ranging from cell cycle and 
metabolism to neuroprotection and dorsal-ventral patterning during embryonic development [124]. In 
addition, GSK3 represents an important enzyme in insulin signaling; over-expression of GSK3β has 
been reported in type 2 diabetes and GSK3β inhibitors have shown anti-diabetic effects in vitro and in 
vivo [125]. Moreover, GSK3β in cooperation with CDK5 mediates hyperphosphorylation of the 
microtubule binding protein, tau which is a diagnostic marker in certain neurodegenerative diseases, 
including Alzheimer’s disease [121]. In light of this, it has been reported that several indirubin derivatives 
which were initially introduced as potent CDK inhibitors, block the GSK3β enzyme in an ATP-competitive 
manner similar to their interaction with CDKs, and by doing so represent the first class of GSK3β 
pharmacological inhibitors that are effective at low nano molar concentrations (5-50 nM) [113]. Leclerc 
and colleagues showed that the indirubin-3’-oxime derivative inhibits tau protein aggregation in vitro and 
in vivo by the concomitant inhibition of two protein kinases, CDK5/p25 and GSK3β. Additionally, this 
analogue was found to block the phosphorylation of dopamine- and cyclic adenosine 3′-5′-
monophosphate-regulated phosphoprotein 32 (DARPP-32) by CDK5, thus imitating dopamine effects 
in the stratum [126]. Looking for new scaffolds that are able to selectively target GSK3β, it has been 
reported by Meijer et al. that a simple substitution at position 6 increases the GSK3 specificity over 
CDKs. In this regard, 6-bromoindirubin derived from “tyrian purple” dye of mollusks and its oxime 
substituent, 6-bromoindirubin-3’-oxime (6BIO) have been reported as selective small molecule inhibitors 
of GSK3α/β. The compounds were found to mimic Wnt signaling, and to reduce phosphorylation of β-
catenin in vivo. Additionally, they showed more than 16-fold higher specificity for CDK2 as compared to 
CDK5 [127]. With this information in mind, indirubin and its derivatives present promising candidates 
not only in cancer therapy, but also in the treatment of other diseases in that selective GSK3 inhibition 
is profitable, such as diabetes and Alzheimer’s disease. Importantly, the dual and opposing roles of 
GSK3β in oncogenesis should be taken into consideration when applying GSK3β inhibitors for cancer 
treatment. On the one hand, GSK3β inhibits Wnt signaling by phosphorylation and subsequent 
proteasomal degradation of β-catenin; in this context GSK3β acts as a tumor suppressor. On the other 
hand, it can switch to a tumor promoter by stimulating the activity of Wnt/β-catenin signaling through 
phosphorylation of Wnt co-receptor, LRP 5/638 [128]. The latter mechanism might explain the tumor-
suppressive effects observed with GSK3β inhibitors, such as indirubins. In addition, this kinase is 
increasingly identified as a modulator of invasion and metastasis. Williams and colleagues 




demonstrated that the GSK3β inhibitory activity of indirubins offers a new therapeutic mechanism 
through preventing invasion of glioma cells and glioma-initiating cells in vitro and in a glioma bearing 
mouse model [129]. Moreover, indirubins were found to decrease cellular migration of endothelial cells, 
an essential component of tumor angiogenesis [129]. Mechanistically, GSK3β inhibition causes 
dephosphorylation, thereby stabilization of β-catenin, leading to reduced migratory phenotypes. Despite 
the significance of β-catenin in the proposed mechanism, they showed that silencing this protein does 
not completely rescue the anti-migratory effects of indirubins in glioma [129], implicating additional 
targets other than GSK3β in mediating the observed effects. In a different study, Braig et al. reported 
the IRD 6BIO significantly diminishes migration of breast cancer cells into the lungs at subtoxic 
concentrations (1 mg/kg) in an aggressive breast cancer mouse model (4T1). While GSK3β as well as 
the phosphoinositide-dependent tyrosine kinase 1 (PDK1)12 should be granted for the overall anti-
migratory activity of 6BIO in this study, they did not appear to be the major targets. Instead, the inhibition 
of two other kinases, Src and janus kinase (JAK), followed by decreasing the activity of their substrate, 
signal transducer and activator of transcription 3 (STAT3) turned out to be the dominant mechanism. 
STAT3 inhibition caused decreased expression of the cellular migration regulators C-terminal tension 
like protein (CTEN) and MMP2 [130]. The combined inhibition of multiple kinases by the IRD 6BIO 
enables the simultaneous targeting of different cellular networks related to cancer, ranging from 
extensive proliferation of cells to migration, invasion, angiogenesis and metastasis. 
1.2.2.3. molecular targets–receptor and non-receptor tyrosine kinases 
The invention of imatinib–the first FDA-approved tyrosine kinase inhibitor (TKI)–in late 1990s has 
transformed the approach to the treatment of various cancers by offering a new form of targeted therapy, 
i.e., selective inhibition of protein tyrosine kinases (PTKs). PTKs represent one of the major enzymes in 
the process of cellular signal transduction; they possess tyrosine kinase activity, which enables them to 
catalyze the transfer of phosphate groups from ATP to the tyrosine residues on their substrates (e.g., 
STATs), in order to phosphorylate them. The phosphorylated substrates then transfer the signal to the 
nucleus in order to regulate various cellular functions; cell survival- growth- and differentiation, to name 
a few. Based on their structure, PTKs are classified as either receptor tyrosine kinases (RTKs) or non-
receptor tyrosine kinases (NRTKs). The former includes epidermal growth factor receptor (EGFR), 
platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR) 
as well as insulin receptor (InsR) family and so on. Unlike RTKs, NRTKs have no extracellular structure, 
instead they are usually tethered to the cell membrane or reside in the cytoplasm; the examples include 
ABL kinase, Janus tyrosine kinase (JAK), and Src family kinases (SFKs). NRTKs have a crucial role in 
signal transduction pathways initiated by various membrane receptors (e.g., tyrosine kinase receptors, 
growth factor receptors, and G-protein coupled receptors); additionally, they are involved in the so-called 
"inter-pathway" crosstalks. The latter is exemplified in the effects of activated STAT3 on Ras- and 
PI3K/Akt pathways, and in the association of JAK2 with PI3K- and Erk signalings (reviewed in [131]). 
In light of this, it has been reported by Nam et al. that a number of IRDs–designated as E564, E728, 
and E804–inhibit the constitutively active STAT3 signaling in human breast- and prostate cancer cell 




lines. One of the derivatives, indirubin-3’-(2,3 dihyroxypropyl)-oximether, referred to as E804, was found 
to have a direct interaction with Src at sub-micromolar concentrations (IC50 = 0.43 μM), leading to 
reduced tyrosine phosphorylation of its substrate, STAT3 in both an in vitro kinase assay as well as in 
human breast (MDA-MB-468 and -435) and prostate (DU145) tumor cells. Moreover, two of the STAT3-
induced pro-survival proteins, Mcl-1 and survivin, were strongly decreased in response to E804 in breast 
cancer cells, triggering apoptosis. Importantly, the induction of apoptosis by E804 was not found in cells 
lacking elevated STAT3 activity, suggesting that the anti-tumoral effects of E804 occur at least in part 
through targeting Src/STAT3 signaling [132]. Another member of the STAT family with a key role in 
tumorigenesis, particularly in hematopoietic cancers, is STAT5, which is activated via the action of the 
non-receptor tyrosine kinases, BCR-ABL and SFKs [133]. With regards to indirubins' effects on the 
status of the latter kinases, Nam et al. have shown in a different study that among a series of derivatives, 
IRD E804 is the most potent analogue to induce apoptosis in CML through inhibiting SFK/STAT5 
signaling, down-stream of BCR-ABL kinase. This inhibition was followed by the small molecule’s pro-
apoptotic effects against human K-562 CML cells, the imatinib-resistant KCL-22 CML cells, expressing 
mutant BCR-ABL, as well as the CD34-positive primary CML cells from patients. Moreover, the 
expression of Mcl-1, known to be upregulated in CML, was decreased upon E804 treatment [134]. It is 
worth mentioning that the IRD E804 is also a potent CDK inhibitor, a common feature of most indirubin 
derivatives. Through CDK-inhibition, the compound has shown anti-proliferative effects in different in 
vitro cancerous models, namely human HCT116 colon cancer, human MCF-7 breast cancer, as well as 
in the human lung carcinoma cell line, LXFL529L [121].        
As described earlier, JAK and Src kinases share STAT3 as their substrate. It has been reported that 
prolonged inhibition of Src triggers a compensatory mechanism in which STAT3 is alternatively 
phosphorylated and activated through the JAK/STAT3 interaction, mediating cancer cell survival and 
proliferation [135]. Therefore, dual inhibition of SFKs and JAK may have synergistic effects by blocking 
STAT3 reactivation, a common drawback of Src-specific inhibitors (e.g., dasatinib). In view of this, the 
IRD E738, possessing a propanediol group at 3’- and a methoxy group at 5-position has been introduced 
by Nam and colleagues as the first dual inhibitor of JAKs and SFKs with IC50 values between 0.7-74.1 
nM and 10.7-263.9 nM, respectively. As compared to E804, E738 showed 40-fold increase in the Src 
inhibitory activity. Combined inhibition of JAK/Src by IRD E738 caused reduced tyrosine phosphorylation 
of STAT3, followed by reduced Mcl-1 levels, and apoptosis in human pancreatic cancer cells [136]. 
Several other studies have identified the JAK/Src/STAT signal transduction as a mode of action of 
indirubin's bromo-substituents. It has been reported by Liu and colleagues that the compound, 6BIO 
induces apoptosis in melanoma by selective targeting of JAK/STAT3 signaling. 6BIO, among a series 
of IRDs, showed the most efficacy in reducing the phosphorylation of JAK and STAT3, and was found 
to suppress tumor growth in a human melanoma xenograft mouse model [137]. In a different study, the 
anti-cancer activity of a 7-bromoindirubin derivative (known as MLS-2438) against human melanoma 
cells was attributed to the inhibition of STAT3 and Akt kinases. The compound also reduced tumor 
growth in vivo with relatively low toxicity [138]. Interestingly, 7BIO, unlike its close isomers 5- and 6-




bromoindirubins, showed insignificant inhibition of the classical targets, CDKs and GSK3β, which 
account for most of the anti-tumoral effects of indirubins [139]. Instead, 7BIO with a minimal kinase 
inhibitory activity was able to induce a rapid cell death without triggering the typical markers of apoptosis 
[139, 140]. 
In addition to non-receptor PTKs, RTKs could be also targeted by indirubins. An early example is the 
anti-angiogenic properties of the water-soluble derivative, indirubin-3’-oxime, which were found to occur 
through inhibiting VEGFR-2 [141]. Besides the oxime derivative, indirubin itself has been shown to inhibit 
tumor angiogenesis in human prostate cancer cell line, PC-3 via preventing VEGFR2-mediated 
JAK/STAT3 signaling in endothelial cells [142]. With regards to IRD E804, several molecular targets, 
including CDKs, Src/STAT3, and BCR-ABL/STAT5 had been described so far. In a different context, 
Chan et al. tested the anti-angiogenic profile of the compound, and showed a potent in vitro angio-
suppression by reducing the proliferation, migration, and tube formation of human umbilical vein 
endothelial cells (HUVECs). Additionally, E804 (at a concentration of 4 μM) completely inhibited the 
outgrowth of endothelial cells from the rat aorta, as determined by the ex vivo aortic ring assay, as well 
as the activity of two members of the MMP family, MMP-2 and MMP-9 [143]. The anti-angiogenic activity 
of the cell permeable derivative, E804, was further confirmed in a different study where the compound 
inhibited the angiogenic markers in HUVECs and micro-vessel sprouting from the rat aortic ring. 
Mechanistically, E804 inhibited the kinase activity VEGFR-2 in vitro and in endothelial cells, blocking 
receptor phosphorylation, and subsequently the activity of its down-stream kinases, Akt and Erk MAPK 
[144]. 
Similar to other kinase alterations, fibroblast growth factor receptors (FGFRs)–which also belong to 
the family of RTKs–are targetable by different approaches, such as antibodies, DNA/RNA aptamers, as 
well as small molecules (reviewed in [131]). In the context of indirubins as FGFR small molecule 
inhibitors, Zhen et al. have reported that indirubin-3’-oxime strongly and selectively inhibits the activity 
of this tyrosine kinase receptor at concentrations below those required for CDK2 inhibition (5 μM vs. 20 
μM, respectively). Additionally, the compound was found to enhance Erk1/2 activity, independently of 
FGFR1 inhibition, but through p38 MAPK activation. Blocking FGFR1 activation, indirubin-3’-oxime 
caused reduced proliferation of the FGF1-stimulated NIH/3T3 cell line and the human acute 
myelogenous leukemia (AML) cells, KG-1a. At a higher concentration (20 μM), the small molecule was 
able to show similar effects on the FGFR-1-negative leukemia cell line, K-562, which may be through 
the inhibition of CDK [145]. These findings become particularly significant in the treatment of FGFR1-
dependent cancers (e.g., the AML-derived cancer cell line, KG-1a), however, as aforementioned (in 
case of K-562 cells), the anti-cancer properties of indirubin-3’-oxime is not limited to FGFR-1-sensitive 
tumor cells due to the pleotropic nature of cellular responses to this derivative as well as other IRDs. 
Overactivation of the receptor tyrosine kinase, insulin-like growth factor 1 receptor (IGF1R) and its 
ligands, IGF1/2 have been associated with various human diseases, including a number of different 
cancers (e.g., breast- colorectal- and prostate cancers). Like other RTKs, several strategies, including 




antibodies, neutralizing ligands, as well as chemical TKIs have been tested for targeting IGF1R 
signaling, some of which are in late phases of clinical trials (reviewed in [146]). Recently, screening a 
series of newly synthesized 5’-carboxy substituents of indirubins identified a water-soluble derivative, 
indirubin-3′-[2-(4-methylpiperazino)ethyl]oxime ether hydrochloride–referred to as 6ha–with a potent 
inhibitory activity against IGF1R, and only a marginal inhibition of CDKs and GSK3β. Accordingly, 6ha 
showed cytotoxic effects in the NCI-60 cell line panel at low micro molar concentrations [147].  
1.2.2.4. molecular targets–interfering with the TGF/BMP pathway 
As thoroughly discussed above, the TGF/BMP pathway is regulated at multiple levels, in particular, 
through controlling the duration of activated- and steady-state R-Smad signaling, a process that requires 
a continuous cooperation between phosphorylation, ubiquitination, and deubiquitination.  We have 
tested the biological activity of indirubins in this context, and showed that among a series of derivatives, 
IRD E738 has the strongest effect in depleting steady-state R-Smad levels of both major TGF-family 
pathways–Smad2/3 and Smad1/5/8–Detailed analyses of the molecule's effects revealed that this 
intervention with the signaling happens at clearly separated levels: (i) reduction of total R-Smad pools, 
(ii) transient stabilization of receptor-activated R-Smads (possibly due to the GSK3 inhibitory activity of 
E738), and (iii) activation of the noncanonical TGF signalings, p38- and JNK MAPKs [148]. The latter 
effect is consistent with the previously reported induction of MAPKs in response to other derivatives 
[145]. Importantly, the E738-mediated R-Smad depletion was found to occur through the control of 
protein stability and was associated with the deubiquitinating enzymes, USP9x and USP34, adding a 
new target to indirubins' profile; the ubiquitin-proteasome pathway. Inhibition of these enzymes, using 
either IRD E738 or siRNA caused reduced levels of steady-state Smad2/3 and Smad1/5/8, downstream 
of the TGF- and BMP pathways, respectively [148]. Altogether, these findings highlight the 
regulation of TGF/BMP signaling by reversible ubiquitination, which occurs not only through 
controlling activated R-Smad pools, but also through that of total non-activated R-Smads. 
Moreover, this regulatory mechanism could be modulated using small molecules, as shown by 
the action of IRD E738. 
1.2.2.5. molecular targets–other mechanisms 
In addition to the aforementioned cellular networks, many more signaling molecules have been 
shown to be regulated by indirubin analogues, including the cytoplasmic kinases, IKK and casein 
kinases (CKs). With regards to the former, Sethi et al. reported that the indirubin-mediated inhibition of 
IKK leads to the inactivation of the NF-B pathway, an effect which most likely has a crucial role in the 
small molecule's anti-inflammatory effects [149]. With regards to the latter, IRD 7,7’-diazaindirubin–from 
the family of azaindirubins with a more metabolically stable profile–has been found to selectively inhibit 
CKs. Interestingly, the anti-proliferative and pro-apoptotic effects of this derivative in MCF-7 breast 
cancer cells were abrogated upon knocking down CK2, implicating the role of this kinase in the 
molecule's mode of action [150]. 




In a new context, the bioactivity of indirubins was investigated against the tumor initiating cancer 
stem cells. So far, several combinations of cell surface markers are known to be selectively expressed 
in CSCs, such as CD44+/CD24-, CD44+/CD24+/ESA+, and CD34+/CD133+104 (recently reviewed in 
[151]). In this respect, meisoindigo, an analogue of isoindigo with a methyl group at 1-position, has been 
shown to preferentially decrease CSC populations (CD133+ and CD24+/CD44+/ESA+ cells) of PDAC 
[152]. Previous studies had reported on the ability of this derivative in inducing apoptosis, inhibiting cell 
proliferation and differentiation, as well as angiogenesis in both in vitro and in vivo leukemia models. 
Notably, meisoindigo, in contrast to its parental molecule–indirubin–does not interact with protein 
kinases, suggesting other mechanistic pathways than the conventional targets (e.g., CDKs and GSK3β) 
underpinning the anti-tumoral effects of isoindigo analogues (reviewed in [113]). For example, we have 
proposed that meisoindigo triggers AMPK activation through the altered mitochondrial function, followed 
by oxidative stress-related apoptosis in PDAC cells. Additionally, the upstream kinase of AMPK, liver 
kinase B1 (LKB1) was inhibited upon meisoindigo treatment, which was accompanied by a decrease in 
cancer stem cell markers (e.g., CD133 and CD44) [152]. These results provide a deeper understanding 
into the molecular basis of the cytotoxic- and apoptogenic responses, as well as anti-cancer stem cell 
properties of the new generation of indirubins, isoindigo derivatives. 
In summary, protein kinase inhibition is seemingly the main contributor to the in vitro and in 
vivo effects of indirubins in the context of cancer and other diseases. However, as described in 
detail, recent studies have proposed new targets, such as the ubiquitin-proteasome pathway. 
The bioactivity of indirubins extends even further through the regulation of microRNAs, as 
recently described for indirubin and indirubin-3'-oxime to regulate the tumor suppressor 
microRNA, let7 [153]. Another example is the decreased global microRNA maturation in 
response to IRD 6BIO, as well as another small molecule inhibitor of GSK3, CHIR [154]. These 
findings provide more interesting aspects to the multi-faceted biological profile of this family of 
natural compounds.  
1.2.3. Indirubins–clinical perspectives 
As briefly mentioned above, the clinical use of indirubin was first tested in 1970-1980s in a number 
of clinical trials for the treatment of CML patients and showed more than 50% partial or complete 
remission (summarized in [113]). In comparison to the standard regimen, busulfan, indirubin exhibited 
similar efficacy, however with a lower rate of complete hematologic response (CR) [155]. Regarding 
toxicity, indirubin was associated with minor side effects in most cases which were limited to abdominal 
pain, diarrhea, and nausea, except for three cases who experienced reversible pulmonary hypertension 
and cardiac insufficiency [156]. Lately, a complete cytogenetic response and survival of 32 years in a 
CML patient was reported who was treated with a combination of the TKI, imatinib, indirubin, and 
meisoindigo [157]. Comparing indirubin and meisoindigo, they showed similar efficacy, however with 
lower side effects in case of the latter. In another clinical study, similar rates of partial and complete 
remission were observed between meisoindigo- and busulfan-treated groups of CML patients [156]. A 




phase II clinical trial involving 134 newly diagnosed CML patients treated with meisoindigo (75-150 
mg/d) demonstrated a rate of 32.1% and 48.5% of CR and hematological partial response (PR), 
respectively. The treatment also showed comparable CR and PR rates between newly diagnosed- and 
previously treated-CML patients in a phase III clinical trial [156, 158]. Based on a retrospective study 
with 274 CML patients who were followed over a period of 5 years, no major difference was observed 
regarding hematological response, median duration of chronic phase, median duration of survival, and 
blast crisis rate at 60 months from diagnosis between meisoindigo, hydroxyurea, and busulfan. 
However, combination therapy with meisoindigo and hydroxyurea was found to significantly improve all 
the aforementioned markers, compared with meisoindigo, hydroxyurea, and busulfan as single 
treatments [156, 158]. This suggests a possible synergy between meisoindigo and hydroxyurea in the 
treatment of CML. At present, indirubin is being evaluated in a multicenter randomized trial to improve 
the outcome of acute promyelocytic leukemia (APL) in children (clinical trials.gov identifier: 
NCT02200978). 
1.3. Project narrative–rationale, hypothesis, and purpose 
In light of the abovementioned data on the cellular mechanisms of indirubin analogues, which involve 
multiple signaling molecules with an essential role in the regulation of the TGF/BMP pathway (e.g., 
MAPKs, CDKs, and GSK3), we proposed if the new IRD–designated as E738–is able of interfering with 
TGF- and BMP signals (see Figure 6). Our previous knowledge could show the ability of indirubin 
derivatives to inhibit the signaling outcome though reducing the stability of basal R-Smads, which was 
found to occur by blocking deubiquitination (Figure 6). This has provided us with a less investigated 
theme in the regulatory mechanisms of the TGF/BMP signal transduction, i.e., (i) the significance of 
steady-state R-Smad regulation–in addition to that of the receptor-activated R-Smads–in cellular 
responses to TGF- and BMP signals, and (ii) the importance of reversible ubiquitination in 
controlling total R-Smad pools, apart from its role in the regulation of activated R-Smads, which 
has been thoroughly investigated in literature. 
In the present research, we have focused on the effects of IRD E738, as it had shown the most 
efficient depletion of total R-Smads, among several tested derivatives. As previously discussed, a series 
of sequential post-translational modifications, including ubiquitination and phosphorylation (see Figure 
2 and Figure 6), works cooperatively in order to regulate the half-life of R-Smad signaling. With a focus 
on TGF-related Smad2/3, we aimed at exploring (i) how the abundance of total R-Smad pools is 
maintained through the dynamic interplay between phosphorylation and ubiquitination, and (ii) 
how accessible this regulatory mechanism is for small molecule intervention. As discussed 
earlier, during cancer progression, the tumor-suppressive TGF/Smad signaling can shift to the 
oncogenic pathway; this malignant switch is associated with the aberrant phosphorylation pattern of R-
Smads. Having this in mind, we sought of (iii) translating the cellular effects of phospho-Smad 
signaling into a therapeutic strategy by using cholangiocarcinoma (CCA) cells as a cancerous 
model. Finally, we intended to (iv) investigate whether the kinase inhibitory activity of IRD E738 is 




able to inhibit the oncogenic phospho-Smad signaling in CCA, given that the phosphorylation 
status of R-Smads relies on the activity of several membrane bound- cytoplasmic and nuclear kinases.  
 
Figure 6. Rationale and working hypothesis of the present chapter. The schematic illustration 
summarizes our previous understanding of the regulation of "steady-state" (herein also referred to as 
basal- total- or non-activated) R-Smads by the ubiquitin-proteasome pathway (UPP) using small 
molecule intervention. The indirubin derivative (IRD), E738 depletes total R-Smads via inhibiting the 
deubiquitinating enzymes, USP9x and USP34, proposing a role for the "UPP" in maintaining steady-
state R-Smad pools. Red question marks demonstrate the unaddressed issues of the small molecule's 
mode of action, and so the specific objectives of the current study. As shown by a blunt-headed arrow, 
IRD E738–similar to most of the indirubins–is a potent kinase inhibitor, targeting several kinases involved 
in R-Smad linker phosphorylation. Given that linker phosphorylation boosts R-Smad transcriptional 
activity (referred to as "pSmad signaling"), we asked if E738 (and/or other kinase inhibitors) is capable 
of interfering with pSmad signaling, with a particular implication in certain cancerous contexts. Modulation 
of Smad linker phosphorylation by the molecule, on the one hand, and its inhibitory effect on total Smad 
levels, on the other hand, pose another interesting question with regards to the control of TGF signaling; 
how relevant is linker phosphorylation to steady-state R-Smad stability? and if so, which ubiquitin ligases 
are involved? The following sections tackle these questions and discuss the findings and limitations of 










2.1. The indirubin derivative–E738–interferes with the TGF/BMP/Smad pathway at multiple 
separated levels. 
 
Figure 7. The indirubin derivative–E738–depletes steady-state R-Smad levels in cell lines of 
various tissue origin. Immunoblots showing the regulation of non-activated R-Smad levels in cells of 
the indicated cancerous- and non-cancerous tissue origin upon treatment with increasing concentrations 
of E738 for either 6 h or 24 h. All tested cell lines demonstrate a clear decrease in TGF-related Smad2/3 
and BMP-related Smad1/5/8 in response to the small molecule, however, with different sensitivities. 
actin and vinculin served as loading controls.     





2.1.1. IRD E738 reduces the protein levels of steady-state R-Smads in various cell lines of both 
cancerous and non-cancerous tissue origin. 
We had previously shown that the protein expression of Smad1/5/8 is reduced upon treatment with 
several indirubin derivatives in HeLa cells as well as in human foreskin fibroblasts (HFFs) [148]. Based 
on the structure-activity relationship (SAR) studies, a propanediol group on 3'-position and/or a methoxy 
group at 5-position causes the strongest depletion of total- and C-terminally phosphorylated Smad1/5/8 
[148]. With this in mind, we chose IRD E738–carrying both substituents, a propanediol- and a methoxy 
group on 3'- and 5-positions, respectively–to study the regulation of R-Smad signaling. To find the most 
suitable in vitro model, we sought to perform a large screen encompassing cell lines of various 
cancerous- and non-cancerous origin. For this, immunoblotting was used and the protein levels of both 
TGF- and BMP-related R-Smads were determined upon treatment with increasing doses of E738 at 
short- and long-term time points. The results clearly showed a reproducible reduction in R-Smad protein 
levels, however, with different sensitivities among the tested cell lines (Figure 7). 
In addition to E738, the IRD E860–carrying a methoxy- and a large basic group on 5- and 3'-positions, 
respectively (Figure 8A)–was tested in several cell lines, including HEK-293, T cells, as well as 
colorectal- and leukemia cancer cells, and HeLa. In comparison to E738, this analogue showed less 
efficiency in terms of R-Smad depletion (Figure 8B); this is consistent with the previous SAR studies, 
showing the positive effects of both propanediol- and methoxy substituents at 5- and 3'-positions on the 
indirubin-mediated inhibition of TGF/BMP signaling [148]. 
 
Figure 8. Comparison of IRD E860 with E738 in reducing steady-state R-Smad levels. (A) Chemical 
structures of the indirubin derivatives, E738 and E860. (B) Immunoblots compare the efficacy of E860 
with E738 in depleting TGF-related Smad2/3 and BMP-associated Smad1/5/8 upon 24 h treatment with 
the small molecules at the indicated concentrations. In general, E860 does not show a clear decrease 
of R-Smad protein expression except for the leukemia cell line, HL-60 and T lymphoblast cells, SUPT1. 
actin served as the loading control.   





2.1.1.1. Biotinylated E738 displays similar regulation of steady-state R-Smad levels compared 
with its parental molecule.  
To identify E738's interacting proteins, with a special focus on components of the ubiquitin-
proteasome pathway, we sought to synthesize biotin-conjugated E738 (designated as E738 B). The 
schematic synthesis procedure is illustrated in Figure 9A. After successful characterization of E738 S–
containing the spacer region (colored in blue)–we tested the new molecule's effects on total Smad2/3 
levels, using E738 as a reference. Although in some cases higher concentrations were required as 
compared to that of the parental molecule, E738 S was able to significantly reduce Smad2/3 levels in 
the tested cell lines, HEK-293 and HCT116 (Figure 9B and 9C). We then completed the synthesis of 
E738 B (colored in red) by attaching the NHS-activated biotin to the spacer and assessed E738 B's 
regulation of Smad2/3 levels in the HCT116 colorectal cancer cell line. As shown in Figure 9D and 9E, 
the newly synthesized small molecule led to a profound depletion of Smad2/3 levels in HCT116 cells 
with similar or even higher efficacy compared with that of E738. 
 





Figure 9. Biotinylated E738's regulation of R-Smad protein levels is comparable to that of the 
parental molecule. (A) schematic representation of the synthesis procedure of biotin-conjugated E738 
(E738 B). (B) Immunoblots and the corresponding densitometric quantification (C), showing a 
concentration-dependent decrease of Smad2/3 in HCT116 and HEK-293 cells after 24 h treatment with 
E738 carrying the spacer region (E738 S), as indicated. 24 h treatment with E738 (1 M) was used as 
reference. (D) 24 h treatment with increasing concentrations of E738 B depletes non-activated Smad2/3- 
and Smad1/5/8 protein levels in a similar manner to that of the parental small molecule, E738. (E) 
Densitometric quantification of the Smad1/5/8 bands normalized to the respective loading control. Error 
bars indicate the SEM of at least two biological replicates, one of those is presented in (D) and (B). 
Vinculin served as the loading control. 0.1% DMSO was used as mock treatment.     
2.1.2. E738's effect on steady-state R-Smad levels is independent of that on receptor-activated 
R-Smads.  
As described above, most of indirubin derivatives are potent protein kinase inhibitors, among others, 
are kinases involved in the duration of R-Smad activation, for example GSK3 and CDKs [113, 148]. We 
could previously show that IRD E738 delays the degradation of activated pSmad1/5/8 in HeLa cells, an 
effect which was attributed to its kinase inhibitory function [148]. In the present research, the focus was 
drawn to the TGF-associated Smad2/3. HEK-293 cells–which were found to be one of the most 
sensitive cells based on the initial screen (see Figure 7)–were stimulated with a pulse of TGF1 (10 
ng/mL) for 1 h, followed by treatment with E738 (2.5 M) or not (Figure 10A). Similar to the effects of 
the small molecule on C-terminally phosphorylated Smad1/5/8, activated pSmad2 and pSmad3 levels 
were found to be stabilized in the presence of E738, as determined by immunoblotting and the 
respective densitometric quantification (Figure 10B and 10C). 
 





Figure 10. IRD E738 stabilizes the transcriptionally active Smad2/3. (A) schematic presentation of 
the treatment. HEK-293 cells were stimulated with TGF1 (10 ng/mL) 1 h prior to the addition of E738 
(2.5 M), thereafter were lysed at the indicated time points for immunoblotting. (B) The protein levels of 
C-terminally-phosphorylated Smad2/3 (pSmad2C and pSmad3C) are higher in the presence of E738 at 
most tested time points. (C) Densitometric quantification of pSmad2/3 bands normalized to total Smad2/3 
levels and the respective loading control (vinculin). Error bars ± SEM; n=2. Multiple comparisons were 
made by a two-way ANOVA test, followed by a post-hoc Tukey test. * presents a p-value less than or 
equal to 0.05.   
2.1.3. E738-mediated Smad2/3 reduction is linked to Smad stability. 
Given that the proteasome-mediated degradation is one of the major routes through which R-Smad 
signaling is regulated [52], we sought to see if the E738's effect on total R-Smad levels is associated 
with the stability of the protein. We had previously shown that ubiquitin-proteasome-mediated 
degradation is required for E738's depletion of both activated and non-activated R-Smads of both TGF- 
and BMP pathways in HeLa and HFF cell lines [148]. Focusing on TGF-related Smad2/3 levels in HEK-
293 cells, we found that co-treatment with the proteasome inhibitor, MG132, prevents E738-induced 
Smad2/3 depletion and increases the levels of C-terminally phosphorylated Smad2 (Figure 11A-E). In 
addition, the use of the protein synthesis inhibitor, cycloheximide (CHX) together with E738, further 
showed that the small molecule destabilizes total Smad2/3 protein levels, while it increases the stability 
of receptor-activated Smad2 (Figure 11). 
2.1.4. IRD E738 regulates TGF's target gene transcription.  
Our initial screen (see Figure 7) showed different degrees of E738-mediated R-Smad depletion 
among different cell lines. We therefore postulated that this may result from differential regulation of 
genes, among others, those encoding the key players of the ubiquitin-proteasome pathway. In light of 
this, comprehensive mRNA analyses using qRT-PCR revealed that most of the E3 ligases responsible 
for polyubiquitination of activated R-Smads, such as Smurf1/2 and NEDD4L are reduced in response to 
E738 (Figure 12A). This suggests that E738's modulation of E3 ligases is possibly not involved in the 
observed degradation of total R-Smads, which is in line with our previous report [148]. On the other 
hand, mRNA levels of a number of ubiquitin proteases, namely USP4, USP9x, and USP34 were found 
to be downregulated with treatment (Figure 12A), implicating a possible role for these enzymes in the 
small molecule's effects on R-Smad stability, as previously shown in case of USP9x and USP34 [148]. 
With regards to TGF/BMP target genes, we observed a clear reduction in the mRNA levels of 
ID1/2/3 transcription factors across all tested cell lines (Figure 12A), consistent with the inhibition of the 
signaling. Inhibitors of cell differentiation, IDs, are well known TGF- and BMP target genes during both 
normal development and cancer progression [159, 160]. For example, ID1 and ID2 expression is 
positively regulated by BMP in myoblasts, osteoblast-like cells, multiple myeloma, breast- and lung 
cancer cells, whereas ID3 gene expression is enhanced by TGF1 in progenitor- and mature B-
lymphocytes, as well as in glioblastoma [159]. The extracellular matrix (ECM) protein, CTGF, was 
consistently upregulated in response to E738, in contrast to our previous report in HeLa cells (Figure 
12A) [148]. CTGF is known to interact with a variety of molecules, including the growth factors; TGF, 





BMP4, and BMP7. Its interaction with TGF positively regulates the signaling pathway and its target 
genes, which includes CTGF itself, in order to stimulate ECM synthesis, mediating pro-fibrotic actions 
of this cytokine. On the other hand, the interaction of CTGF and BMP is rather antagonistic, inhibiting 
downstream mediators, such as Smad1. Interestingly, the TGF- and BMP target gene and the 
transcriptional corepressor, SKIL (coding for SnoN), was found to be regulated in a p53-dependent 
manner, i.e., in cells harboring wild-type (wt) p53 (HEK-293, HCT116 wt, and HEPG2) a decrease in its 
mRNA expression was observed, whereas in cells lacking wt p53 expression (HL-60 and HCT116 p53-
/-) the mRNA levels were induced (Figure 12A). SnoN and p53 have been shown to be related through 
several mechanisms, among others, is the interaction of SnoN with PML, which stabilizes p53, turning 
SnoN from being an oncogene into a tumor suppressor [161]. In addition to SnoN, we observed that 
several other genes, namely Smad7, DUSP14, c-Myc, and CDKN1A (coding for p21) are regulated in 
an opposite manner between wt- and p53-deficient cells (Figure 12A). To this end, we broadened our 
investigation by adding more p53 target genes (MDM2 and BBC3, encoding Puma) as well as by 
including an additional p53-null cell line, HEP3B, and observed a similar pattern (Figure 12A and 12B). 
This suggests a role for the p53 pathway in E738's mode of action, in particular the small molecule-
mediated cytotoxic and pro-apoptotic effects. The mRNA levels of Runx2, a cofactor of Smad 
transcriptional complexes and a well-known target of TGF1 and BMP2 [162] were reduced upon E738 
treatment across all tested cell lines (Figure 12A). Finally, the mRNA expression of TGF- and BMP 
receptors, ALK4 and ALK3 [2], respectively as well as that of R-Smads, downstream of both major 
pathways was found to be downregulated (Figure 12A) similar to their protein expression (see Figure 
7). With regards to other families of Smads, the common Smad, Smad4 showed a slight downregulation 
(Figure 12A), whereas Smad7 was found to be modulated p53-dependently, as mentioned earlier 
(Figure 12A). In view of this, it has been reported that p53 activation might mediate apoptosis in a 
Smad7-dependent manner [163]. 
2.2. "Linker" phosphorylation is involved in E738's effects on Smad 2/3 stability. 
2.2.1. The linker domain of Smad2/3 plays an important role in the E738-mediated reduction of 
Smad protein expression.  
As described above and schematically represented in Figure 13, R-Smad proteins share three 
structural regions: (i) DNA binding domain at their N-termini (MH1), (ii) the transcriptional activation 
domain at their C-termini (MH2), and (iii) the inter-domain linker region. We aimed to identify which of 
the three domains is most crucial to the regulation of R-Smad stability in response to IRD E738 with a 
focus on TGF-associated Smad2/3. For this, different constructs, including the wt protein, truncated 
forms, as well as Smad2/3 EPSM, possessing mutations in the Erk/proline-directed kinase sites were 
transiently over-expressed in HEK-923 cells, followed by treatment with E738 for 6 h. Taking a close 
look at the regulation of flag-tagged Smad expression in different mutants, we observed similar or even 
higher reduction of flag protein levels upon treatment in case of the C-terminally truncated Smad (Figure 
13B, 13C, 13F, and 13G). 





      
Figure 11. IRD E738-induced Smad2/3 depletion is most likely mediated via a reduction in R-Smad 
stability. (A) Treatment scheme performed in (B), (C), (F), and (G). HEK-293 cells were treated with a 
pulse of TGF1 (5 ng/mL) for 1 h after which the drugs, MG132 (10 M), CHX (100 g/mL), and E738 
(2.5 M) were added for the indicated time points. (B) and (C) Immunoblots and the respective 
densitometric quantification show that receptor-activated Smad2 (pSmad2C) is stabilized with E738 
treatment, an effect which is enhanced in the presence of the proteasome inhibitor, MG132. On the other 
hand, steady-state Smad2/3 protein levels (without TGF stimulation) are clearly reduced in response to 
E738 and appear to be partially rescued upon co-treatment with MG132 for 0.5 h, as shown by 





immunoblotting (D) and the corresponding densitometric analysis (E). SE; short exposure and LE; long 
exposure. (F) and (G) Concomitant treatment with the protein synthesis inhibitor, CHX demonstrates a 
higher protein stability of pSmad2C in the presence of E738, further showing the stabilization of the 
receptor-activated Smad2 by the small molecule. This is independent of E738's regulation of non-
activated Smad2/3 levels, which are reduced upon adding the molecule, and are further destabilized 
when cells are co-treated with CHX, as depicted by immunoblotting (H) and the respective quantification 
(I). actin and vinculin served as loading controls.    
              
Figure 12. Regulation of TGF-related gene expression by IRD E738. (A) mRNA expression 
analyses of several signaling molecules associated with the TGF/BMP pathway, including target genes 
(e.g., IDs) as well as signaling molecules responsible for the regulation of the pathway (ubiquitin ligases 
and deubiquitinases), assessed by qRT-PCR analysis of the indicated cell lines treated with 1 M of 
E738 for 24 h. (B) Multiple p53 target genes are differentially regulated between wild-type (wt) harboring 
cells and their p53-deficient counterpart upon 24 h treatment with E738 (1 M), as determined by qRT-
PCR. p53-related genes have been underlined in (A). Relative expression was calculated by the Ct 
method, with vinculin and/or actin as the housekeeping gene.    





As aforementioned, C-tail phosphorylation of Smad2/3 at the SXS motif by the active receptor complex 
is a prerequisite step in R-Smad/Smad4 complex assembly and nuclear localization, which later on, in 
cooperation with other phosphorylated residues, targets activated phospho-Smads for proteasomal 
degradation [35]. With this in mind, a clear reduction in the C truncates with treatment shows another 
proof of the E738's depletion of total Smad2/3 being independent of receptor-mediated activation (also 
see Figure 10 and Figure 11). Regarding the role of the MH1 (N-terminal) domain in the E738-mediated 
Smad depletion, we found less reduction in flag protein expression comparing Smad2 N and Smad3 N 
with wt Smad2/3 (Figure 13B, 13C, 13F, 13G). This suggests that the DNA binding domain, although 
being crucial to the transcription of target genes, is not sufficient for E738's regulation of Smad stability. 
Similar to Smad2 N and Smad3 N, forced expression of the MH2 (C-terminal) domain of Smad3 did not 
appear to cause a significant alteration in flag expression, while cells over-expressing the linker- and C-
terminal regions (Smad3 LC) showed similar levels of flag reduction, compared with that of full-length 
Smad3 (Figure 13F and 13G). Considering the aforementioned data, it is likely that the presence of the 
linker region is required for the E738-mediated R-Smad degradation. The linker domain is of particular 
interest due to the presence of multiple phosphorylation sites that are essential for the regulation of R-
Smad activity/stability, as well as its nuclear-cytoplasmic shuttling, as described earlier. In this regard, 
we observed that ectopic expression of Smad2/3 EPSM caused a greater E738-mediated reduction of 
flag expression, as compared to that of the wt protein, as well as several other truncates (Figure 13B, 
13C, 13F, and 13G). Smad2- and Smad3 EPSM carry mutations in several S/T residues that are 
phosphorylated by various protein kinases (see Figure 13A and 13D), most of which are inhibited by 
IRD E738, based on the in vitro kinase profiling (refer to Figure 19). The role of these kinases in the 
stability of ligand-activated Smads has been thoroughly demonstrated [35], whereas their significance 
in the regulation of steady-state R-Smad levels is yet to be fully understood. Our results from transient 
over-expression of mutant constructs suggest a possible role for MAPKs, CDKs, and GSK3 in controlling 
the half-life of non-activated Smad2/3.  
2.2.2. MEK1/Erk-mediated phosphorylation influences the stability of steady-state Smad2 and 
Smad3.     
We had previously shown that two branches of the noncanonical (non-Smad) TGF signaling, p38 
and JNK MAPKs are enhanced with E738 treatment [148]. In contrast to pp38 (T180/Y182) and pJNK, 
protein levels of active Erk1/2–pErk (T202/Y204)–were found to be significantly reduced in response to 
the indirubin derivative (Figure 14A-C) in HEK-293 as well as in CCA cell lines, which were used as a 
cancerous context. Having the E738-mediated inhibition of Erk1/2 in mind, we sought to further confirm 
the involvement of this kinase using known chemical inhibitors. In this regard, a more profound depletion 
of total Smad2 and Smad3 was observed when combining E738 with the MEK/Erk inhibitors, U0126 
and PD0325901 (Figure 14A, 14B, 14D, and 14E).  
Next, we tested if the proteasome inhibitor, MG132 is able of protecting Smad2/3 EPSM from E738-
mediated degradation. As shown in Figure 14F and 14G, in the presence of MG132, both Smad2- and 
Smad3 protein levels were partially recovered, suggesting that E738-mediated reduction of the latter 





constructs is most likely due to the proteasomal degradation. As aforementioned, Erk phosphorylation 
has been reported to stabilize Smad2 protein levels [21]. Using the translation inhibitor, CHX, we 
observed that the phosphorylation-defective mutant of Smad3 is less stable as compared to the wt 
protein, regardless of the treatment (Figure 14H). As expected, the addition of E738 further reduced 
the half-life of both wt Smad2/3 and Erk phosphorylation site mutants, compared with that of the non-
treated cells (Figure 14H-K). 
 
Figure 13. IRD E738-mediated Smad2/3 reduction relies on the linker (L) domain. (A) A schematic, 
illustrating the structural domains of full-length (FL) Smad2, as well as the three used mutant forms. The 
linker phosphorylation sites together with the involved kinases are depicted in Smad2 EPSM, which 
carries serine-to-alanine or threonine-to-valine (S-to-A/T-to-V) mutations in the indicated residues. All 
constructs are tagged with a flag sequence in their N-termini. (B) and (C) HEK-293 cells were transiently 
transfected with the constructs presented in (A), followed by E738 treatment (1 M, 6 h) 48 h post-
transfection. Smad2 levels were then monitored by the expression of flag. As shown by immunoblots (B) 
and the respective quantification (C), ectopic Smad2 EPSM demonstrates a significantly higher reduction 
in response to the small molecule, as compared to that of the FL protein. (D) Schematic presentation of 
Smad3 constructs used for the transient over-expression. C-tail- and linker phosphorylation residues as 
well as the responsible protein kinases are depicted in Smad3 EPSM schematic structure (D) and in 
wild-type Smad3 protein depicted in (E). (F) and (G) Representative immunoblots (F) and quantification 
(G) showing a greater reduction of Smad3 EPSM compared with the FL protein at 6 h post-treatment 
with E738. Additionally, ectopic expression of constructs lacking the linker domain (Smad3 N and Smad3 
C) abolished E738's depletion of Smad3, highlighting the significance of this region in the small molecule-





mediated R-Smad reduction. Error bars present the SEM of at least two biological replicates, one of 
which is shown in (B) and (F). Multiple comparisons were performed by a two-way ANOVA test, followed 
by a post-hoc Tukey test. * indicates a p-value less than or equal to 0.05. 0.1% DMSO served as mock 
treatment.       
 
Figure 14. Erk1/2 most likely plays an important role in IRD E738's regulation of Smad2/3 stability 
through modulating the phosphorylation of multiple S/T residues in the linker domain. (A-C) 
immunoblots (A) and (C) and the densitometric analysis (B) show a profound inhibition of Erk activity by 
E738 (24 h treatment with the indicated concentrations) in HEK-293 (A) and (B) as well as in 
cholangiocarcinoma cells (C). The small molecule inhibitor of Erk1/2/MEK, PD0325901 was used as 
reference. (D) and (E) Representative immunoblots (D) and the corresponding quantification (E), 
showing a more profound reduction in steady-state Smad2- and Smad3 levels upon treatment with E738 
(24 h) in combination with chemical inhibitors of Erk (PD0325901 and U0126). (F) and (G) The observed 
Smad depletion upon the ectopic expression of Smad2 EPSM- and Smad3 EPSM mutants is most likely 
due to Smad proteasomal degradation, judged by the partial rescue upon co-treatment with MG132. 
HEK-293 cells were transfected with either full-length (FL) Smad2/3 or the mutant construct (EPSM). At 
48 h post-transfection, cells were treated with E738 for 24 h, MG132 was added 6 h before lysing the 
cells. (H-K) The use of CHX (100 g/mL for the indicated time points) shows a reduction of Smad2/3 





stability in HEK-293 cells over-expressing either FL- or mutant Smad2/3, an effect which is enhanced in 
the presence of E738, as determined by immunoblotting and the respective quantifications. Error bars ± 
SEM, n = 2. Multiple comparisons were made using a two-way ANOVA test, followed by a post-hoc 
Tukey test. *, **, and *** represent p-values less than or equal to 0.05, 0.01, and 0.001, respectively.      
2.3. E738-mediated regulation of Smad2/3 stability is coupled to "phospho-Smad signaling".   
As abovementioned, the role of TGF signaling in cancer involves the dysregulation of phospho-
Smad2/3 signaling. The so-called "pSmad signaling" relies on linker phosphorylation (L) at multiple 
serine/threonine residues by CDKs, MAPKs, and GSK3, on the one hand, and the receptor-mediated 
C-tail phosphorylation (C), on the other hand (reviewed in [164]). Based on the kinases involved, 
different phosphorylated forms of Smads are created (see Figure 15A), that will either enhance- or 
suppress TGF responses associated with Smad stability and cancer progression. Given the 
mechanism of E738-mediated regulation of Smad turnover, which was shown to involve modulation of 
specific phosphorylation sites in the Smad2/3 linker domain, we were inclined to explore whether there 
is a link between the small molecule's effects and the Smad phospho-isoform pathways. 
 
Figure 15. The regulation of phospho-Smad (pSmad) signaling in cholangiocarcinoma (CCA). (A) 
The Smad2/3 pathway shifts between tumor suppression and tumor progression based on the different 





phosphorylation patterns, which are achieved by the action of various membrane bound- cytoplasmic- 
and nuclear kinases, as indicated. Such Smad phospho-isoforms induce distinct- and overlapping 
cellular phenotypes, as summarized in the blue box (thoroughly reviewed in [164]). (B) and (C) In the 
intrahepatic CCA cell line, CCSW1, C-terminally- and linker (L)-phosphorylated Smad3 are regulated in 
an opposite manner to one another, as detected by immunoblotting (B) and the respective densitometric 
quantification (C). (D) and (E) Immunohistochemistry (D) and immunoblotting (E) of a subgroup of CCA 
patient samples reveal a similar pattern of pSmad signaling compared with that of CCSW1 cell line in 
which the cytostatic pSmad3C- and the oncogenic pSmad3L levels are reduced and induced, 
respectively. Patient samples were analyzed in collaboration with the group of Prof. Steven Dooley 
(Heidelberg University, Germany).   
2.3.1. Phospho-Smad3 signaling is impaired in cholangiocarcinoma.   
Abnormal pSmad3 signaling has been shown to contribute to the pathogenesis of several human 
malignancies, such as colorectal- and liver cancers [164], however, its significance in the treatment of 
cholangiocarcinoma remains to be thoroughly investigated. We therefore sought to assess the 
relevance of different Smad3 phospho-isoforms to CCA, using healthy and tumorigenic tissues from 
patients, as well as a panel of patient-derived cell lines from both intra-(iCCA) and extra-hepatic (eCCA) 
origins. Importantly, we observed a cell-type specific regulation of pSmad3 signaling in the iCCA cell 
lines, CCSW1, showing a counter-regulation between the tumor-suppressive pSmad3C (S423/425)- 
and the oncogenic pSmad3L (S213) pathways (Figure 15B and 15C). Consistent with this, a subgroup 
of CCA patients displayed a similar pattern, as determined by immunohistochemistry and 
immunoblotting (Figure 15D and 15E). 
2.3.2. Erk/p38 MAPKs and GSK3 are involved in the regulation of phospho-Smad signaling in 
cholangiocarcinoma cells.  
As described above, various S/T kinases stemming from other pathways (e.g., MAPKs and Wnt 
signaling) phosphorylate Smad2/3 linker residues (see Figure 16A). In light of this, we sought to perform 
a kinase inhibitor screen in the iCCA cell line, CCSW1. As depicted in Figure 16B-D, different small 
molecule inhibitors, including SB-431542 (targeting TGFRI/ALK4/5/7), SP600125 (targeting JNK), 
U0126 (targeting MEK1/2/Erk), SB203580 (targeting p38), and CHIR (targeting GSK3) were incubated 
with the cells 1h prior to the treatment with TGF1 for 6h or not (Figure 16B). Looking into the 
phosphorylation status of the Smad3 linker domain, we found reduced levels of pSmad3 (S213) upon 
inhibition of p38/Erk MAPKs and GSK3, and a clear decrease of pSmad3 (S204) protein levels when 
targeting GSK3 in CCSW1 cells stimulated with TGF (Figure 16C and 16D). C-tail phosphorylated 
Smad3 (pSmad3C), on other hand, was found to be abolished upon treatment with the TGF receptor 
inhibitor (TGFRi), as expected, and was induced with the rest of the inhibitors (Figure 16C and 16D). 
This could be explained by linker phosphorylation being a prerequisite step in the recognition of R-
Smads by the ubiquitin ligases, followed by proteasome-mediated degradation [35]. Altogether, these 
results suggest the requirement of MEK1/2/Erk- and p38 MAPKs, as well as GSK3 in the Smad3 linker 
phosphorylation in CCA cells. 






Figure 16. The oncogenic pSmad3L signaling in cholangiocarcinoma (CCA) cells is mediated via 
the action of various S/T kinases. (A) A scheme illustrating an intricate crosstalk between the canonical 
TGF signaling, which is mediated through the ALK4/5/7-mediated phosphorylation of Smad2/3 at the 
SXS motif located in the MH2 (C-terminal) domain, and the noncanonical pathways, such as MAPKs, 
which are induced by various growth factors and the TGF receptors themselves. The canonical- and 
noncanonical pathways come together onto Smads through post-translational modifications (e.g., 
phosphorylation) of the linker domain, as depicted. Although linker phosphorylation occurs regardless of 
TGF stimulation via the action of intracellular kinases (CDKs, MAPKs, and GSK3), it is enhanced in the 
presence of the ligand [165]. (B) Treatment scheme for the kinase screen shown in (C) and (D). CCSW1 
CCA cells were pre-treated for 1 h with the indicated inhibitors at a concentration of 10 M, followed by 
the addition of TGF1 (5 ng/mL for 6 h) or not. For more details regarding the tested kinase inhibitors 
see the text above. (C) and (D) Representative immunoblots (C) and the respective quantifications (D), 
showing the involvement of Erk- and p38 MAPKs as well as GSK3 in the regulation of pSmd3L signaling 
in CCA. Multiple comparison was performed using a two-way ANOVA test, and a post-hoc Tukey test. 
Error bars indicate the SEM of at least two biological replicates. *** denotes a p-value less than or equal 
to 0.001.  
2.3.3. The oncogenic phospho-Smad3 signaling appears to be abrogated by the IRD E738.   
As aforementioned, IRD E738 is a multiple kinase inhibitor ([148], also see Figure19), similar to 
most of indirubin analogues [113]. Considering the role of MAPKs and GSK3 in the regulation of Smad3 
phospho-isoforms, we hypothesized that E738 can reduce pSmad3L levels through a mechanism 





similar to that of the abovementioned kinase inhibitors (see Figure 16). We therefore used our panel of 
patient-derived CCA cell lines, and tested E738's effects on pSmad3C (S423/425) and pSmad3L 
(S204/213) protein levels. As shown in Figure 17 Upon treatment with E738 and its biotinylated form–
referred to as E738 B–a clear reduction in the protein levels of pSmad3L (S204/213) was observed in 
the absence/presence of TGF stimulation. The protein expression of pSmad3C, on the other hand, 
showed an opposite pattern, with significantly higher levels when compared to those of pSmad3L (for 
more details see Figure 17). 
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Figure 17. IRD E738 inhibits the carcinogenic Smad3 phospho-forms in a panel of patient-derived 
cholangiocarcinoma (CCA) cell lines. (A-D) 24 h treatment with the indirubin derivative, E738 and its 
biotinylated form (E738 B) has a strong inhibitory effect against Smad3 linker phosphorylation (204 and 
213 serine residues) in extrahepatic CCA cells, CCC5 and GBC, as illustrated by the representative 
immunoblots and their respective densitometric analyses. (E-H) A similar pattern of E738's regulation of 
Smad phospho-isoforms was detected in case of the intrahepatic CCA cell lines, CCSW1 and HUCCT1. 
(I) The reduction of Smad3 linker phosphorylation could be also observed upon TGF1 stimulation (5 
ng/mL) prior to the addition of E738 (5 M) at the indicated time points. In contrast to pSmad3L levels, 
the protein levels of the cytostatic pSmad3C were found to either remain stable or even increased. 
Quantifications of the immunoblots were performed by normalizing the pSmad3 levels to the respective 
total Smad3 levels and loading controls (vinculin and actin). Error bars represent the SEM of three 
biological replicates. Statistical significance between mock (0.1% DMSO) and E738 treatment was 
calculated using a one-way ANOVA test, and a post-hoc Tukey test. *, **, and *** indicate p-values less 
than or equal to 0.05, 0.01, and 0.001. A color code is used to distinguish between intra- and extrahepatic 
CCA cells, with blue indicating the former and red indicating the latter.    
2.3.4. E738 synergizes with known kinase inhibitors, targeting MEK1/2/Erk, GSK3, and CDK to 
reduce pSmad3L protein levels.   
Based on the results from the kinase inhibitor screen (see Figure 16), we were inclined to investigate 
the combinatory effects of pharmacological inhibitors of the involved kinases and IRD E738 on pSmad3L 
protein levels. As shown in Figure 18, the concomitant use of the Erk1/2 MAPK inhibitor (U0126) with 
E738 led to a more profound reduction of pSmad3L (S213) protein levels, as compared to single-
treatments in HUCCT1 and CCSW1 iCCA cell lines. GSK3 and CDK inhibition showed similar effects 
on S213 phosphorylation status when combined with E738 in the CCSW1 cell line, whereas p38 
blockage was not found to induce a major alteration in the pSmad3L levels in our experimental setting 
(Figure 18). With regards to the S204 residue, which is known to be phosphorylated by Erk and p38 





MAPKs, as well as by GSK3, we observed a mild decrease in its phospho-levels upon treatment with 
most inhibitors, as expected, in CCSW1 cells. This effect, however, was not found to be clearly 
enhanced in the presence of E738 (Figure 18). Collectively, these results further confirm the 
involvement of Erk1/2/MEK, p38, and GSK3 in the regulation of pSmad3L signaling. Furthermore, they 
suggest a potential synergy between indirubin derivatives and small molecule inhibitors of the 
aforementioned kinases, which is most likely due to the simultaneous targeting of multiple protein 
kinases involved in Smad3 linker phosphorylation.  
 
Figure 18. IRD E738 synergizes with other S/T kinase inhibitors to reduce Smad3 linker 
(pSmad3L) phosphorylation. The intrahepatic cholangiocarcinoma cell lines, HUCCT1 and CCSW1 
were treated with E738 or the inhibitors of Erk1/2 (U0126), p38 (SB203580), GSK3 (BIO), and CDK 
(Flavopiridol, also known as Alvocidib) kinases at the indicated concentrations for 24 h with TGF1 (5 
ng/mL) pre-treatment for 1 h. Immunoblotting was then performed using site-specific antibodies against 
pSmad3L. As indicated by red asterisks, the combination of the indirubin derivative (E738) and Erk- 





GSK3- and CDK inhibitors causes a more profound reduction in pSmad3L levels. Vinculin was used as 
the loading control.   
2.3.5. The kinase inhibitory activity is most likely indispensable to the E738-mediated Smad2/3 
reduction, as well as to the inhibition of phospho-Smad3 signaling. 
To further investigate whether the E738's kinase inhibitory function has a role in mediating R-Smad 
depletion and pSmad3L inhibition, we aimed to synthesize a kinase-inactive analogue of E738 by 
replacing the H-atom at 1-position with a methyl group, expecting to impair the binding ability of the 
small molecule to the kinases' ATP-binding pocket (see Figure 19 and Figure 20). The resulting 
derivative–referred to as XC47–showed no significant inhibitory activity when screened against 410 
kinases (see the results from the in vitro kinase profiling, Figure19). Looking at steady-state 
Smad2/3 protein levels, we observed no major alteration in response to various concentrations of XC47 
as compared to its parental derivative, E738, in all tested CCA cell lines (Figure 20). Additionally, the 
small molecule failed to inhibit the oncogenic pSmad3L (S213) protein expression (Figure 20), 
suggesting that E738's inhibition of protein kinases is essential to the observed R-Smad depletion and 
the regulation of linker phosphorylation. This is consistent with our previously published results on two 
7'-aza-indirubin derivatives, namely E846 and E847, which could neither deplete total R-Smads nor 
inhibit phosphorylation of Stat3, due to the lack of kinase inhibitory activity [148]. 
 
Figure 19. E738 is a strong kinase inhibitor, blocking the activity of several kinases responsible 
for Smad linker phosphorylation, an effect which is lost in case of XC47 (also see Figure 20). In 
vitro kinase profiling of 0.5 M of E738 and its kinase-inactive counterpart, XC47 in a screen 
encompassing 410 wt- and mutant kinases (WildType+ 2Point-Profiler from ProQuinase). TGF 
signaling-related protein kinases with more than 50% inhibition by E738 are presented and the size of 
circles conversely correlates with %residual activity. A color code has been used for discrimination 
between different families of kinases, with blue indicative of CDKs, green indicative of JNK MAPKs, 





yellow indicative of Erk MAPKs, red presenting GSK3, pink representative of MAPKKKs, orange 
presenting TGFRII (TGFbR2), and violet showing MAPKKs. The dashed circle highlights the kinases 
directly involved in Smad linker phosphorylation. The map is generated using the open-access web-
based tool described by Eid et al. [166] and the illustration reproduced courtesy of Cell Signaling 
Technology, Inc.  
   
Figure 20. IRD E738's regulation of Smad3 linker phosphorylation is, at least in part, linked to 
total Smad3 degradation and the kinase inhibitory function of the molecule (also see Figure 19). 
(A) Chemical structures of E738 and its kinase-inactive analogue, XC47. The H-atom in E738 is replaced 
with a methyl group in XC47 (colored in red) in order to disturb its binding ability to the ATP-binding 
pocket of protein kinases. The methoxy- and propanediol moieties (colored in blue), which have been 
previously shown to enhance indirubin-mediated Smad2/3 reduction were kept in the new derivative 
[148]. (B) Intra- and extrahepatic cholangiocarcinoma cells (colored in blue and red, respectively) were 
treated with increasing concentrations of XC47 and 5 M of E738 for 24 h, as indicated. Unlike E738, 
XC47 was not found to be capable of depleting non-activated Smad2/3 protein levels, as well as Smad3 
linker phosphorylation, suggesting a role for the kinase inhibition in the observed effects. Vinculin and 
actin served as loading controls.    
2.4. phospho-Smad3L signaling in cholangiocarcinoma cells is associated with tumorigenic 
behavior.   
2.4.1. Concomitant inhibition of TGF/Smad signaling, Erk/p38 MAPKs, and GSK3 appears to 
have synergistic cytotoxic effects in cholangiocarcinoma cells.  
In addition to the inhibition of TGF signaling through depletion of steady state Smad2/3 pools, E738 
blocks the activity of Erk1/2 (see Figure 14) and several other kinases, among others, GSK3 and CDKs 
(see Figure 19). Putting this in the context of cholangiocarcinoma, it has been reported that blocking 
the canonical TGF pathway, as well as the noncanonical signaling (e.g., Erk MAPKs) is an effective 
approach for inducing cytotoxic- and apoptogenic responses in human CCA cells [167, 168]. We 
therefore aimed to examine whether the E738-mediated inhibitory effects on Smad2/3 stability as well 
as pSmad3L signaling relate to the small molecule's cytotoxic response in CCA cells. Moreover, we 
sought to compare the E738-mediated cytotoxicity with that of other known kinase inhibitors, looking for 





any potential combinatory effect. As shown in Figure 21, different eCCA and iCCA cells were treated 
with increasing concentrations of E738, BIO (GSK3 inhibitor), SB203580 (p38 MAPK inhibitor), and 
U0126 (Erk1/2 inhibitor) as mono-treatments and a combination of E738 with either of the three 
inhibitors. Cellular viability was then assessed using SRB and MTT assays. We observed lower cellular 
survival percentages when using E738 together with the pharmacological inhibitors of GSK3, Erk1/2- 
and p38 MAPKs in the intrahepatic HUCTT1 cell line as compared to single-treatments, assessed by 
SRB assay (Figure 21A). With regards to the extrahepatic GBC cells, changes in cellular survival were 
less profound as compared to other cells and were found to be significant only when E738 was combined 
with BIO and with 20 M of U0126 (see Figure 21A, results of the SRB assay). We broadened our 
investigation by including more cell lines from either intra- or extra-hepatic origin and observed a similar 
cytotoxic response in the CCSW1 cells compared with that of HUCCT1, i.e., significantly reduced 
cellular survival when using a combination of E738 with either BIO or U0126 compared with either small 
molecule alone, as measured by MTT cytotoxicity assay (Figure 21B and 21C). Importantly, the 
combination of E738 and BIO led to the highest toxicity in all tested cells, and in CCC5 cells was found 
to be the only combination, which led to a significant decrease in cellular viability, as compared to single-
treatments (Figure 21B and 21C). Additionally, we determined the coefficient of drug interaction (CDI) 
for combinatorial treatments to better describe the nature of drug combination outcomes. CDI is 
calculated as follows; (A+B)/A*B, a CDI of <1 was defined as synergistic, =1 as additive, and >1 as 
antagonistic. Several combinations were found to induce synergistic effects, however, as 
aforementioned, the "E738 and BIO combination" showed the lowest CDI across all tested cell lines 
(Figure 21B). 
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Figure 21. Inhibition of TGF signaling in combination with blocking Erk1/2- p38- and GSK3 
kinases induces synergistic effects on cholangiocarcinoma cytotoxicity. (A) The intrahepatic CCA 
cells, HUCCT1 and the extrahepatic GBC cells were treated with various concentrations of E738 and 
small molecule inhibitors of Erk/MEK, p38, and GSK3 for 24 h. For combination treatments, increasing 
concentrations of E738 were combined with the indicated concentrations of each of the kinase inhibitors. 
For more information regarding the name of the kinase inhibitors see the text in 2.4.1. Cytotoxicity 
was then measured, using SRB assay. (B) The intrahepatic CCSW1 and HUCCT1 as well as the 
extrahepatic CCC5 cell lines were treated with increasing concentrations of E738 and the inhibitors 
targeting Erk/MEK- and GSK3 kinases, as single-treatments, and the combination of various 
concentrations of E738 and fixed concentrations of Erk/MEK- and GSK3 inhibitors, as indicated. MTT 
cytotoxicity assay was performed at 24 h post-treatment. The combination index (CDI), which is indicative 
of nature of drug combination, was then calculated using the "(A+B)/A*B" formula. A CDI less than 1 is 
considered a synergistic effect. (C) E738 (5 M), MEK- and GSK3 chemical inhibitors (10 M), as well 
as a combination of E738 with each of the latter drugs were employed on different cell lines and MTT 
assay was carried out after 24 h. Based on the data obtained from SRB and MTT assays, the combination 
of E738 and BIO (GSK3 inhibitor) appears to induce the highest synergy in all tested cell lines. 
Percentage cellular viability was determined as the number of treated- over control (0.1% DMSO) cells. 
Error bars indicate the SD of at least three independent experiments, each done in triplicates. Multiple 
comparisons were performed using a two-way ANOVA test, followed by a post-hoc Tukey test. *, **, ***, 
and *** denote p-values less than or equal to 0.05, 0.01, 0.001, and 0.0001, respectively. A color code 
is used to distinguish between intra- and extrahepatic CCA cell lines, with blue representative of the 
former and red representative of the latter.       
2.4.2. IRD E738 induces apoptotic/necrotic cell death in cholangiocarcinoma cells, an effect 
which is also observed with GSK3 chemical inhibition.     
Based on the promising data obtained from cytotoxicity assays (see Figure 21), we sought to see 
whether the E738-mediared pro-apoptotic effects, in addition to that of the cytotoxic effects, could be 
enhanced upon combining the small molecule with other known S/T kinase inhibitors involved in Smad3 
linker phosphorylation. Using annexin V/propidium iodide (AV/PI) staining, we could show that E738 
treatment results in the transition of cells through the early apoptotic quadrant (AV+/PI-) in CCSW1 and 
HUCCT1 intrahepatic CCA cell lines (Figure 22A and 22B). Chemical inhibition of MEK1/2/Erk using 
U0126 was not found to cause a significant change in the number of early- or late apoptotic/necrotic 
(AV+/PI+) cells. In addition, its combination with IRD E738 was not found to enhance the pro-apoptotic 
response of the latter in our experimental setting (Figure 22A). On the other hand, the indirubin 
derivative, BIO, which is known to be a potent GSK3 inhibitor (recently reviewed and originally 





described in [113, 127], respectively) showed a clear increase in the number of late apoptotic/necrotic 
cells at the tested concentration in both HUCCT1 and CCSW1 cell lines (Figure 22A and 22B). 
Combining E738 and BIO demonstrated a similar apoptogenic response compared to that of BIO alone 
but significantly higher than that of E738 (Figure 22A and 22B), suggesting that the observed apoptosis 
is mostly mediated by BIO. It has to be taken into concentration that the concentrations used and/or 
duration of the treatment have a crucial role in the small molecules' pro-apoptotic effects, and hence a 
concentration/time-dependent assay appears to be necessary in order to draw a precise conclusion with 
regards to the pro-apoptotic effects of each of the molecules alone and in combination. Despite this, we 
could show strong apoptosis in response to GSK3 chemical inhibition by BIO, which fits well with the 
results of SRB/MTT assays wherein BIO and its combination with E738 induced the most potent 
cytotoxic effects (also see Figure 21).  
     





Figure 22. The indirubin derivatives–E738 and BIO–induce pro-apoptotic effects in 
cholangiocarcinoma cell lines. (A) 24 h treatment with 5 M of E738 increases the number of early 
apoptotic cells (AV+/PI-) in HUCCT1 and CCSW1 cells, as determined by flow cytometric analysis of 
annexin V/propidium iodide (AV/PI) staining. BIO, the GSK3 small molecule inhibitor (designated as 
GSK3i) induces late apoptotic/necrotic cell death (AV+/PI+) at the tested concentration and time point (10 
M for 24 h). U0126, which targets Erk MAPKs (designated as MEK1/2i) was not found to cause a major 
change in the apoptotic population. Percentage cell population in each quadrant was normalized to the 
respective mock (0.1% DMSO) treatment. (B) Representative density plots illustrate a clear transition 
towards the AV+/PI- and AV+/PI+ quadrants upon treatment with E738 and BIO (GSK3i), respectively. 
Data in (A) present mean  SD of three biological replicates, one of which is depicted in (B). Multiple 
comparisons were made using a two-way ANOVA test, and a post-hoc Tukey test. **** denotes a p-value 
less than or equal to 0.0001.       
2.4.3. IRD E738 regulates mRNA expression of multiple signaling molecules associated with 
apoptosis and EMT in cholangiocarcinoma cells.   
 
Figure 23. IRD E738's regulation of genes involved in apoptosis and EMT in cholangiocarcinoma 
cells. (A) HUCCT1 and GBC cholangiocarcinoma cells were treated with 5 M of E738 for 24 h, after 
which qRT-PCR was performed for assessing the mRNA levels of genes related to cytotoxicity and 
apoptosis. In GBC, E738 appeared to induce the pro-apoptotic molecules, p53 (coded by TP53), p21 
(coded by CDKN1A), Bax, and Bad. In HUCCT1, a similar pattern was observed with an exception for 
CDKN1A, which showed no significant alteration with E738 treatment. c-Myc, a well-known oncogene 
and a crucial mediator of TGF-mediated cellular invasion, was found to be strongly reduced by the small 
molecule in both cell lines. (B) E738 (5 M, 24 h) up/downregulates/ E/N-cadherin (coded by CDH1/2, 
respectively) as well as the pro-EMT molecule, SNAIL2 (also known as Slug, coded by SNAI2) in 
HUCCT1 cells, suggesting the possibility of EMT suppression in cholangiocarcinoma by the indirubin 
derivative. Relative mRNA expression was calculated using the  Ct method where the Ct values of 
each gene were normalized to those of the housekeeping gene (vinculin) and mock (0.1% DMSO) 
treatment. Data represent mean of two biological replicates, each done in triplicate. A color code is used 
to distinguish between intra- and extrahepatic CCA cells, with blue presenting the former and red 
presenting the latter.          
Based on the results obtained from MTT/SRB cytotoxicity assays and flow cytometric analysis of 
apoptosis (refer to Figure 21 and Figure 22), we aimed at investigating the regulation of multiple genes 
related to pro-apoptotic and anti-proliferative effects in response to E738. As shown in Figure 23A, the 
small molecule was found to upregulate the mRNA levels of several pro-apoptotic- and anti-proliferative 





genes in HUCCT1 and GBC cell lines, namely TP53 (coding for the tumor suppressor, p53), p53's 
downstream gene and the cell cycle regulator, CDKN1A (coding for p21), as well as the anti-survival 
BCL2 family members, Bax and Bad. In addition to this, we observed a strong downregulation of the 
proto-oncogene and one of the key molecules of the TGF-induced cytostatic program, c-Myc (Figure 
23A), altogether suggesting an induction of the apoptogenic program by the molecule. Additionally, we 
sought to assess the status of genes mediating the epithelial-to-mesenchymal transition. As thoroughly 
described in the introduction, EMT is one of the key biological features of the TGF pathway in cancer 
and development, which is mostly mediated through crosstalks with TGF's noncanonical signaling 
networks, such as Erk/p38/JNK MAPKs [79] (for more details see sections 1.1.3. and 1.1.5.2.). In 
cholangiocarcinoma, inhibition of canonical- and noncanonical TGF signaling has been shown to be 
an effective therapeutic approach through blocking TGF-induced EMT [167, 169-171]. In light of this, 
we looked into the regulation of multiple EMT-associated genes by E738 and found increased and 
decreased mRNA levels of CDH1 (coding for E-cadherin) and SNAI2 (coding for SNAIL2, also known 
as Slug), respectively (Figure 23B). This might suggest the ability of the small molecule in inhibiting the 
EMT process in CCA cell lines, which however requires in depth investigation of the signaling molecules 
involved, as well as the functional assays such as the cellular migration/invasion analyses. Other tested 
EMT-associated genes, VIM (encoding vimentin) and TWIST1 remained either stable or slightly 
increased in response to E738, and CDH2, which codes for N-cadherin was found to be downregulated 
by E738 in case of HUCCT1 and upregulated in case of GBC (Figure 23B).      
2.5. The direct interaction of IRD E738 with components of the ubiquitin-proteasome pathway 
appears to have a role in the control of R-Smad stability. 
2.5.1. Biotinylated E738 displays decreased and increased binding to several subunits of the 
proteasome complex.  
As described in the section 2.1.1.1., we have synthesized the biotin-conjugated small molecule 
(designated as E738 B) and confirmed its biological functions with respect to TGF/Smad signaling (see 
Figures 9 and Figure 17). We then performed pull-down assays in vitro and in cells followed by mass-
spectrometry analyses in order to identify E738 B's interacting partners. As depicted in Figure 24A, we 
could find some hits with key roles in the proteasome complex, showing either increased or decreased 
binding to biotinylated E738, as compared to that of biotin- and mock-treated cells. The proteasome 
complex consists of two subcomplexes: (i) the 20S catalytic core and (ii) the 19S regulatory particles 
[172]. The former includes four hetero-heptameric  rings that are flanked on either side by two  rings; 
PSMA3 and PSMA6 are  subunits of the 20S core particle and PSMD4 is a subunit of the regulatory 
particle (see Figure 24B) [172]. To validate these hits, we used siRNA-mediated knockdown of the 
aforementioned subunits and monitored for Smad2/3 reduction in response to E738 B treatment. As 
determined by immunoblotting and the respective densitometric quantification, upon inhibition of 
PSMA3, the small molecule-mediated Smad2/3 degradation was found to be less efficient (Figure 24C 
and 24D), suggesting that this subunit may contribute to E738's mode of action with regards to 
modulation of R-Smad stability. In case of PSMD4, the basal levels of Smad2/3 appeared to be 





decreased, thus causing a further reduction in the protein levels upon drug treatment (Figure 24C and 
24D). 
  





Figure 24. Proteasome complex subunits might be responsible for IRD E738-mediated steady-
state Smad2/3 degradation. (A) HCT116 cells were incubated with E738 (5 M) for 24 h, after which 
cell lysates were pulled down using immunoprecipitation by streptavidin beads, ran on SDS-PAGE, and 
analyzed by mass-spectrometry. Red and blue in the heatmaps are indicative of proteins with more- and 
less binding ability to biotin-conjugated E738, respectively. Data were normalized to the respective biotin-
only-treated cells and mock (0.1% DMSO) treatment. (B) A schematic taken from Bhattacharyya et al. 
[172], illustrating the proteasome complex structure, which consists of the 20S catalytic core and the 19S 
regulatory particles. Hits obtained from our proteomics analysis, PSMA3/6 are  subunits of the 20S 
particle, and PSMD4 is a subunit of the 19S regulatory particle (Rpn10). (C) and (D) PSMA3/6 and 
PSMD4 were knocked-down (KD) in HCT116 cells using the respective siRNA. A non-targeting siRNA 
was used as the negative control (designated as siRNA NC). At 48 h post-transfection, cells were treated 
with E738 B at the indicated concentrations for 24 h. As shown by representative immunoblots (C) and 
the corresponding densitometric quantifications (D), knocking down PSMA3 leads to a less profound 
Smad2/3 reduction, whereas genetic inhibition of PSMD4 causes a greater depletion of total Smad2/3 
levels by E738 B. actin served as the loading control. Error bars  SEM, n = 3. Statistical significance 
was made between the negative control and knockdown cells using a one-way ANOVA test, and a post-
hoc Tukey test. * denotes a p-value less than or equal to 0.05.         
2.5.2. Biotinylated E738 demonstrates a direct interaction with several E3 ubiquitin ligases.  
Next, we looked for hits from the family of E3 ubiquitin ligase enzymes in the in vitro proteomics 
analyses (Figure 25A), and found several E3 ligases, showing a direct interaction with biotinylated 
E738. These include HERC5 from the HECT-domain containing family of E3 ligases as well as the 
RING-domain enzymes, RNF2 and RBBP6. Using siRNA-mediated repression of the respective genes 
followed by E738 B treatment or not, we found significantly higher Smad2/3 protein levels when knocking 
down RBBP6 compared with that of the non-targeting siRNA (Figure 25B). Inhibition of HERC5 and 
RNF2 genes demonstrated no major alteration either in basal Smad2/3 levels or in its levels upon small 
molecule treatment (data not shown).  
In addition to the aforementioned enzymes, we included two other E3 ubiquitin ligases in our siRNA 
screen, MDM2 and VHL. MDM2 is a RING domain-containing protein ligase with the tumor suppressor, 
p53 being its primary target [173]. We could previously show a p53-dependent regulation of cytostatic 
genes with E738 treatment, which was further confirmed by an opposite pattern of p53 target gene 
expression–including MDM2–between cells harboring wt p53 or not (see Figure 12). Additional 
experiments showed a strong accumulation of p53 protein levels with treatment due to an increase in 
the stability of the protein by E738, which most likely involves p53's negative regulator, MDM2 (data not 
shown). This prompted us to look for the effects of MDM2 on E738-mediated Smad2/3 depletion, using 
genetic repression of MDM2. As shown in Figure 26A, in MDM2-knockdown cells, basal levels of 
Smad2/3 appear to be elevated regardless of E738 treatment. A similar pattern was observed in case 
of VHL knockdown, where baseline Smad2/3 showed a profound increase, which in turn led to higher 
protein levels in E738-treated cells compared with that of the negative control (Figure 26B). VHL is the 
substrate recognition subunit of the von Hippe-Lindau (VHL) E3 ligase complex with hypoxia-inducible 
factor 1 (HIF 1) being its main substrate [174]. The increased Smad2/3 protein levels upon genetic 
inhibition of VHL stimulated us to investigate whether this E3 ligase is related to R-Smad protein stability, 
irrespective of E738 treatment. For this, we first knocked down both E3 ligases–MDM2 and VHL–whose 
repression was shown to increase baseline Smad2/3 protein status. As demonstrated in Figure 26C, 





upon dual inhibition of MDM2 and VHL, we observed a clear induction in Smad2/3 protein levels, which 
was found to be clearly higher than MDM2 knockdown, but not significantly different than that of VHL, 
suggesting that the effects are most likely resulting from VHL repression. In addition, we checked for 
the protein levels of BMP-related Smad1/5/8 and found higher levels in case of VHL knockdown 
compared with negative control, however, the effect was less profound than that of Smad2/3 (Figure 
26C). We then tested TGF target gene expression in cells transfected with siRNA against VHL, MDM2, 
or both and compared it with that of the negative control, using qRT-PCR. As shown in Figure 26D, 
most of TGF target genes namely, ID1, ID2, ID3, and CTGF were found to be upregulated in 
MDM2/VHL-knockdown cells. ID3 and CTGF showed the highest fold change in mRNA expression 
compared with negative control in case of both single- and double knockdown cells (Figure 26D). 
Importantly, Smad2- and Smad3 mRNA levels were found to be either unaffected or reduced, 
respectively (Figure 26D), implicating that the strong accumulation of proteins is most probably not 
controlled transcriptionally, but rather directly at the protein level. Consistent with the upregulation of 
TGF target genes, protein levels of the transcriptionally active Smad3–pSmad3 (S423/425)–were 
found to be increased in VHL-knockdown HEK-293 cells (Figure 26E).   
 
Figure 25. The E3 ubiquitin ligase, RBBP6 might be responsible for E738-mediated Smad2/3 
degradation through a direct protein-small molecule interaction. (A) Schematic illustration of the in 
vitro streptavidin-based immunoprecipitation. HCT116 cell lysates were incubated with biotin-conjugated 





E738 (E738 B) at a concentration of 100 M for 24 h, then pulled down by streptavidin beads, followed 
by SDS-PAGE and mass-spectrometry (MS) analyses. (B) One of the hits obtained from MS analysis, 
the E3 ligase RBBP6, was genetically repressed (KD) in HCT116 cells using siRNA. 48 h after 
transfection, cells were treated with increasing concentrations of E738 B for 24 h. A non-targeting siRNA 
was used as the negative control (denoted as siRNA NC). Immunoblots (top) and the respective 
quantification (bottom) demonstrate a more profound reduction of Smad2/3 in the presence of RBBP6, 
suggesting the involvement of this E3 ubiquitin ligase in the E738's regulation of Smad2/3 stability. 
Vinculin served as the loading control. Red asterisks highlight the difference in Smad2/3 protein 
expression between the negative control and RBBP6-knockdown cells. Statistical significance was 
calculated between mock (0.1% DMSO) and E738 B treatment using a one-way ANOVA test, and a 
post-hoc Tukey test. Error bars represent the SEM of three biological replicates. * indicates a p-value 
less than or equal to 0.05.        
 





Figure 26. Smad2/3 might be a new substrate for the E3 ubiquitin ligases, MDM2 and VHL. (A-C) 
The RING-finger ubiquitin ligase, MDM2, as well as VHL were knocked-down (KD) either individually or 
simultaneously in HCT116 cells. At 48 h post-transfection, cells were treated with various concentrations 
of biotin-conjugated E738 (E738 B) for 24 h, then immunoblotting was performed. Cells were transfected 
with a non-targeting siRNA (denoted as siRNA NC) as the negative control. (A) We found that in MDM2-
knockdown cells, steady-state Smad2/3 protein levels are increased regardless of the treatment. p53 
was used as reference, as it is the most well-known substrate for MDM2. (B) A similar pattern (regarding 
the Smad2/3 baseline status) was observed upon siRNA-mediated suppression of VHL. Importantly, 
VHL protein levels were concentration dependently decreased with E738 B treatment. (C) Dual inhibition 
of MDM2 and VHL revealed that the increase in basal Smad2/3 protein expression is most likely more 
efficient in VHL-knockdown cells. (D) qRT-PCR analysis of TGF target genes as well as Smad2/3 upon 
genetic inhibition of MDM2, VHL or both, as indicated. We found a profound upregulation of ID3 and 
CTGF in VHL-knockdown cells and a mild upregulation of ID1/2 in the double knockdown cells, 
suggesting the activation of the TGF/Smad pathway in the absence of the E3 ligases. mRNA expression 
of Smad2 and Smad3, on the other hand, was found to be either unchanged or decreased, respectively, 
implicating that the observed accumulation of proteins occurs independently of the transcriptional 
regulation. Data present the mean of two biological replicates, each done in triplicates. (E) Knocking 
down VHL in HEK-293 pre-treated with TGF1 (5 ng/mL, 1 h) demonstrates an increase in the protein 
levels of the receptor-phosphorylated Smad3 (pSmad3 (S423/425)), further showing the activation of the 
signaling.           
Altogether, our in vitro and cell-based proteomics analyses suggest RBBP6 as a direct 
binding partner of E738, which most probably plays a critical role in E738-mediated R-Smad 
degradation. Additionally, our results from the siRNA screen implicate Smad2/3 as a potential 
new substrate for MDM2 and VHL E3 ubiquitin ligases. In both cases, further experiments are 
required in order to confirm ubiquitination of Smad2/3 by the abovementioned protein ligases 
upon E738 treatment or at the basal level. In addition to this, the biological outcome of increased 
Smad2/3 protein levels (in the context of development and/or cancer) as a result of VHL 
repression is an exciting topic for future experiments.  
 
  




The idea of the work presented in this chapter was initially sparked by our previous knowledge in the 
group regarding the contribution of total R-Smads to the control of TGF- and BMP signal transduction 
pathways. As thoroughly discussed in the introduction (see section 1.1.4.), TGF/BMP signaling is 
regulated at several separated levels and through various mechanisms, among others, is the 
ubiquitination of receptor-activated R-Smads, which marks them for degradation, and hence limits the 
duration of TGF/BMP/Smad signaling. Unlike transcriptionally active R-Smads, steady-state (total or 
non-activated) pools of TGF- and BMP central mediators have not been considered to be a major 
regulatory mechanism of the pathways. The results of this chapter illuminate this poorly investigated 
matter using small molecule approaches. In particular, we could show the interference of multiple 
indirubin derivatives with TGF signaling in the following ways: (i) reduction of steady-state 
Smad2/3 pools and (ii) stabilization of transcriptionally active Smad2/3. Detailed analyses of the 
small molecules' actions revealed that the two aforementioned effects, at least in part, reconcile 
on the kinase inhibitory function of indirubin derivatives. Interestingly, the latter quality of indirubin 
analogues was shown to antagonize the oncogenic R-Smad signaling, using patient-derived 
cholangiocarcinoma cell lines as a cancerous context. The following sections discuss in detail the above 
findings with regards to the modulation of TGF/Smad signaling by indirubins, on the one hand, and the 
translation of these effects into a potential therapeutic strategy for certain tumorigenic contexts, on the 
other hand.   
3.1. Regulation of TGF/Smad signaling: insights from small molecule approaches 
Our results from a large screen encompassing cell lines of various cancerous and non-cancerous 
origin showed a profound and reproducible R-Smad reduction upon treatment with the indirubin 
analogues; E738, E738 B, and E860, with the first molecule showing the strongest effect (see Figure7, 
Figure 8 and Figure 9). E738-mediated depletion of non-activated R-Smads at the protein level was in 
line with reduced transcription of R-Smads, as well as the TGF- and BMP target genes (e.g., IDs) in 
response to the small molecule (see Figure 12), altogether suggesting IRD E738 as an inhibitor of the 
TGF- and BMP pathways. These findings are consistent with a previous study of the group, showing 
the ability of indirubin analogues–particularly E738–in inhibiting BMP/Smad1/5/8 signaling through 
transcriptional regulation as well as protein degradation [148]. The latter is known to be a major 
mechanism by which R-Smad signaling is terminated [52]. Having that in mind and with a special focus 
on TGF-related Smad2/3, we could show that the E738-induced reduction of steady-state Smad2/3 
pools is, at least in part, due to a decrease in protein stability, as co-treatment with proteasome- and 
protein synthesis inhibitors decreased and increased the molecule's effects, respectively. This highlights 
the importance of the ubiquitin-proteasome pathway not only in the control of transcriptionally active 
Smad2/3 but also in the maintenance of total Smad2/3 levels. Although most studies have focused on 
the ubiquitination of receptor-activated R-Smads in the control of TGF signaling (reviewed in [40]), 
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there is evidence supporting the idea of non-activated Smad2/3 being regulated through similar 
dynamics. Related examples are the ubiquitination of baseline Smad2/3 by Smurf2 [43, 75, 76] and the 
control of steady-state Smad3 stability by the U-box-containing E3 ligase, CHIP (also known as STUB1) 
[77]. 
The activity and duration of the TGF/Smad pathway is not only determined by the abundance of 
ligands and receptors, but also through an intricate interplay between post-translational modifications of 
Smads, including phosphorylation, ubiquitination, and deubiquitination [52]. Through undergoing 
sequential steps of phosphorylation: (i) TGFRI-induced phosphorylation of the SXS residues in the 
MH2 domain followed by (ii) phosphorylation of (S/T) P motifs in the linker region, Smad2 and Smad3 
reach their maximum transcriptional potential, on the one hand, and are marked for proteasomal 
degradation, on the other hand [34, 35]. The "last minutes of Smads" prior to their degradation is 
therefore characterized by boosted transcriptional activity due to phosphorylation, which is 
essential for canonical TGF signaling-induced target gene expression, differentiation, and 
tissue formation. In this context, the indirubin derivative, E738 was found to stabilize the receptor-
activated pools of Smad2 and Smad3, as determined by increased levels of C-tail phosphorylated forms 
of the proteins in the presence of the small molecule alone, or in combination with chemical inhibitors of 
protein synthesis (see Figure 10). This observation may look paradoxical, considering the profound 
decrease in the protein stability of non-activated Smad2/3. The explanation, however, underlies the 
molecular mode of action of most indirubin analogues; their strong inhibitory function against several 
protein kinases, with many of those being required for the Smad linker phosphorylation (e.g., GSK3 and 
CDKs) (reviewed in [113]). As described earlier, this modification eventually marks Smads for 
recognition by the respective E3 ligases, leading to their destruction. IRD E738, therefore, is most likely 
able to prolong the half-life of receptor-phosphorylated Smad2/3 through inhibiting their subsequent 
linker phosphorylation by S/T kinases. Consistent with TGF-associated Smad2/3, we could previously 
show the short-term stabilization of C-terminally phosphorylated Smad1/5/8 by E738 upon BMP 
stimulation [148].   
The protein kinase inhibitory function appears to give sufficient rationale for the transient phospho-
Smad2/3C stabilization by indirubins, but not for the strong inhibition of TGF signaling observed at the 
level of non-activated Smad2/3 pools. The minimal effect of other pharmacological inhibitors targeting 
various S/T kinases, for example CDKs and GSK3 on total Smad2/3 levels (also see Figure 18), 
suggests that kinase inhibition is possibly not the major route by which E738 inhibits R-Smad 
expression. To address this issue, we adopted two strategies; (i) synthesis of a kinase-inactive analogue 
of E738 (designated as XC47) and (ii) over-expression studies using various truncated- and mutant 
forms of Smad2 and Smad3. Taking the first approach, we observed a significantly less efficient 
Smad2/3 reduction upon treatment with XC47 compared with that of E738 (see Figure 20), which 
implicates a potential role for kinase inhibition in E738's reduction of Smad2/3. This conclusion, 
however, has to be drawn cautiously, since the two small molecules may have other differences in their 
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mode of action in addition to that of protein kinase inhibition. This may include the negative regulation 
of deubiquitinating enzymes (e.g., USP34), which has been previously proposed as a mechanism 
through which E738 attenuates total R-Smad levels [148].  
Our results from the transient over-expression of different Smad2/3 mutants revealed multiple 
important facts with regards to E738's regulation of steady-state R-Smad pools (also see Figure 13); 
(i) E738's depletion of non-activated Smad2/3 occurs independently of TGFRI-induced Smad 
activation, as over-expressing truncated forms lacking the SXS motif resulted in similar or even a higher 
reduction in response to the indirubin derivative, (ii) the linker domain of Smad2 and Smad3 is essential 
for the E738's regulation of Smad2/3 stability, as overexpressing truncated proteins lacking this region 
caused almost none Smad2/3 reduction, and (iii) linker phosphorylation influences E738-mediated 
degradation of Smad2/3, as forced expression of Smad2/3 constructs carrying mutations in the 
conserved (S/T) P motifs leads to a more profound reduction of Smad2/3 half-life. The latter finding 
associates E738's regulation of signaling modules stemming from other pathways with its effects on 
Smad2/3 degradation. Such pathways include p38- JNK- and Erk MAPKs, as well as Wnt signaling, all 
of those are either directly or indirectly involved in Smad linker phosphorylation (see Figure 16) [20, 
165, 175-178]. We could previously show the activation of the two branches of noncanonical TGF 
signaling, p38 and JNK, by E738 [148]. On the other hand, Erk activity (unlike the rest of MAPKs) was 
found to be attenuated in response to the indirubin derivative in HEK-293 and a set of primary CCA cell 
lines (see Figure 14). Putting this next to the observation, showing a stronger Smad2/3 depletion in 
cells over-expressing constructs with Erk site-mutants compared with wt Smad, we hypothesized that 
the E738-mediated Erk inhibition might contribute to the stability of non-activated Smad2 and Smad3. 
In support of this, combining E738 with known chemical inhibitors of MEK1/2/Erk was found to have a 
synergistic effect on reducing the protein levels of Smad2/3. Consistent with our results, it has been 
previously reported that Erk phosphorylation stabilizes Smad2 protein levels, and hence enhances 
TGF responses [21]. Additionally, the study showed that the amount of exogenous Smad2 protein 
levels is decreased and increased in case of phosphorylation-defective- and phosphorylation-mimicking 
mutants, respectively [21]. Despite the combinatory effect of E738 and Erk chemical inhibitors on 
Smad2/3 depletion, single-treatments with the two tested inhibitors, U0126 and PD0325901, showed no 
significant alteration in Smad2 or Smad3 levels, suggesting that E738's regulation of Smad2/3 pools–
although related to Erk-mediated phosphorylation–involves additional molecular targets. One possibility 
could be the involvement of other kinases required for Smad linker phosphorylation, such as CDKs and 
GSK3, whose activity was shown to be strongly inhibited by E738 in our in vitro kinase profiling or 
p38/JNK MAPKs, which are known to be activated by the indirubin derivative. In support of the 
contribution of GSK3 to non-activated Smad stability, is the work of Guo et al. who showed that GSK3-
mediated phosphorylation of Smad3, but not Smad2, promotes its ubiquitination, followed by 
proteasomal degradation [78]. Considering this, GSK3 inhibitory function of E738 is most likely not a 
determinant of reduced Smad3 stability by the molecule. Whether other kinases, including CDK, p38, 
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and JNK, which phosphorylate distinct and overlapping residues in the linker domain are involved in 
baseline properties of Smad2 and Smad3 proteins could be an interesting topic for further investigations. 
3.2. Regulation of "phospho-Smad signaling": implications in cholangiocarcinoma 
The malignant switch in the TGF pathway involves, among other mechanisms, abnormal 
phosphorylation patterning of R-Smads (see also sections 1.1.5. and 2.3.). The so-called "pSmad 
signaling" relies on linker phosphorylation on conserved (S/T) P motifs by various kinases originating 
from other pathways, on the one hand, and C-tail phosphorylation by the active receptor complex, on 
the other hand [164]. Depending on the kinases involved, different phosphorylation forms of R-Smads 
are created with either anti- or pro-cancer effects [164]. Our finding with regards to E738's effects on 
Smad turnover, which was shown to involve modulation of specific linker residues prompted us to 
explore a potential connection between the small molecule's mode of action and the pSmad pathway. 
Aberrant Smad phosphorylation has been shown to play a role in the pathogenesis of some human 
malignancies, such as liver- and colorectal cancer [164, 179, 180]. However, its role in the diagnosis 
and treatment of cholangiocarcinoma remains to be investigated. With that in mind, we thought of using 
CCA as a cancerous model for studying the relevance of pSmad signaling to human cancer, on the one 
hand, and the accessibility of this signaling pathway for small molecule intervention, on the other hand. 
In close collaboration with Prof. Dooley's lab (Heidelberg University, Germany), we detected impaired 
pSmad signaling in CCA patients and cell lines, i.e., a decrease in the tumor-suppressive pSmad3C 
protein levels and an increase in those of the oncogenic pSmad3L (S204 and S213 residues) (see 
Figure 15). Considering the primary mode of action of indirubins–protein kinase inhibition–we tested 
the effects of different kinase inhibitors, including IRD E738, on pSmad3L protein levels. Promising data 
not only identified several S/T kinases, such as MEK/Erk, p38, and GSK3, as regulators of pSmad3L 
levels in CCA (Figure 16), but also demonstrated potent inhibition of the pro-cancer Smad3 phospho-
isoforms by E738 (Figure 17 and Figure 18). By including the kinase-inactive analogue of E738–XC47–
we could provide further evidence that modulation of pSmad3L signaling relies on the protein kinase 
inhibitory function of E738, although it does not fully rule out the possibility of alternative mechanisms.  
At the molecular level, several signaling networks have been shown to drive the pathogenesis of 
cholangiocarcinoma, which could be classified as follows: (i) signaling pathways related to cellular 
survival (e.g., Ras-MAPK and PI3K/Akt pathway), (ii) signaling pathways related to cellular fate and 
differentiation (e.g., Wnt and TGF pathways), as well as (iii) metabolic- and epigenetic-related signaling 
modules (e.g., isocitrate dehydrogenase (IDH)1/2) (recently reviewed in [168]). Focusing on TGF 
signaling, multiple reports have shown that both canonical- and noncanonical branches of this pathway 
could be exploited for the treatment of CCA [181]. For example, blocking TGF-activated ERK1/2 has 
been reported to suppress TGF-mediated invasion and metastasis in intrahepatic CCA cell lines, while 
maintaining its tumor-suppressive functions [167]. Another example with regards to the in vitro effects 
of TGF signaling modulation on CCA is the work of Lustri et al. who showed that chemical blockage of 
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TGFRI is capable of reducing cellular migration in human CCA cell lines [170]. The above reports 
together with our mechanistic insight on the involvement of various kinases–including those mentioned 
in the CCA treatment–in the control of pSmad3L signaling inspired us to investigate whether the 
inhibition of oncogenic pSmad3L could alter the tumorigenic features of our panel of patient-derived 
CCA cell lines. In light of this, the combination of IRD E738 and pharmacological inhibitors of the 
involved kinases, namely ERK1/2, p38, GSK3, and CDKs was found to induce synergistic effects on the 
inhibition of pSmad3L protein levels, on the one hand (see Figure 18), as well as cellular viability and 
apoptogenic responses, on the other hand (see Figure 21 and Figure 22). In view of our results, several 
lines of studies have recently shown the beneficial outcome of targeting the aforementioned kinases 
and related signaling modules in the treatment of CCA. With regards to the MAPK pathway, anti-MEK 
therapies have shown promising results in the control of intrahepatic CCA. Interesting examples are the 
use of chemical inhibitors of Erk, PD901 and U0126, which showed high efficacy against in vitro and in 
vivo iCCA models, in particular in tumors harboring KRAS mutations, through reducing cellular 
proliferation, induction of apoptosis, as well as effects on the stroma [182]. Small molecule inhibitors of 
CDK4/6, such as ribociclib and palbociclib have also shown to be a promising approach in the treatment 
of iCCA [183, 184]. In particular, concomitant administration of the CDK4/6 inhibitor, palbociclib with 
MLN0128, which inhibits mTOR was found to induce profound and synergistic growth inhibitory 
functions in vitro and in vivo [183]. Sparse reports on the regulation of p38 signaling in CCA have 
suggested a tumor-promoting role for this pathway [168], implicating the potential benefit of p38 
inhibitors either as mono-treatment or in combination with other drugs in CCA therapy [185]. The use of 
p38 inhibitors gets more desirable, given their activation by TGF through the noncanonical (non-Smad) 
pathways (also see section 1.1.3.). This may explain the observed combinatory effect of p38 inhibitors 
and E738, as the latter is known to promote p38 activation, while inhibiting TGF signaling. By combining 
p38 inhibitors with the indirubin derivative, both molecular mechanisms could be targeted, which will 
then enhance the cytotoxic response as compared to either molecule alone. Finally, the role of GSK3 
in CCA formation and progression appears to be highly context-dependent similar to other cancer types. 
Although GSK3/ phosphorylation at S21/9, which is mediated by Akt in order to inactivate GSK3, has 
been reported to be increased in CCA tumorigenic areas compared with normal biliary tissue, the 
cancerous contexts in which GSK3 inhibition is beneficial remains to be thoroughly investigated [186].  
What is clear, however, is the key role of this enzyme in cholangiocarcinoma, as it bridges the PI3K/Akt 
and Wnt/-catenin pathways, both of which are part of CCA driver signaling network. Based on our 
results, we demonstrated a potent cytotoxic- and apoptogenic response to GSK3 chemical inhibition in 
CCA cell lines, and the strongest synergy, among other inhibitors, when combined with IRD E738 (see 
Figure 18, Figure 21, and Figure 22). Altogether, our findings suggest a potential synergy upon 
simultaneous targeting of TGF signaling, MEK/Erk, p38, and GSK3 in terms of reducing oncogenic 
pSmad3L levels, as well as inducing cytotoxic effects.    
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3.3. Concluding remarks and future perspectives 
The results presented in this chapter emphasize on the less-studied regulatory mechanisms of the 
TGF/Smad signal transduction, i.e., the significance of non-activated R-Smad pools in the control of 
TGF's responses. For this, we adopted a chemical approach and showed a multi-layer modulation of 
the pathway in response to indirubin derivatives; (i) inhibition of TGF signaling through proteasome-
mediated degradation of steady-state Smad2/3, (ii) short-term stabilization of receptor-activated 
Smad2/3, and (iii) regulation of noncanonical TGF signaling, including Erk inhibition and p38/JNK 
activation. Our results from transient over-expression studies demonstrated that modulation of certain 
phosphorylation sites in Smad2/3 linker domain by IRD E738 is most likely involved in the reduced 
smad2/3 stability in response to the small molecule. Mechanistically, we could show the importance of 
Erk-mediated phosphorylation in E738's regulation of total Smad2/3 levels. What remains to be 
addressed in this regard is the role of other kinases, such as CDKs and GSK3 in the control of steady-
state Smad2/3 levels in the absence or presence of the indirubin derivative. This becomes particularly 
important, considering the strong inhibition of the aforementioned kinases by IRD E738. Additionally, 
our results suggested that proteasomal degradation is most probably involved in reducing protein levels 
of Smad2/3 carrying mutations in the conserved (S/T) P motifs of the linker region. Whether linker 
phosphorylation through the action of various S/T kinases plays a major role in the 
ubiquitination of non-activated Smad2/3, and if so, which E3 ubiquitin ligases are involved in 
this process presents an exciting topic for future projects.  
Our mechanistic insight with regards to the role of certain linker phosphorylation residues in E738's 
regulation of Smad turnover sparked the idea of the potential modulation of "pSmad signaling" by IRD 
E738, as well as other derivatives. Based on our promising preliminary data on the dysregulation of 
pSmad signaling in cholangiocarcinoma, and due to a lack of knowledge regarding the diagnostic- and 
therapeutic value of this pathway in CCA, we sought to use a panel of patient-derived CCA cell lines as 
a cancerous context in which we could study the relevance of E738's mode of action to Smad phospho-
isoforms pathways. This approach provided us with multiple important facts with regards to pSmad3 
signaling and CCA; (i) the most predominant Smad3 linker phosphorylation sites in CCA are the Serine 
residues, S204 and S213, which could counteract the cytostatic pSmad3C (S423/S425) signaling, and 
hence induce a malignant switch in TGF's responses, (ii) several S/T kinases, namely MEK/Erk, p38, 
GSK3, and CDKs are most likely responsible for Smad3 linker phosphorylation in CCA cell lines, (iii) the 
indirubin derivative, E738, causes a profound decrease in the oncogenic pSmad3L (S204/S213) protein 
levels, most likely through its kinase inhibitory function, and (iv) the combination of E738 and 
pharmacological inhibitors of the involved kinases causes a stronger inhibition of pSmad3L signaling, 
an effect which coincides with a synergy in cytotoxic- and pro-apoptotic effects. Nonetheless, several 
issues remain to be addressed with regards to the translation of pSmad3 signaling into a 
therapeutic strategy against CCA, which we are currently working on. Firstly, the anti-tumor 
efficacy of indirubin derivatives as well as other inhibitors in CCA cell lines and its connection 
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to pSmad3L signaling requires more investigations. In particular, cellular migration/invasion has 
to be taken into consideration, as it is one of the major features of TGF signaling overactivation 
in CCA. Additionally, knockin mutant cell lines, carrying phosphorylation-defective residues are 
planned to be generated in order to study their tumorigenic features in the absence/presence of 
treatment. Secondly, the molecular mechanism behind the in vitro effects of E738 remains to be 
further studied. Through including the kinase-inactive analogue of E738, we could propose the 
kinase inhibitory activity as a mechanism by which the molecule reduces pSmad3L levels. 
However, this requires further validation, for example by comparing the differentially regulated 
pathways between a none/less-responsive cell line and the most-responsive cell line (CCSW1) 
upon E738 treatment using RNA-sequencing. Lastly, the in vivo anti-tumor effects of IRD E738, 
other inhibitors, and their combination could be tested in a xenograft mouse model, using 
CCSW1, which showed the most promising results in the in vitro assays.   
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1.INTRODUCTION 
1.1. Transcription factor-mediated cellular reprogramming towards pluripotency 
The first example of cellular reprogramming was reported by Sir John Gurdon in 1962 through 
somatic cell nuclear transfer (SCNT). SCNT is the process of transferring the nucleus of a somatic cell 
to an enucleated egg, which then starts to divide, and generates an embryo, that is genetically identical 
to the donor of the somatic cell [187, 188]. Gurdon's discovery suggests that all genetic information is 
maintained in the nuclei of somatic cells, thus these cells can be reprogrammed to an embryonic, 
pluripotent state. Following experiments by several groups led to the establishment of embryonic stem 
cells (ES cells), with a developmental capacity to give rise to all cell types in our body, a property which 
is known as "pluripotency" [189, 190]. Finally, in the late 20th century, the development of cloned 
animals such as, mice and sheep was repeatedly reported using SCNT [191, 192]. During this time and 
later on, several studies suggested the existence of "reprogramming factors" that can change cellular 
fate. Early evidence came from cell fusion experiments, showing that the profile of gene expression in 
somatic cells can be modified through fusion with other cell types, leading to the reprogramming of these 
cells [193, 194]. The prospect of the existence of reprogramming factors was further shown by several 
other studies, reporting the induction of transdifferentiation via introducing a single transcription factor, 
for example the conversion of mouse fibroblasts to myoblasts through ectopic expression of MYOD 
[195] and the generation of megakaryocyte and erythrocyte precursors from myeloblasts by 
exogenously-expressed GATA1 [196]. The increasing evidence finally led to the influential discovery of 
induced pluripotent stem cells (iPSCs), which are somatic cell-derived pluripotent cells with a close 
resemblance to ES cells (the history of reprogramming research has been summarized in an 
excellent review by Takahashi K. and Yamanaka S. in [197]). 
From a technical perspective, the generation of iPSCs from terminally differentiated somatic cells 
represents a remarkably simpler approach compared with SCNT, i.e., ectopic expression of a defined 
combination of transcription factors–OCT4, SOX2, KLF4, and MYC (collectively known as "OSKM")–in 
the host cell. The first evidence of the ability of this cocktail in the induction of pluripotency came from 
the generation of mouse iPSCs (miPSCs) through introducing a retroviral transduction system in mouse 
embryonic fibroblasts (MEFs) [198]. For this, Yamanaka's group first aimed at identifying critical factor(s) 
that contribute to the pluripotent identity of ES cells, using in silico differential display. This led to the 
recognition of ES cell-specific genes, referred to as ES cell-associated transcripts (ECATs), with Nanog 
being the first identified gene that has a crucial role for the maintenance of pluripotency in ES cells and 
early embryos [199, 200]. They followed the experiments by testing each- and a combination of all 24 
candidates using the "Fbxo15–β‐geo" reporter system in which β‐galactosidase expression correlates 
with the promoter activity of F-box only protein 15 (Fbxo15)–one of the ECATs–The results showed that 
none of the individual factors is able to support colony formation, whereas 22 colonies were observed 
in cells transduced with all 24 genes, which were similar to those of ES cells. Next, they narrowed down 
the combination by eliminating a single factor at a time, which eventually led to the finding that 
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elimination of four genes, encoding OSKM factors, inhibits ES cell-like colony formation. Further testing 
of OSKM-transduced MEFs revealed that this combination represents the minimal set of reprogramming 
factors necessary for the generation of miPSCs [198]. Human iPSCs could also be developed with a 
similar approach, however, with several optimizations due to the poor transduction efficiency [201]. 
Simultaneously, a group led by James Thomson reported the generation of human iPSCs with a cocktail 
containing four alternative factors, namely OCT3/4, SOX2, NANOG, and LIN28 [202], which later on 
was used by several other groups and has even shown synergistic effects in generating human iPSCs 
when combined with OSKM [203, 204].  
1.1.1. Transcription factor-mediated reprogramming–enhancers   
One of the major concerns with regards to OSKM-mediated reprogramming is its time-consuming 
process (3-4weeks) as well as the extremely low efficiency (<0.01%) [197]. In this context, 
"reprogramming enhancers" have been identified and used in order to increase the reprogramming 
efficiency.  
1.1.1.1. Reprogramming enhancers–pluripotency-associated genes       
Further investigations of the minimal required reprogramming factors suggested that except for 
OCT3/4, the rest of the transcription factors (SKM) could be replaced; for example, SOX2 can be 
substituted by SOX1 or SOX3, and KLF4 is replaceable with KLF2 or KLF5 [197]. In case of MYC, it 
was shown that among different isoforms, L-MYC has the lowest proto-oncogenic activity, thus provides 
a safer approach for the generation of human iPSCs with clinical potential [205]. The redundancy in the 
role of "SKM" pluripotency factors allows different combinations in addition to the OSKM cocktail. Aside 
from this, reprogramming efficiency was shown to be enhanced by using certain transcription factors–
with high expression levels in ES cells–together with OSKM. Of those, we can mention the role of cell 
transcription factor 1 (UTF1), Sal-like protein 4 (SALL4), LIN28, and the E3 ubiquitin ligase, TRIM71 in 
facilitating the generation of human iPSCs, as well as the ability of NANOG in replacing KLF4 in the 
OSKM combination [197]. The rationale behind the use of the aforementioned reprogramming 
enhancers for the induction of pluripotency comes from the relationship between these factors. 
In fact, many of these enhancers are most likely part of the gene signature induced by OSKM. 
Therefore, studying the downstream targets of OSKM not only provides mechanistic insights 
into the reprogramming process, but also allows the improvement of OSKM-mediated 
reprogramming protocols. 
One of the characteristics of iPSCs is their infinite capacity for proliferation, giving iPSCs the self-
renewal ability in order to differentiate into any cell type. Having this in mind, it is easy to assume that 
cell cycle regulating genes may promote the generation of iPSCs, as it is indeed the case for one of the 
original pluripotency factors, MYC. The first evidence in this regard came from the inhibitory role of the 
tumor suppressor, p53 in reprogramming, which was followed by several studies showing that 
repressing p53 strongly enhances the generation of human and mouse iPSCs (examples are; [206-
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208]). Further supporting examples are the positive and negative effects of other cell cycle promoters 
(e.g., cyclin D1) and -inhibitors (e.g., ARF) on the reprogramming efficiency, respectively [209, 210].   
1.1.1.2. Reprogramming enhancers–epigenetic modifiers  
Transcription factor-mediated reprogramming is largely dependent on epigenetic modifications. In 
fact, the epigenetic signature of the somatic cell has to be removed during the process of conversion to 
iPSCs, so the cells can adopt a stem cell-like epigenome. These epigenetic changes include chromatin 
remodeling, DNA demethylation of promoter regions of reprogramming factors, such as OCT3/4, Sox2, 
and NANOG, reactivation of the somatically-repressed X-chromosome, as well as genome-wide 
reorganization of histones' modifications (reviewed in [211, 212]). The latter is regulated by enzymes, 
which mediate the post-translational modifications of histones; lysine methylation and -acetylation, to 
name the most frequent ones. Unlike DNA demethylation and X-chromosome reactivation, changes in 
histone methylation- and acetylation patterns represent an early event during the reprogramming 
process, implicating that resetting of histone marks is necessary in initiation of the process. In light of 
this, it has been reported that immediately upon introducing the reprogramming factors, histone H3 
dimethylated at lysine 4 (H3K4Me2) accumulates at promoter and enhancer regions of many 
pluripotency-related genes (e.g., SALL4), that are rich for SOX2 and OCT4 binding sites but deficient 
for H3K4Me1 or H3K4Me3 marks. In an opposite manner to H3K4Me2, H3K27Me3 is known to be 
depleted, showing a promoter hypomethylation in regions important for the induction of pluripotency. 
This stage is parallel to the loss of H3K4Me2 at the promoters and enhancers of somatic genes, leading 
to hypermethylation and silencing at later stages of reprogramming [211, 212]. Altogether, 
concomitant changes in histone marks of key somatic factors and early pluripotency genes, 
which result in down- and upregulation of mesenchymal- and pluripotency genes, respectively 
are among the early events in reprogramming, driving the cellular fate in a particular direction 
(either towards pluripotency or differentiation).  
The existence of specific histone marks during OSKM-mediated reprogramming raises the 
following questions; (i) what are the chromatin modifier enzymes, which participate in reshaping 
the epigenetic landscape of somatic cells during the process of conversion to stem cells? and 
(ii) how are these chromatin modifiers targeted to the pluripotency- and/or somatic genes 
responsible for the reprogramming process? One way to answer this is to assume that genome-
wide OSKM binding sites mark the regions that are meant to be epigenetically modified. An 
example is the interaction of OCT4 with the WD repeat protein 5 (WDR5) on pluripotency gene 
promoters in order to maintain H3K4 methylation, which in turn facilitates the activation of the respective 
genes [213]. Another example is the interaction of H3K27 demethylase enzyme–UTX–with OSK 
(OCT3/4, SOX2, and KLF4) to remove the repressive histone mark, H3K27Me3 from early pluripotency 
genes (e.g., SALL4 and UTF1). Accordingly, inhibition of UTX has been reported to be associated with 
H3K27 hypermethylation, and hence attenuation of reprogramming efficiency [214]. In addition to WDR5 
and UTX, modifying the expression of several other epigenetic modifier enzymes, such as SUV39H1, 
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SETDB1, EZH2, and DOT1L has been reported to either enhance or decrease the efficiency of 
reprogramming [215, 216]. 
Apart from the enzymes involved in the regulation of histone modifications, histone composition–in 
particular oocyte-enriched histone variants, TH2A and TH2B–has been reported to improve the quality 
of both mouse- and human iPSCs generated by OSKM-mediated reprogramming [217]. In addition to 
this, removal of histone H1 from chromatin was found to reduce chromatin condensation, resulting in 
enhanced reprogramming efficiency in mice [215]. 
Lastly, the methylation status of the DNA itself serves as an epigenetic modifier, influencing the 
reprogramming progression. Although de novo DNA methylation by the DNA methyltransferases, 
DNMT3a and DNMT3b has been reported to be dispensable for reprogramming [218], oxidative 
demethylation of DNA appears to be an essential step in the path to pluripotency during the early phases 
of reprogramming [219]. 
As implied earlier, histone modification is a reversible process. Focusing on H3K4 methylation as an 
example, it is known that the complex proteins-associated with SET1 (COMPASS)-like proteins serve 
as the "writers" of H3K4 methylation, whereas members of the KDM (also known as JMJC and JARID) 
and LSD families of histone demethylases counteract this process, performing as "erasers" of 
methylated H3K4. Histone demethylases or the "erasing enzymes" may be selective for one or more 
specific histone proteins (e.g., H3 or H4), location of methylation sites i.e., lysine residues (e.g., K4, K9, 
and K27), as well as for the degree of methylation at these sites (e.g., Me1, Me2, and Me3). For example, 
LSD1 catalyzes demethylation of H3K4Me1, H3K4Me2, as well as H3K9Me1 and HeK9Me2, whereas 
KDM5s (also known as JARIDs) are thought to be specific to H3K4Me2/3 (reviewed in [220]). 
Additionally, the JMJC-domain containing enzyme, NO66 (also referred to as MAPJD) is known to 
demethylase H3K4 not only when it is di- or tri-methylated (which is the case for KDM5s), but at all three 
states of methylation [220]. This dynamic regulation of histone methylation through the action of 
demethylase enzymes provides even more opportunities in the use of epigenetic modifiers as enhancers 
of the reprogramming process. In view of this, small molecule-mediated inhibition of LSD1 has been 
reported to promote the generation of human iPSCs [221]. Another example in this respect is the role 
of vitamin C in enhancing reprogramming efficiency through increasing the activity of KDM2A and 
KDM2B, which are responsible for demethylation of H3K36 [222]. 
1.1.2. Transcription factor-mediated reprogramming–models and mechanisms 
1.1.2.1. Models of somatic cell reprogramming 
Early after the generation of cloned animals by SCNT, and later the discovery of transcription factor-
mediated induction of pluripotency, the "elite" model was proposed in order to explain the extremely low 
efficiency of cellular reprogramming [223]. According to this model, only a small number of cells with 
progenitor and/or stem cell-like qualities–the "elites"–within the somatic cell population have the capacity 
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for conversion to iPSCs, and the differentiated cells are resistant to reprogramming [223]. However, 
several lines of lineage tracing studies and clonal analyses ruled out the possibility of "elite" model by 
showing that all cells, including the terminally differentiated cells (e.g., T and B lymphocytes and 
albumin-expressing hepatocytes) have the potential to generate iPSCs [224, 225]. We now know that 
the low efficiency of cellular reprogramming is not related to the heterogenicity of the somatic 
cell population, but rather to the fact that most of cells never complete the path towards 
pluripotency, and only a small fraction of cells becomes iPSCs (for more details regarding the 
molecular mechanisms of somatic cell reprogramming refer to [226]). 
 
Figure 1. "Stepwise model" of somatic cell reprogramming. The schematic illustration puts the 
somatic cell reprogramming process in the so-called "stochastic-deterministic" model. Doing so, 
reprogramming will be divided into 3 phases, the early (initiation) phase, the intermediate phase, and the 
late (maturation) phase, as depicted. After the introduction of OSKM factors into a given somatic cell, 
cells undergo a stochastic gene activation and assume one of the many possible fates, such as 
apoptosis, transdifferentiation, transformation, senescence, and reprogramming. Among a mixed cell 
population, the reprogrammable cells will then increase their proliferation rate and undergo some 
epigenetic changes (e.g., enrichment of active histone marks, such as H3K4Me2) at the 
promoters/enhancers of somatic genes in order to facilitate the mesenchymal-to-epithelial (MET) 
transition, as well as DNA repair, RNA processing, and metabolic rewiring. In parallel to this, genes 
important for the somatic cell identity, as well as the epithelial-to-mesenchymal (EMT) process lose the 
active histone marks and start to gain the repressive modifications (e.g., H3K9Me3). These cells then 
enter an intermediate phase in which the stochastic gene activation could lead to the expression of some 
predictive markers, for example UTF1 and LIN28, as indicated. This will then instigate the initiation of 
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the deterministic phase through which the so-called "pre-iPSCs" stabilize into a mature pluripotent state. 
The gene expression in this phase is seemingly more hierarchical, starting with the activation of SOX2. 
The promoter/enhancer regions of early pluripotency genes in this phase contain high levels of H3K4Me2 
and other active epigenetic modifications. Simultaneously, late pluripotency genes are switched on, 
which can possibly loosen the compacted chromatin through the removal of the repressive epigenetic 
marks and the enrichment of active histone marks.  
As described earlier, a successful reprogramming process requires many steps, which occur either 
sequentially or in parallel. Some events, such as the mesenchymal to epithelial transition (MET), as well 
as suppression and activation of somatic genes and early pluripotency genes, respectively must occur 
during early phases, whereas other events, for example activation of late pluripotency-associated genes 
or repression of tissue-specific transcription factors and developmental genes occur during later stages 
of reprogramming. Starting from a mixed cell population in which every cell is permissive to OSKM 
factors, reprogramming can be induced and completed in either a "stochastic" or a "deterministic" 
fashion [223, 227]. According to the latter, all cells are reprogrammed with a so-called "fixed latency", 
meaning that every cell follows the exact same path to reach pluripotency. According to the former, 
iPSCs are generated with "variable latencies", which means that transition steps vary within the somatic 
cell population, and hence it is not possible to predict if the progeny of somatic cells becomes an iPSC, 
and if so when it will complete the process. In support of the stochastic model, it has been shown by 
single-cell cloning studies that sister cells from an early colony give rise to iPSCs with variable latency, 
with some sister cells never finishing the process. Although one cannot anticipate whether and when 
the reprogramming process is completed, activation of certain genes, for example UTF1 (as 
abovementioned) can serve as a marker that rare early cells are on their way towards a pluripotent 
state, as it implicates that their promoters are available for OSKM. In contrast, pluripotency loci marked 
with H3K9me3 (e.g., SOX2 and NANOG) are activated later in reprogramming and are not responsive 
to OSKM binding at early stages. Therefore, H3K9 methylation represents an epigenetic roadblock for 
"pre-iPSCs", that has to be overcome in order to generate fully reprogrammed iPSCs (also see Figure 
1). 
Applying the "stochastic-deterministic" model to the process of somatic cell reprogramming, 
one may breakdown the pluripotency path into smaller steps; (i) early (initiation) phase, which 
is a long stochastic step of gene activation, (ii) intermediate phase where the partially 
reprogrammed cells–pre-iPSCs–are generated, and (iii) late (maturation and stabilization) phase, 
that is a shorter, hierarchical, and deterministic phase, starting with the activation of the SOX2 
locus (schematically illustrated in Figure 1). In the early phase of reprogramming, OSKM bind to 
genomic loci, including enhancers, then the promoters of somatic and pluripotency genes in order to 
repress and induce their expression, respectively. This phase appears to be stochastic and inefficient 
most probably due to the presence of many permissive and repressive histone marks as well as other 
epigenetic markers. In fact, any factor that can destabilize the compacted chromatin (typical of somatic 
cells) allows the initial OSKM-genome interaction [228]. Supporting evidences are several studies, 
showing that general DNA methyltransferases- and histone deacetylase inhibitors, such as 5-azacitidine 
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and valproic acid enhance reprogramming in combination with OSKM (reviewed in detail in [229]). 
Next, the reprogrammable cells enter an intermediate phase wherein they undergo a stochastic 
activation of pluripotency markers, which in some cases can lead to the expression of predictive markers 
(e.g., UTF1 and LIN28, as mentioned earlier), driving the so-called "second wave" of reprogramming–a 
seemingly more predictable and hierarchical event–During this late phase, the expression of late 
pluripotency genes takes place through the interaction of OSKM with late pluripotency loci marked with 
methyl histones (e.g., H3K4, as abovementioned). This initiates with the activation of SOX2–one of a 
group of pluripotency initiating factors–and is followed by the hierarchical activation of a series of genes, 
which eventually allows cells to stabilize into the pluripotent state. Consistent with this "stepwise model" 
of reprogramming, it has been suggested that transcription factors other than OSKM are sufficient for 
generating iPSCs due to the hierarchical network of gene activation. In light of this, it has been reported 
that a combination of OSKM downstream targets; ESRR, LIN28, DPPA2, and SALL4 is able of inducing 
iPSCs from MEFs [227]. 
1.1.2.2. Markers of somatic cell reprogramming 
When discussing reprogramming markers, it is very important to keep in mind that due to the 
stochastic nature of somatic cell reprogramming, no set of molecular markers is able to predict whether 
a given cell early in the reprogramming path will eventually produce a pluripotent progeny or not. Another 
important concern in this regard is the ability to differentiate the partially-reprogrammed cells from 
established iPSC. For example, although activation of some genes, such as stage-specific embryonic 
antigen 1 (SSEA) and/or alkaline phosphatase is considered to be an essential step during the 
reprogramming process, such markers are not necessarily confined to the cells destined to become 
fully-reprogrammed iPSCs (reviewed in [211]).  
Despite the abovementioned issues, global gene expression- and proteomics analyses of enriched 
population of cells at different phases of reprogramming (see Figure 1) suggest a set of transcription 
factors as the representative of each stage [230-233]. In light of this, it has been shown that (i) Fbxo15, 
FGF4, SALL1, fucosyltransferase 9 (Fut9), chromodomain helicase DNA binding protein 7 (Chd7) and 
E-cadherin (Cdh1) are indicative of the initiation phase of reprogramming, (ii) genes coding for NANOG, 
OCT4, SOX2, SALL4, NODAL, ESRR, and ERAS are normally activated during the intermediate phase 
where the so-called "pre-iPSCs" are generated, and (iii) genes including REX1, GDF3, DPPA2, DPPA3, 
and UTF1 most likely mark the late- or maturation phase (also refer to Figure1). Importantly, there are 
some limitations associated with the information obtained from gene expression/proteomics analysis of 
heterogenous populations owing to the small number of cells that are destined to become full iPSCs. In 
this regard, technological advancements, such as single-cell expression analysis have redefined our 
understanding of the mechanisms- and markers of reprogramming. An example is the single-cell 
analysis of SSEA1-positive pre-iPSCs, which identified early- intermediate- and late reprogramming 
markers, including epithelial cell adhesion marker (EPCAM), representative of the early phase; KIT 
receptor, representative of the intermediate phase; and platelet endothelial cell adhesion molecule 
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(PECAM1), indicative of the late stabilization phase. Consistently, sorting SSEA1- and EPCAM-positive 
early cells showed a slight increase in the reprogramming efficiency [232]. Using two complementary 
single-cell approaches, Buganim et al. identified UTF1, DPAA2, LIN28, and ESRR as the "predictive 
genes" that are expressed in a small subpopulation of cells early in the process, marking those that are 
meant to become iPSCs (also refer to Figure 1) [227]. Taken together, the critical endogenous 
reprogramming factors (e.g., OCT4 and SALL4), which are conventionally used as reprogramming 
markers appear to be poor predictors of iPSC generation. What supports this idea the most is that 
although these markers are expressed only in rare cells early in the process, they are as well activated 
in partially-reprogrammed cells.  
1.1.2.3. Mechanisms of somatic cell reprogramming–role of the OSKM factors, levels, and 
stoichiometry  
How ectopic expression of the OSKM combination drives the pluripotency path is not thoroughly 
understood. Putting the process of reprogramming in the "two-step" model (as described above), it has 
been shown that the first transcriptional wave is mainly mediated by MYC, which occurs in all transduced 
cells, while the second wave is limited to reprogrammable cells and is induced by a slow increase in 
OCT3/4 and SOX2 target gene expression, leading to the activation of other pluripotency genes. Finally, 
KLF4 is thought to support both phases through repressing somatic genes in the early phase and 
enhancing the expression of pluripotency genes during the late phase (reviewed in [211]). As 
abovementioned, immediately upon OSKM transduction, these factors occupy open and accessible 
chromatin, binding promoters of genes marked with activating- or repressing histone modifications. In 
this regard, it has been reported that MYC binding–significantly more than the rest of the factors–is 
associated with an active epigenetic state of the genomic loci. An example is the occupation of 
methylated H3K4- or acetylated H3K27-marked loci (a sign of open chromatin) by MYC for repressing 
somatic genes (the role of MYC in transcription regulation was revisited as a global gene amplifier 
in [234, 235]). This finding could let us assume that MYC does not initiate the reprogramming process, 
but rather potentiates the action of the other three factors. In addition to active chromatin being a pre-
requisite for MYC binding, there are other lines of evidence, which support the above hypothesis in 
differentiating between the role of "OSK" and "MYC" in reprogramming. In view of this, it has been 
demonstrated that the OSK factors bind multiple distal sites of many genes with no or minimal pre-
existing epigenetic modifications, which shows that these initially OSKM-bound sites are distinct from 
those occupied by OSK in ESCs. On this basis, it has been suggested that "OSK" act as "pioneering 
reprogramming factors", meaning that they are able to bind closed chromatin on their own without the 
help of other transcription factors. They will then open the inactive chromatin regions for the activation 
of pluripotency genes. MYC, on the other hand, only facilitates this process, as it largely relies on pre-
existing chromatin modifications (for more details refer to [228], which raises the notion of OSK 
proteins being the pioneer factors of reprogramming through promiscuous binding to distal 
elements). 
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The comparison of two doxycycline-inducible transgenic reprogrammable mice strains in their ability 
to generate all-iPSC mice was one of the early evidences, showing a crucial role for the appropriate 
stoichiometry of OSKM factors in the induction of pluripotency [236, 237]. This idea was supported by 
the fact that the only difference between the two transgenic systems was a different factor stoichiometry, 
with the high quality iPSCs being associated with the strain producing 10- to 20-fold higher protein levels 
of OCT3/4 and KLF4 and lower levels of SOX2 and MYC. This was further confirmed by two other 
studies, that showed high and low OCT3/4 and SOX2 expression corresponds to the highest 
reprogramming efficiency, respectively (reviewed in [211]).  
In addition to factor stoichiometry, the expression levels of the OSKM transgenes influence the 
success rate of reprogramming. In this regard, continuous OSKM expression has been reported to be 
essential for iPSC generation until the intermediate phase of partially reprogrammed cells with unstable 
fates has been passed. Therefore, disrupting OSKM expression before this stage (~8-12 days after 
OSKM transduction in mouse cells) leads to a failure in iPSC generation (reviewed in [197]). Another 
example of the different transgene expression between intermediate- and fully-reprogrammed iPSCs is 
the OSKM-genome interaction. With regards to this, it was shown that partially-reprogrammed iPSCs 
express a unique set of genes bound with more reprogramming factors compared with that of ESCs, for 
example promoter or enhancer genes bound with only OCT3/4 and SOX2 in ESCs are bound with 
OSKM in the intermediate state. In contrast, genes that are highly expressed in ESCs were found to be 
bound with fewer reprogramming factors in the intermediate cells [238]. Another parameter which 
contributes to the generation of fully-reprogrammed cells is the timing of factor expression. As an 
example, during the early phase, the "OCT3/4high/SOX2low stoichiometry" leads to the activation and 
suppression of the mesodermal- and ectodermal genes, respectively. This expression pattern appears 
to be also important in the late phase wherein the endogenous factors are expressed in a similar 
manner, with OCT4 levels being high, whereas SOX2 levels remaining low. Therefore, the 
"OCT3/4high/SOX2low" stoichiometry determines mesodermal features, which is essential in the 
establishment and development of intermediate cells on the path to fully-reprogrammed iPSCs [197, 
239]. These observations are the basis of the so-called "seesaw model" of reprogramming, which 
emphasizes on the importance of a balanced expression of lineage-specifying factors for a 
successful reprogramming route.  
1.1.2.4. Mechanisms of somatic cell reprogramming–signaling networks  
Multiple signaling pathways, including TGF, PI3K, MAPK, and Wnt have been shown to come 
together in a finely-balanced manner in order to induce and maintain the stem cell identity during 
the process of reprogramming. From a simplistic viewpoint, these signaling networks must 
interact and crosstalk to sustain a long-term proliferative state, on the one hand, and to repress 
differentiation, on the other hand (signaling networks involved in somatic cell reprogramming 
as well as the small molecules targeting such pathways are summarized in two excellent 
reviews; [229, 240] and Figure 2). 
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The transition from using MEF as a feeder-layer for culturing PSCs to feeder-free culture systems 
represents a turning point in our understanding of self-renewal signaling. The latter approach utilizes 
Matrigel or laminin as attachment matrices and substitutes the MEF feeder layer with MEF-conditioned 
media, fetal calf serum or knockout serum replacement supplement (KSR), and FGF2 for maintenance 
[241]. Early on, it was reported that Activin A–from the TGF superfamily of cytokines–is secreted by 
MEF feeder layers and that its addition to hPSC culture media maintains their pluripotency for more than 
20 passages [242]. Later, it was shown that Activin A could be replaced with other TGF family 
members, including TGF and Nodal, which signal through the Smad2/3 pathway, targeting pluripotency 
genes, such as NANOG [243]. The role of PI3K/Akt signaling in hPSC culturing came to our 
understanding immediately upon using fetal calf serum or KSR supplement in feeder-free formulations, 
as all these components contain factors, such as insulin or IGF, which are known to be a potential 
activator of the canonical PI3K pathway [244, 245]. Other studies have suggested a critical role for the 
canonical Wnt signaling in pluripotency [246]. Altogether, FGF2 through Erk MAPK, Activin A 
through Smad2/3, insulin/IGF through PI3K, as well as canonical Wnt signaling form the basis of 
our current understanding of self-renewal signaling. Importantly, what establishes a stable 
pluripotent state is the crosstalk of these signaling pathways, which will be described in detail 
in the following sections.    
FGF2 and MAPK/Erk signaling. As abovementioned, under feeder-free culture systems, FGF2 is 
used in order to supplement the activities of the feeder layer in MEF conditioned media. Initially, it was 
thought that FGF2 functions through the MAPK/Erk pathway, which we now know has a more 
complicated scenario. Several lines of studies have shown conflicting roles for the Erk pathway in 
hPSCs, which could be potentially reconciled (reviewed in [240]). In fact, a minimal level of Erk is 
required for cell cycle progression, cell proliferation, and inhibition of apoptosis. It has been shown that 
above a certain threshold, Erk signaling represses pluripotency genes and activates developmental 
genes, and hence an intermediate level of Erk activation is optimal for maintaining pluripotency. With 
regards to its relationship with FGF2, it has been reported that both high- and low concentrations of the 
cytokine are capable of sustaining the basal Erk activity–compatible with pluripotency–however through 
distinct mechanisms. Low levels (<10 ng/mL) of FGF2 support self-renewal through a mild activation of 
Erk, while higher levels (>50 ng/mL) activate the PI3K pathway in parallel to Erk induction, which in turn 
suppresses MAPK/Erk signaling via a crosstalk mechanism [247]. This explains how Erk activity is 
adjusted at an optimal level under a wide range of FGF2 concentrations. Despite these observations, 
more recent studies have questioned the absolute necessity of FGF2 for reprogramming, as hPSCs 
could be generated in its absence [247]. The reason might be due to the secretion of FGF2 from hPSCs 
themselves, which leads to the activation of Erk signaling through an autocrine/paracrine signaling.  
Activin A and canonical TGF signaling. Activin A represents the first bioactive molecule derived 
from MEF feeder layers, which is essential for hPSC maintenance, as described earlier. In addition, new 
generations of culture methods, such as most of the chemically-defined media, also use Activin A or 
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other TGF family members to support hPSC generation and culturing [240]. In this context, Activin A 
is assumed to signal through the canonical TGF pathway–Smad2/3–which then activates pluripotency-
associated genes, with NANOG, being the most well-known target [243]. 
 
Figure 2. Schematic summary of key signaling pathways and epigenetic modifications associated 
with somatic cell reprogramming and their availability for chemical modulation. The schematic 
illustration summarizes the reprogramming-related signaling networks; TGF- Wnt- PI3K- MAPKs- and 
AMPK, as well as the crosstalk between the first four pathways. In addition, the key epigenetic 
modifications; DNA methylation and histone methylation/acetylation are shown. A color code has been 
used for discrimination between small molecules targeting different pathways and epigenetic changes, 
as indicated. For detailed information refer to section 1.1.2.4.   
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Despite this, a major concern regarding the role of TGF/Smad signaling in hPSC maintenance was 
long-existed due to its opposing functions in pluripotency and early differentiation [244]. This 
discrepancy has been resolved through a crosstalk mechanism between Smad2/3 and PI3K/Akt, which 
controls the balance between self-renewal and differentiation [247]. Simply, when PI3K/Akt is active, it 
establishes conditions in which Activin A/Smad2/3 has a pro-self-renewal function by activating target 
genes, such as NANOG. On the other hand, when PI3K/Akt activity is low, Wnt signaling is activated 
and works together with Smad2/3 to promote differentiation [247].  
PI3K/Akt signaling.  How PI3K/Akt regulates hPSC maintenance could be easily clarified by 
understanding its central role in an elaborate crosstalk signaling network between (i) PI3K/Akt, (ii) 
Raf/MEK/Erk, and (iii) the canonical Wnt pathway, which converges on Smad2/3. Besides impacting the 
level of Smad2/3 activation (as pointed out above), PI3K/Akt inhibits Erk, which in turn suppresses 
GSK3, and by doing so the PI3K/Akt pathway reaches over to Wnt signaling [247]. In addition to this, 
GSK3 activity could be directly inhibited through Akt-mediated phosphorylation (at Ser9), an effect which 
in this context leads to the stabilization of MYC, a key regulator of PSC generation and maintenance. In 
light of this, it has been reported that small molecule inhibition of PI3K (e.g., by LY294002) or removal 
of PI3K activators, as well as the inhibition of mTOR–a downstream kinase of Akt–by rapamycin leads 
to the loss of pluripotency and triggers differentiation [244, 248]. Interestingly, several evidences have 
shown that usually more than one PI3K activator is required for maintaining PSCs. For example, 
StemPro-based media use both IGF and the EGF family member, heregulin, which both signal through 
the PI3K pathway, but one is insufficient in the absence of the other [240]. The immediate explanation 
could be that these factors have functions outside of PI3K/Akt signaling, however, another possibility 
would be that different ligands signal with different temporal kinetics, such as duration of the signaling 
and changes in the signal intensity overtime. Detailed time-course experiments regarding the effects of 
the individual factors on PI3K signaling are therefore necessary to address this question.  
Wnt signaling. The role of the Wnt pathway as a pro-self-renewal signaling has always been 
controversial, as there is little evidence, supporting the importance of the pathway in the induction of 
pluripotency in human, and more drastically its positive impact on promoting differentiation [247, 249]. 
The latter is also consistent with numerous lines of in vivo studies, showing that Wnt is required for germ 
layer formation during gastrulation. This confusion appears to have been generated by overlooking 
different pools of GSK3 [250], and hence their different sensitivities to small molecule inhibitors 
frequently used to improve the reprogramming process. For example, blocking GSK3 activity using the 
indirubin derivative, BIO has been shown to maintain human- and mouse pluripotent state, and this has 
been interpreted as Wnt being a positive regulator of pluripotency [246]. However, another way to 
interpret this would be that inhibition of the GSK3 pool downstream of Akt (not that of Wnt signaling) is 
required for stem cell maintenance, which involves stabilization of several transcription factors, such as 
MYC (as mentioned above). In view of these observations, it has been reported that when all pools of 
GSK3 are inhibited, Wnt signaling is activated through -catenin, leading to differentiation of hPSCs 
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[247, 251]. In summary, it seems that different pools of GSK3 have distinct roles in determining 
PSCs' cellular fate, and the general belief is that suppression of the canonical Wnt pathway 
stabilizes hPSCs. In support of this, OCT4 has been shown to repress -catenin, promoting self-
renewal and pluripotency [249].  
1.2. Pharmacological reprogramming towards pluripotency  
Reprogramming can be achieved by genetic means, such as forced expression of pluripotency 
transcription factors (as described in depth in section 1.1.), which could be further enhanced or even 
avoided using pharmacological means, such as small molecules and growth factors. Chemical 
reprogramming becomes even more desirable when considering the slow process of transcription 
factor-mediated reprogramming as well as its extremely low efficiency. From a therapeutic perspective 
and in the context of regenerative medicine, pharmacological methods of reprogramming allow a safer 
approach–compared with viral transduction–to generate patient's own iPSCs, which can replicate 
indefinitely and differentiate into any somatic cell type, giving rise to unlimited number of therapeutic 
cells for cell transplantation.  
1.2.1. Pharmacological reprogramming–small molecule epigenetic modulators 
Gene expression is largely dependent on epigenetic regulatory mechanisms, involving chemical 
modifications of chromatin, such as DNA methylation as well as histone methylation and -acetylation 
(reviewed in [212]). Therefore, small molecules that modulate the activity of the enzymes responsible 
for these modifications may change the chromatin organization in a manner that it would be suitable for 
transcription of genes required for cellular reprogramming. In light of this, chemical epigenetic modifiers 
have been reported to enhance somatic cell reprogramming towards pluripotency. For example, BIX-
01294, an inhibitor of histone methyl transferase–G9a–has been shown to induce the generation of 
mouse iPSCs from neural progenitor cells when combined with the ectopic expression of "SKM" 
pluripotency factors [252]. Another example is the generation of iPSCs from MEF using a combined 
genetic and chemical approach by means of the DNA methyl transferase (DNMT) inhibitor, RG108 and 
BIX-01294 in cells only expressing two of the core pluripotency factors, OCT4 and KLF4 [253].  
In addition to RG108, which is a non-nucleoside DNMT inhibitor, 5-azacitidine (known as 5-aza, also 
see section 1.1.2.1.), as well as its related analogue, 5-aza-2'-deoxycitidine (5-aza-dc) represent two 
examples from the family of nucleoside DNMT inhibitors and have been shown to enhance OSKM-
mediated cell reprogramming (reviewed in [229]). Additionally, 5-aza was shown to be able to complete 
the reprogramming process of partially-reprogrammed cells (pre-iPSCs) [254]. 5-aza-dc has the 
advantage of incorporating exclusively into DNA, compared with 5-aza, which can incorporate in both 
DNA and RNA when used at high doses. This allows the use of lower concentrations of 5-aza-dc for 
inhibition of DNMTs, thus reduces its toxicity [255]. Despite this, both analogues share a similar 
mechanism by incorporating into DNA, which can induce DNA damage. Therefore, further investigation 
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is required to better determine their pharmacological activity and the optimal concentration for safer and 
more efficient generation of iPSCs.       
1.2.2. Pharmacological reprogramming–small molecule modulators of signaling networks 
Modulating signaling pathways involved in reprogramming (see section 1.1.2.4.) provides another 
approach to rewire the gene transcription in favor of pluripotency. In view of this, it has been reported 
that dual inhibition of TGF- and MEK/Erk signaling using SB431542 and PD0325901, respectively is 
able to induce pluripotency by promoting the process of MET. Other MET-relevant chemicals include A-
83-01 and RepSox, both of which are known to blunt the TGF pathway [229]. The use of SB431542 
and RepSox has been found to substitute SOX2 in the process of iPSCs generation [256], and A-83-01 
has been used in chemical cocktails, which mediate cellular reprogramming in combination with OCT4 
ectopic expression, replacing the other three reprogramming factors [257].  
GSK3 inhibitors have been repeatedly shown to enhance reprogramming. A good example is the 
role of CHIR99021, a small molecule inhibitor of GSK3 and activator of Wnt, in enhancing 
reprogramming. The proposed mechanism is that activation of Wnt stabilizes -catenin, which then 
transfers to the nucleus and exploits homeodomain-interacting protein kinase 2 to phosphorylate TCF3. 
By doing so, the repressive effect of TCF3 on the promoter regions of reprogramming factors is relieved, 
facilitating the reprogramming process [258]. Additionally, CHIR99021, in combination with other small 
molecules, has been shown to replace SOX2 and MYC in inducing ground state pluripotency of mouse 
brain-derived neural stem cells [259], as well as human keratinocytes [260].  
In addition to the MEK/Erk- TGF- and GSK3 small molecule modulators, activation of cAMP 
signaling has been long-established for iPSC generation. In light of this, 8-bromo-cAMP, a cell-
permeable analogue of cAMP, was shown to increase the efficiency of OSKM-mediated reprogramming 
of human neonatal foreskin fibroblasts by 2-fold, and its combination with valproic acid was found to 
synergistically increase the efficiency by 6.5-fold [261]. Another interesting example of cAMP signaling 
modulators is forskolin–an adenylyl cyclase activator–which was found to functionally replace OCT4 for 
the generation of iPSCs from MEF when combined with the other three transcription factors, "SKM" (the 
first example of chemically-generated miPSCs; [262]). Further investigations suggested that the 
downstream exchange protein directly activated by cAMP (EPAC)–rather than protein kinase A (PKA) 
signaling–is necessary and sufficient for lowering the reprogramming barrier through enhancing MET 
and proliferation [263].  
1.2.3. Pharmacological reprogramming–small molecule modulators of cell metabolism 
During reprogramming, a major metabolic switch from mitochondrial oxidative phosphorylation 
towards glycolysis is required (for more details on the metabolic regulation during reprogramming 
refer to [264]). The early evidence with regards to metabolic modulation in cellular reprogramming came 
from the use of a small molecule activator of pyruvate dehydrogenase kinase 1 (PDK1), PS48, for 
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generating human iPSCs in combination with OCT4 expression, as well as other epigenetic- and 
signaling modulators [257]. Consistent with this finding, it was reported that promoting glycolytic 
metabolism using various small molecules, such as fructose 2,6-bisphosphate (through activating 
phosphofructokinase 1) and quercetin (through promoting HIF1 activity) enhances reprogramming. In 
contrast, inhibition of glycolytic metabolism blocks reprogramming; the examples are the effects of 2-
deoxyglucose (2DG, a glycolysis inhibitor), 3-bromopyruvic acid (a hexokinase II inhibitor), as well as 
dichloroacetate (a PDK inhibitor) in blunting the reprogramming process [265]. 
The necessity of glycolytic metabolism for iPSC generation was further confirmed by showing a 
negative role for rapamycin (a mechanistic target of rapamycin (mTOR) inhibitor) and a positive role for 
AICAR (a small molecule activator of AMP-activated protein kinase (AMPK)) in OSKM-mediated iPSC 
generation [266]. Importantly, this study shed new light on the mechanism of metabolic reprogramming 
associated with the induction of pluripotency, as it suggested that the noncanonical autophagy pathway 
(ATG5-independent) plays a crucial role in mitochondrial clearance, harboring the oxidative 
phosphorylation machinery [266]. This finding is particularly interesting, as it shows that iPSC 
generation and tumorigenesis share a similar metabolic switch, which appears to be accessible 
for small molecule modulation.    
1.2.4. Pharmacological reprogramming–combined chemical treatments 
The chemical approaches described in the previous sections demonstrate that multiple mechanisms, 
such as epigenetic- and signaling pathways could be targeted concomitantly using certain small 
molecules or their combination in order to compensate for the absence of most pluripotency transcription 
factors. In this regard, a combination of A83-01 (targeting TGF signaling) and AMI-5 (a protein arginine 
methyltransferase inhibitor) was shown to enable OCT4-induced reprogramming of MEF to iPSCs [267]. 
In addition, AMI-5 has been used in combination with the MEK/Erk inhibitor (PD0325901) to induce 
pluripotency in human keratinocytes with ectopic expression of OCT4 and KLF4. This was further 
improved when adding PS48 (also see section 1.2.3.) and sodium butyrate (NaB; an inhibitor of histone 
deacetylase) to the cocktail, which enabled OCT4-only induction of pluripotency [268]. Adding the GSK3 
inhibitor, CHIR99021 (also see section 1.2.2.) and parnate, which is a small molecule inhibitor of lysine-
specific demethylase 1 (LSD1) to this cocktail was found to further improve the reprogramming of human 
keratinocytes, which are known to be resistant to reprogramming. On the basis of these findings, an 
optimized protocol has been developed using the combination of these six small molecules with forced 
expression of OCT4 alone for the generation of iPSCs from human epidermal keratinocytes (reviewed 
in [269]). Altogether, it seems that screening small molecule enhancers of reprogramming not 
only provides us with new tools for generating iPSCs, but also unravels previously unknown 
mechanisms underlying the reprogramming process. 
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1.3. Project narrative–rationale, hypothesis, and purpose 
Several lines of preclinical- and clinical evidence have pinpointed the need of safer and more efficient 
approaches for the generation- and maintenance of iPSCs. In light of this, pharmacological 
reprogramming using chemical enhancers of pluripotency appears to offer an alternative route, which 
can complement, reduce, or even avoid the use of genetic tools for example, delivery of exogenous 
transcription factors in somatic cells. The ability to generate such chemically induced pluripotent stem 
cells (referred to as ciPSCs) may provide us with a safer reprogramming method for various applications, 
including iPSC-based cell therapies as well as drug development in the field of regenerative medicine.  
One way to identify small molecules that are able to facilitate reprogramming is functional screen of 
known drugs, i.e., searching for chemicals sharing similar backbones with approved drugs in order to 
have advantages in terms of pharmaco-kinetic and -dynamic properties. We therefore adopted this 
strategy with the aim of (i) finding new candidates capable of inducing pluripotency-associated 
markers. The focus was particularly drawn to one of the "master genes" of reprogramming, OCT4, as 
it has been frequently shown to be irreplaceable when using chemical cocktails for the induction of 
pluripotency in human somatic cells (see section 1.2.). In view of this, mouse fibroblasts have been 
successfully reprogrammed to iPSCs by a combination of seven small molecule compounds, showing 
that the master pluripotency genes are dispensable for the generation of mouse iPSCs. Despite this 
breakthrough and as mentioned earlier, small molecule cocktails for the generation of human 
chemically-induced iPSCs are yet to be developed mostly due to the lack of a sufficiently strong inducer 
of OCT4. Having this in mind, we aimed at (ii) optimizing a chemical condition using our small 
molecule hits from the screen in order to substitute OCT4 in the context of OSKM-meditated 
reprogramming and referred to them as OCT4 inducing compounds (O4I). 
Reprogramming is a complexed process involving many genetic- and epigenetic alterations and 
intricate crosstalks between multiple cellular signaling pathways (as described in depth, previously). 
After more than a decade of great advances in the field of transcription factor-mediated reprogramming, 
molecular mechanisms underlying this process remain to be thoroughly understood. Upon the 
identification of new small molecules able to enhance OSKM-based reprogramming, we aimed at (iii) 
exploring the mode of action of O4I compounds employing different methods, ranging from DNA 
microarray to RNA-sequencing and ATAC-sequencing. Our findings not only led to the development 
of new chemical tools for the induction of pluripotency in human somatic cells, but also shed new light 
on the molecular events during reprogramming as well as their availability for small molecule 
intervention.




2.1. Cell-based high throughput screening identifies new small molecules able to induce 
pluripotency-associated markers. 
Looking for potential small molecule inducers of pluripotency, we sought to perform a 
high throughput screen (HTS) from a chemical library containing ~250,000 compounds. The 
screen was carried out in HEK-293 cells stably transfected with a reporter construct in which 
the expression of luciferase is under the control of human OCT3/4 promoter (Figure 3). 
Doing so, we identified several lead structures showing potent activity in enforcing OCT4 
expression, among others, are 2-[4-[(4-methoxyphenyl)methoxy]phenyl]acetonitrile (referred 
to as O4I1) and 2-((4-chlorophenyl)amino)-thiazole-4-carboxylate (referred to as O4I2), as 
previously described [270] (Figure 3, also see Figure 4A and 4B for the structures of 
O4I2 and its derivatives). 
2.1.1. The metabolically-stable O4I2 derivatives are potent OCT4 inducers.  
 
Figure 3. Cell-based high throughput screening identifies a series of OCT4-inducing compounds 
(O4Is). Top; HEK-293-OCT4 reporter cell line in which luciferase expression is controlled by the promoter 
activity of the master pluripotency gene, OCT4 was used to screen a chemical library containing 
~250,000 small molecules. Bottom; chemical structures of the hits (herein O4I1/2/3) obtained from the 
screen.  




In addition to HEK-OCT4 cells, we sought to expand our readout by including two additional reporter 
cell lines, human embryonic carcinoma cells stably expressing luciferase under the control of promoter 
regions of either OCT4 or NANOG (designated as NCCIT-OCT4 and NCCIT-NANOG, respectively). 
Almost all analogues were found to activate OCT4 in HEK-OCT4 reporter cells, while they failed to do 
the same in NCCIT cells (Figure 4C).  
Figure 4. OCT4-inducing compound 2 
(O4I2) and its derivatives induce OCT4 
expression. (A) Synthesis procedure of 
O4I2 and its carboxylic analogues. (B) 
Structures of the O4I2 derivatives, indicated 
by numbers. (C) O4I2 and the derivatives 
presented in (B) induce OCT4 expression in 
HEK-293 reporter cells, as determined by 
luciferase activity. This effect was found to 
be lost in the NCCIT-OCT4 and -NANOG 
reporter cell lines. A concentration of 20 M 
of the chemicals was applied to the cells for 
48 h. Relative luciferase activity was 
determined by normalizing the values of the 
treated cells to mock (0.2% DMSO) 
treatment. Data present the mean  SD of 
four independent experiments. Statistical 
significance between mock and treated cells 
was calculated using a two-tailed student's t-
test. *** indicates a p-value less than or 
equal to 0.001.   
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We have previously reported that O4I2 converts to 2-(4-chlorophenylamino)thiazole-4-carboxylic 
acid (O4I2-COOH), a metabolic product that was shown to be inactive in HEK-OCT4 cells [270]. This 
prompted us to hypothesize that acid hydrolysis, for example via the action of carboxylesterase 1 (CES1) 
enzyme, which is responsible for ester-to-acid conversion contributes to the inactivation of O4I2 
derivatives in NCCIT cells. In line with our hypothesis, we observed a significantly higher expression of 
CES1 in NCCIT cells and PSCs when comparing the expression levels of CES1-5 isozymes among 
selected cell lines, using previously published gene expression data [271-273] (Figure 5A). We then 
replaced the ethyl ester with CES1-resistant groups (Figure 5B), recovering the activity of the 
derivatives in the NCCIT reporter cells (Figure 5C). Based on these results, we identified the most 
potent compound (No. 23), and designated it as O4I4.   
      
Figure 5. Metabolic stability is necessary for OCT4-inducing ability of O4I2 and its derivatives. 
(A) Re-analysis of previously published gene expression data [271-273] for comparing the expression 
levels of different isozymes of carboxylesterase (CES) in NCCIT cells, human fibroblasts (HFs), iPSCs, 
as well as human pluripotent naive stem cells. (B) Structures of the non-carboxylic derivatives of O4I2, 
indicated by numbers. (C) OCT4-inducing activity of the compounds presented in (B) was measured in 
the HEK-293 and NCCIT reporter cell lines treated with 20 M of the small molecules for 48 h. Relative 
luciferase activity was calculated respective to mock (0.2% DMSO) treatment. (D) A 5-day treatment with 
the most potent non-carboxylic analogue of O4I2 (No. 23, designated as O4I4) induces OCT4 protein 
levels in HFs concentration-dependently, as determined by immunoblotting. NCCIT cells were included 
as reference. Vinculin served as the loading control. Data in (C) present mean  SD of four independent 
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experiments. Statistical significance was calculated between mock and treated cells using a two-tailed 
student's t-test. *, **, and *** are indicative of p-values less than or equal to 0.05, 0.01, 0.001, 
respectively.   
2.1.2. Imidazopyridine derivatives are potent OCT4 inducers.   
As our next step, we intended to search for small molecules with similar structures to those of 
approved drugs, a strategy which could ultimately lead to "drug repurposing". This approach offers 
various advantages for example, in terms of safety and time over developing an entirely new molecule 
for a given application [274]. In light of this, our initial screen identified more than 4000 imidazopyridine 
derivatives sharing a similar backbone with the FDA-approved sedative-hypnotic drug, zolpidem (Figure 
3B). These analogues showed significantly higher luciferase activity in the HEK-OCT4 reporter cell line, 
as compared to that of the non-treated cells (Figure 3A). In order to study this class of compounds in 
depth, we synthesized the lead structure, 6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridin by heating ɷ-
bromoacetophenone with an excess of 2-aminopyridine for 3 h to achieve a yield of >95%, thereafter 
referred to the compound as O4I3 (Figure 6A). 
 
 Figure 6. The imidazopyridine analogues, O4I3 and zolpidem, show potent OCT4-inducing ability. 
(A) The synthesis procedure of O4I3, the lead structure of imidazopyridine derivatives identified by the 
cell-based high throughput screening. (B) 48 h treatment with various concentrations of O4I3 induces a 
significant increase in OCT4 expression in NCCIT reporter cells. (C) and (D) Similar to O4I3, zolpidem–
also carrying the imidazopyridine backbone–was found to activate the pluripotency-associated genes, 
OCT4 and NANOG in NCCIT reporter cells at 48 h post-treatment with the indicated concentrations. 
OCT4 promoter activation was measured by luciferase assay. 0.1% DMSO was used as mock treatment. 
Data in (B-D) present mean  SD of at least three independent experiments. Statistical significance was 
compared to non-treated (NT) cells and mock using a two-tailed student's t-test. ** and *** are 
representative of a p-value less than or equal to 0.01 and 0.001, respectively.  
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In addition to HEK-293, we tested O4I3 in NCCIT-OCT4 reporter cells and found ~10-fold induction 
in the expression of this master pluripotency gene upon treatment with various concentrations of O4I3 
(Figure 6B). To our expectation, zolpidem, which carries the imidazopyridine backbone showed an 
increase in OCT4 and NANOG expression, although to a lower extent (~2-fold) and at higher 
concentrations (10 M) compared with O4I3 (Figure 6C and 6D). 
A major concern of large screens is pan-assay interference compounds (PAINS), which refer to 
structures from several classes of compounds with non-drug-like mechanisms (discussed by Baell J. 
and Walters M.A. in [275]). To avoid this, O4I3 was chemically expanded by replacing the methyl group 
at the phenyl moiety with several other substituents on the aryl moiety (Figure 7A). These analogues 
were then tested in NCCIT-OCT4 reporter cells and were found to activate OCT4 expression in a 
structure-dependent manner (Figure 7B).   
 
Figure 7. O4I3 analogues induce OCT4 activity in a similar manner to the parental molecule. (A) 
Chemical structures of O4I3 derivatives, indicated by numbers. (B) NCCIT reporter cells were treated 
with 50 nM of the derivatives listed in (A) or O4I3 for 48 h, after which activation of OCT4 promoter was 
measured using luciferase assay. Data present the mean of at least three independent experiments, 
Error bars  SD. 0.1% DMSO was used as mock treatment. Statistical significance was made in 
comparison to O4I3 treatment using a two-tailed t-test. *, **, and *** denote p-values less than or equal 
to 0.05, 0.01, and 0.001, respectively. 
2.2. O4I3 supports the generation and maintenance of human iPSCs.  
2.2.1. O4I3 maintains the pluripotency of human PSCs.  
Our initial functional annotation and enrichment analysis of DNA microarray in O4I3-treated human 
PSCs demonstrated that a concentration of 10 nM of the compound is able to promote PSCs' 
homeostasis as well as repressing their differentiation (Figure 8A). Consistent with this, gene 
expression analysis using qRT-PCR confirmed the stabilization of several pluripotency-associated 
genes (e.g., OCT4, SOX2, and NAONG) together with the inhibition of differentiation markers (Figure 
8B). In addition, cellular viability of human iPSCs was increased by ~4-fold, as compared to the small 
molecule inhibitor of Rho-associated kinase (Rocki; known as Y-27632), which is used as a reference 
compound for maintaining iPSCs [276] (Figure 8C). As expected, zolpidem was found to have 
comparable effects to O413 on iPSCs' cellular survival, however at higher doses (Figure 8C). 
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2.2.2. O4I3 promotes the OSKM-mediated reprogramming process in resistant human 
fibroblasts. 
To investigate whether O413 has a positive impact on OSKM-mediated reprogramming, we first 
treated fibroblasts (HFs) with the compound, and analyzed the expression of reprogramming-associated 
genes, using qRT-PCR. As demonstrated in Figure 9A and 9B, O4I3 treatment led to ~10- and ~100-
fold induction in OCT4 and SOX2 mRNA levels, respectively, compared with non-treated HFs. This was 
found to be ~0.1% of OCT4 expression and ~1% of SOX2 expression in human PSCs, which were 
included as reference (Figure 9A and 9B). 
    
Figure 8. O4I3 supports iPSC pluripotency and viability. (A) Functional enrichment analysis of DNA 
microarray in human pluripotent stem cells (PSCs) treated with 50 nM of O4I3 for 24 h demonstrates a 
significant enrichment in gene ontology terms related to pluripotency, development, and homeostasis. A 
color code has been used for up- and downregulated genes, with red indicative of the former and blue 
indicative of the latter. For more details regarding the analysis see the method section; 4.2.17. 
(B) qRT-PCR analysis of the mRNA levels of several pluripotency- and differentiation-related genes 
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shows a clear increase and decrease with O4I3 treatment (10 nM, 48 h) in human PSCs, respectively. 
Relative mRNA expression was calculated using the  Ct method where the Ct values of each gene 
were normalized to those of the housekeeping gene (actin). (C) O4I3 enhances the viability of iPSCs 
after single-cell expansion using 10 M of Rho kinase inhibitor (designated as ROCKi) for the first 24 h, 
followed by continuous cultivation for 7 days (D, days) in the presence of various concentrations of O4I3 
or zolpidem. Cellular viability was determined as the number of treated cells over mock, using MTT 
cytotoxicity assay. Zolpidem was found to induce a similar pattern in increasing the viability of PSCs, 
however at higher tested doses compared with O4I3. Data in (B) and (C) present mean  SD of at least 
three independent experiments. Statistical significance was performed in comparison to mock (0.1% 
DMSO) treatment or ROCKi-treated cells using a two-tailed student's t-test. *, **, and *** indicate a p-
value less than or equal to 0.05, 0.01, and 0.001, respectively.       
Having confirmed this, we combined O4I3 with a commercially available episome-based reprogramming 
cocktail, which enforces the expression of OCT4, SOX2, KLF4, and L-MYC (or the "OSKM"), as well as 
LIN28 and suppresses the expression of p53 (for simplicity, we will refer to this cocktail as OSKM 
throughout this section, although it contains additional vectors (LIN28 and p53) compared with the 
original OSKM cocktail). Interestingly, O4I3 synergized with OSKM and increased the number of TRA-
1-60-positive colonies by 10- to 20-fold in four different human primary fibroblasts (HF1, HF2, HF3, and 
HF4) when compared with OSKM-only treated HFs (Figure 9C). Through various mechanisms, such 
as senescence donor fibroblasts might confer resistance to transcription factor-meditated 
reprogramming. In view of this, we observed that adding O4I3 to the OSKM cocktail not only promotes 
the generation of TRA-1-60-positive colonies in reprogramming-resistant fibroblasts, (designated as 
HF3 and HF4, Figure 9C), but also enables the generation of iPSC-like colonies, as detected by EGFP-
expressing cells using reporter fibroblasts carrying a LTR7-EGFP construct (Figure 9D). Similar to O4I3, 
zolpidem was able to convert resistant fibroblasts into iPSCs in combination with OSKM ectopic 
expression (Figure 9E). 
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Figure 9. Imidazopyridines promote OSKM-mediated reprogramming of human fibroblasts. (A) 
and (B) O4I3 induces the mRNA levels of the master pluripotency genes, OCT4 (A) and SOX2 (B), as 
determined by qRT-PCR analysis. Human fibroblasts (HFs) were treated with 50 nM of the small 
molecule for the indicated duration (D, days). Relative expression was determined using the  Ct 
method in which the Ct values of OCT4 and SOX2 were normalized to those of the housekeeping gene 
(actin). (C) OSKM-mediated reprogramming efficiency with O4I3 (designated as O3-OSKM, 50 nM) or 
without the small molecule, as determined by TRA-1-60 staining. Reprogramming-resistant fibroblasts 
are denoted as HF3 and HF4. (D) Representative fluorescence images, showing the generation of ESC-
like colonies from resistant fibroblasts using a combination of O4I3 and OSKM forced expression, as 
determined by EGFP expression. The used HFs carry the LTR7-EGFP constructs in which the 
expression of EGFP is under the control LTR7 promoter, which is known to be activated during 
reprogramming [277]. (E) Reprogramming-resistant fibroblasts were transfected with the OSKM cocktail 
in the absence or presence of the imidazopyridine analogue, zolpidem (10 M), after which ESC-like 
colonies were detected using alkaline phosphatase (AP) staining. Data in (A), (B), (C), and (E) present 
mean  SD of three biological replicates. Statistical significance was calculated in comparison to mock 
treatment (0.1% DMSO) in (A) and (B) and to the OSKM-only treatment in (C) using a two-tailed student's 
t-test. * and *** present a p-value less than or equal to 0.05 and 0.001, respectively.      
 
Figure 10. iPSCs generated by O4I3 and OSKM combination express pluripotency markers in a 
similar manner to human PSCs. (A) Bright field images showing the ESC-like morphology of the newly 
generated iPSCs. (B) Immunoblots demonstrating the expression of several pluripotency markers in new 
iPSCs (denoted as iPSC_1-3) in a comparable manner to those in human PSCs and NCCIT cells, which 
were included as reference. Human fibroblasts (HFs) served as the negative control, as they do not 
express the indicated pluripotency proteins. Actin served as the loading control. (C) 
Immunocytochemistry of the master pluripotency factors, OCT4 and SOX2 in the new iPSCs. (D) 
Representative density plots illustrating co-expression of the pluripotency-associated makers, E-
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cadherin and TRA-1-60 (top) as well as OCT4 and TRA-1-81 (bottom) in the new iPSCs, assessed by 
flow cytometry analysis. 
2.2.3. O4I3-generated iPSCs resemble human ESCs.       
Next, we aimed to expand and characterize the new iPSC cell lines generated by means of O4I3 
and OSKM forced expression. For this, iPSC-like colonies were isolated and cultured under feeder-free 
conditions for >30 passages. The newly established iPSCs showed a similar morphology to that of 
human PSCs (Figure 10A) and were found to have a similar expression pattern of pluripotency-
associated markers (e.g., OCT4 and SOX2) with that of human PSCs, as shown by immunoblotting and 
immunocytochemistry (Figure 10B and 10C). In addition to this, flow cytometry analysis of OCT4, E-
Cadherin, TRA-1-60, and TRA-1-81 demonstrated more than 95% of iPSC population, co-expressing 
E-Cadherin and TRA-1-60, as well as OCT4 and TRA-1-81 (Figure 10D). Comparative DNA microarray 
analyses showed an up- and downregulation of pluripotency-associated genes and fibroblast-related 
genes in two cell lines of the new iPSCs (indicated as iPSC_1 and iPSC_2), respectively (Figure 11A). 
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Figure 11. iPSCs generated by O4I3 and OSKM combination resemble human PSCs in their self-
renewal and differentiation properties. (A) Heatmaps of gene expression profiles of human fibroblasts 
(HFs), hPSCs, and the newly generated iPSCs (denoted as iPSC_1-2). hPSCs, iPSC_1, and iPSC_2 
show a high similarity in the expression pattern of the selected pluripotency- (light green) and 
differentiation-related (dark green) genes, which is distinct to that of HFs. For more details regarding 
the analysis refer to the method section; 4.2.17. (B) and (C) Heatmaps- (B) and scatter plots (C) 
of global gene expression profiling in HFs, hPSCs, and the new iPSCs. Heatmaps and scatterplots are 
based on log2-transformed gene expression values. Red dashed lines in (C) depict the 2-fold change in 
expression values. (D) qRT-PCR analysis of differentiation markers indicative of each germ layer. Data 
present the  Ct values of each gene respective to the housekeeping gene (actin). Error bars  SD, n 
= 3. Statistical significance was made in comparison to the undifferentiated iPSCs using a two-tailed 
student's t-test. (E) Immunocytochemistry of selected differentiation markers representative of the 
indicated lineages demonstrate the differentiation ability of the newly generated iPSCs. Scale bar: 40 
M. *** presents a p-value less than or equal to 0.001.      
Furthermore, comparison of global gene expression profiles of iPSC_1 and iPSC_2 with human PSCs 
and HFs revealed a high resemblance of the gene expression pattern among the first three, but not with 
that of HFs, as determined by both heatmap- and scatterplot analyses (Figure 11B and 11C). Finally, 
the newly-generated iPSCs were found to be able to differentiate into the three germ layers (mesoderm, 
ectoderm, and endoderm)–one of the unique properties of PSCs–as determined by qRT-PCR and 
immunocytochemistry analyses of lineage-specific markers (Figure 11D and 11E). 
2.2.4. O4I3 is an epigenetic modifier.  
2.2.4.1. O4I3 protects the methylation of H3K4. 
 
Figure 12. Epigenetic genes are on top of the O4I3-regulated genes. (A) Venn diagrams comparing 
the up- and downregulated genes in human fibroblasts (HFs) treated with 50 nM of O4I3 for 24 h 
(designated as HF-O4I3), HFs transfected with OSKM (HF-OSKM), and iPSCs. (B) Heatmaps of gene 
expression profiles demonstrate that among similarly regulated genes between the three groups, genes 
involved in epigenetic modification and remodeling are on top of the regulated terms. For more details 
regarding the analysis refer to the method section; 4.2.17.  
To gain further insight into the mode of action of O4I3, we sought to compare the gene expression 
profiles of HFs, HFs treated with O4I3 (HF-O4I3), HFs transduced with OSKM (HF-OSKM), as well as 
human iPSCs (as positive control). More than 40% of all the regulated genes were found to be similar 
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among the three groups, of those, ~30% appeared to be involved in epigenetic modification and 
chromatin remodeling (see Figure 12). This encouraged us to study the epigenetic regulatory effects of 
O4I3 and its potential relevance to the reprogramming efficiency. As thoroughly discussed above, 
transcription factor-mediated reprogramming is largely dependent on epigenetic changes, among 
others, rearrangements of histone modifications (summarized in an excellent review [278]). With that 
in mind, we focused on three well-known histone modifications associated with the promoter of OCT4, 
namely H3K4Me3, H3K9Me3, and H3K27Me3 (thoroughly reviewed in [212]). Hypermethylation of 
H3K4 and demethylation of H3K9 and H3K27 represent some of the early epigenetic events during the 
course of reprogramming, which are required for loosening the compacted heterochromatin, and hence 
facilitating the binding of pluripotency transcription factors to the "open" chromatin [212, 278]. In light of 
this, chromatin immunoprecipitation-qPCR (ChIP-qPCR) analysis of reprogrammable fibroblasts 
(designated as HF1 and HF2) and reprogramming-resistant fibroblasts (designated as HF3 and HF4) 
revealed that O4I3 (in combination with OSKM) is capable of protecting H3K4 methylation at the 
promoter of OCT4 at significantly higher levels compared with those treated with OSKM alone in HF2 
as well as the resistant HFs (Figure 13A). H3K27Me3 occupation levels remained to be mostly 
unchanged in our experimental setting (Figure 13A and 13C). Additionally, we also analyzed global 
expression of H3K4Me3, H3K9Me3, and H3K27Me3 by immunocytochemistry and immunoblotting and 
observed an increase in case of H3K4Me3, a decrease in case of H3K9Me3, and no significant change 
in case of H3K27Me3 in response to O4I3 (Figure 13B-D). Moreover, an in vitro methylation assay 
demonstrated the ability of O4I3 in protecting trimethylated H3K4 with an IC50 value of ~20 nM (Figure 
13E), further implicating the regulation of histone methylation as O4I3's mode of action with regards to 
cellular reprogramming.      
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Figure 13. O4I3 is an epigenetic regulator through supporting H3K4 methylation. (A) ChIP-qPCR 
analysis of H3K4Me3- and H3K27Me3 occupation at the promoter of OCT4 in reprogrammable and 
reprogramming-resistant human fibroblasts (HF1/2 and HF3/4, respectively) in the presence of O4I3 
(designated as O3-OSKM, 50 nM) or in the absence of the molecule. The small molecule was found to 
increase the levels of H3K4Me3 at OCT4 promoter, whereas methylated H3K27 remained to be mostly 
unchanged with treatment. (B-D) O4I3 increases the global levels of H3K4 (B) and decreases those of 
H3K9 (C), as determined by immunocytochemistry of HFs treated with 250 nM of the molecule 
transfected with the OSKM cocktail or not. Representative immunoblots (D) show a similar pattern of 
protein expression of the aforementioned histone marks in HFs treated with increasing concentrations 
of O4I3 for 24 h or with 250 nM of the small molecule for the indicated time points. 0.1% DMSO served 
as mock and actin was used as the loading control. (E) O4I3 protects H3K4 methylation with an IC50 
value of ~20 nM, as measured by an in vitro methylation assay. Statistical significance in (A) was 
performed in comparison to OSKM-only treated fibroblasts using a two-tailed student's t-test. Error bars 
 SD, n = 3. *, **, and *** are indicative of a p-value less than or equal to 0.05, 0.01, and 0.001.          
2.2.4.2. O4I3 strongly inhibits the histone demethylase enzyme, KDM5A.  
As discussed in the section 1.1.1.2., histone methylation is a reversible process, meaning that one 
or more of the methyl groups existing on a particular lysine residue could be erased through the action 
of histone demethylases, for example KDM5s and LSD1 in case of H3K4 (reviewed in [220]). This 
sparked the idea of O4I3 acting through the inhibition of specific histone demethylase enzymes. 
Focusing on the H3K4-related HDMs, we sought to test the inhibitory effect of O4I3 on LSD1 and KDM5, 
as well as KDM4, which is known to be selective for demethylation of H3K9 and H3K36 [279]. Our 
results from an in vitro demethylation assay revealed a strong inhibition of KDM4 and KDM5, however, 
with ~300-fold less efficiency in case of the former, as determined by the calculated IC50 values, 249 nM 
and 0.79 nM, respectively (Figure 14). Unlike the KDM family members, O4I3 did not show any major 
inhibitory effect on LSD1 even when using concentrations as high as 100 M (Figure 14A). Having 
confirmed the potent affinity of O4I3 to KDM5, we were interested to assess whether there is a significant 
alteration in the small molecule's effects on different isozymes of the KDM5 family, namely KDM5A, 
KDM5B, KDM5C, and KDM5D. In this regard, O4I3 was found to have the most selectivity against 
KDM5A (with an IC50 value of ~0.19 nM), followed by KDM5D, KDM5C, and finally KDM5B (Figure 
14B). Consistent with our initial hypothesis, suggesting a similar mode of action between zolpidem and 
O4I3 due to the existence of an imidazopyridine backbone, we observed an increase in H3K4 
methylation and a decrease in KDM4/5 activity by zolpidem, however at higher concentrations compared 
with those of O4I3 (Figure 14C). 
2.2.5. KDM5A represents a targetable epigenetic barrier during the process of reprogramming.  
As our next step, we aimed at comparing the effects of known small molecule inhibitors of KDMs on 
the expression of pluripotency-associated markers. In light of this, CPI-455 [280] and JIB-04 [281], 
targeting KDM5 showed a clear induction of OCT4 in NCCIT reporter cells (Figure 15A), an effect which 
could not be observed in cells treated with daminozide (inhibiting KDM2/7) [282] or GSK-J4 (a selective 
jumonji H3K27 demethylase inhibitor) [283]. Consistent with the results of reporter cells, JIB-04 
promoted the mRNA expression of OCT4, SOX2, and E-cadherin in HFs (Figure 15B and 15C). 
 




Figure 14. Imidazopyridines are strong inhibitors of H3K4 demethylase enzymes, KDM5s. (A) 
O4I3's inhibitory effect on histone demethylases, KDM4, KDM5, and LSD1, using an in vitro 
demethylation assay. (B) Among the four different isozymes of KDM5, O4I3 was found to have the most 
potent inhibitory activity against KDM5A in vitro. (C) The imidazopyridine analogue, zolpidem protects 
the methylation of H3K4 and inhibits its demethylases, KDM5s in vitro in a similar manner to O4I3. Data 
in (A) and (B) are mean  SD of three biological replicates.     
 
Figure 15. KDM5 chemical inhibition induces pluripotency-associated factors. (A) Various small 
molecule inhibitors of histone demethylases were employed on NCCIT-OCT4 reporter cells for 48 h, after 
which OCT4 promoter activity was measured by luciferase assay. The selective KDM5 inhibitor, JIB-04 
shows the highest OCT4 induction compared with mock (0.1% DMSO) treatment. (B) and (C) 5 M of 
JIB-04 induces the mRNA levels of the master pluripotency gene, OCT4 (B) as well as SOX2 and E-
cadherin (denoted as E-CAD) in human fibroblasts, assessed by qRT-PCR analysis (D, days). Relative 
mRNA expression was determined using the  Ct method where the Ct values of each gene were 
normalized to those of the housekeeping gene (actin). Data present mean  SD of three biological 
replicates. Small molecule-treated cells were compared with mock treatment using a two-tailed student's 
t-test. *, **, and *** present a p-value of 0.05, 0.01, and 0.001, respectively.    
CHAPTER [2]  [RESULTS] 
 
 98 
Based on our observation with chemical inhibitors (see Figure 15A), showing a higher OCT4 
induction in case of JIB-04, which is more selective towards the KDM5A isozyme compared with CPI-
455, which is known to be a pan-KDM5 inhibitor [280, 281], we were intrigued to investigate the 
differential role of KDM5 family members in promoting pluripotency. For this, we compared the 
expression of KDM5A-D in NCCIT cells, HFs (both reprogramming-sensitive and -resistant), HFs 
reprogrammed by OSKM, as well as iPSCs, and found that KDM5A expression is higher in 
reprogramming-resistant HFs (designated as HF4), whereas KDM5B is rather expressed in cells with a 
pluripotent state (Figure 16A). This was consistent with the previously-published gene expression 
profiles [239] (Figure 16B) as well as our immunoblotting data (Figure 16C), altogether implicating 
KDM5A as an epigenetic barrier during the process of reprogramming. 
  
Figure 16. KDM5A is oppositely regulated in differentiated- and pluripotent states. (A) comparison 
of KDM5A and KDM5B mRNA expression in reprogrammable and reprogramming-resistant fibroblasts 
(HF1 and HF4, respectively), fibroblasts transfected with the OSKM cocktail, as well as iPSCs and 
NCCIT cells, assessed by qRT-PCT analysis. Relative mRNA expression was determined using the  
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Ct method where the Ct values of KDM5A/B were normalized to those of the housekeeping gene ( 
actin). KDM5A and KDM5B were found to have the highest and the lowest expression in HF4, 
respectively. Error bars  SD, n = 3. (B) Consistent with qRT-PCR results, re-analysis of previously 
published gene expression data [239] revealed that KDM5B is mostly associated with a pluripotent state, 
while KDM5A has the highest expression in fibroblasts. (C) Immunoblots showing higher KDM5A protein 
levels in HFs as compared to PSCs and NCCIT cells. In contrast, KDM5B has the highest expression in 
pluripotent stem cells. actin served as the loading control. In (A) statistical significance was performed 
respective to HF4 using a two-tailed student's t-test and in (B) multiple comparisons were employed by 
a two-way ANOVA test followed by a post-hoc Tukey test. *, **, and *** are representative of a p-value 
less than or equal to 0.05, 0.01, and 0.001, respectively.   
In support of the repressing role of KDM5A in pluripotency, we found that genetic inhibition of KDM5A 
by siRNA significantly increases OCT4 expression in NCCIT reporter cells as well as OCT4 and SOX2 
mRNA levels in HFs, an effect which could also be observed in case of KDM5D knockdown cells, but 
not in cells transfected with KDM5B/C siRNA (Figure 17A and 17B). Additionally, KDM5A knockdown 
cells demonstrated increased global methylation of H3K4 in HFs both in the absence and presence of 
OSKM (Figure 17C). As expected, KDM5A ectopic expression counteracted these effects mediated 
either by O4I3 or siRNA knockdown, as determined by significantly less OCT4 induction in HEK-293 
and NCCIT reporter cells (Figure 17D). In addition to this, combining KDM5A chemical inhibitors (JIB-
04 and O4I3) with KDM5A over-expression significantly abrogated OCT4-inducing ability of the former 
(Figure 17E). Finally, KDM5A over-expression was found to reduce the reprogramming efficiency of 
resistant HFs, as indicated by the number of TRA-1-60-positive colonies (Figure 17F). 
Having confirmed KDM5A as an epigenetic barrier of reprogramming, we were inclined to further 
study the relevance of H3K4 methylation as well as its demethylation (which is mostly mediated by 
KDM5A) to the reprogramming efficiency. First, we compared H3K4Me3 occupation at the promoter of 
OCT4 among reprogramming-resistant HFs (HF4), HF4 treated with JIB-04, as well as HF4 
reprogrammed by OSKM in the absence- and presence of genetic/chemical inhibition of KDM5A and 
siRNA-mediated knockdown of KDM5B-D (see Figure 18A). As determined by ChIP-qPCR analysis, 
OSKM forced expression increases the levels H3K4Me3 at the promoter of OCT4, an effect which is 
further enhanced in combination with siRNA-mediated knockdown of KDM5A, but not with that of other 
members of the KDM5 family (Figure 18A). Chemical inhibition of KDM5A (using JIB-04) showed a 
similar pattern either as single treatment or in combination with ectopic expression of OSKM (Figure 
18A). Consistent with this, OSKM-transduced HF3 cells were found to express OCT4, SOX2, and E-
Cadherin mRNAs at significantly higher levels in the presence of anti-KDM5A siRNA or small molecule 
inhibitors, O4I3 and JIB-04 (Figure 18B). This implicates that ectopic expression of OCT4 (using the 
OSKM cocktail) is not sufficient to initiate reprogramming in resistant fibroblasts. Using 11 fibroblast cell 
lines derived from different patients, we showed a negative correlation between KDM5A expression and 
reprogramming efficiency, as measured by the number of AP-positive colonies (Figure 18C). Finally, 
transient repression of KDM5A using either siRNA or the chemical inhibitor, JIB-04, was found to 
facilitate OSKM-mediated reprogramming in both sensitive- (HF1 and HF2) and resistant (HF3 and HF4) 
fibroblasts, as determined by increased number of TRA-1-60-positive cell population (Figure 18D). 




Figure 17. O4I3-mediated induction of pluripotency is associated with its inhibitory activity 
against KDM5A. (A) siRNA-mediated knockdown (KD) of KDMA/D significantly induces OCT4 
transcription in NCCIT-OCT4 reporter cells, as measured by luciferase assay. (B) OCT4 and SOX2 
mRNA levels are upregulated upon knocking down KDM5A and KDM5D, as detected by qRT-PCR 
analysis. A non-targeting siRNA (indicated as siCtrl) served as the negative control. Relative mRNA 
expression was calculated using the  Ct method where the Ct values of each gene were normalized 
to those of the housekeeping gene (actin). (C) Immunocytochemistry of human fibroblasts revealed a 
global increase in H3K4Me3 levels in cells transfected with siRNA against KDM5A (denoted as siKA) in 
the absence or presence of OSKM ectopic expression. (D) In contrast to siRNA-mediated repression of 
KDM5A, its over-expression (denoted as OE5A) compromises O4I3's induction of OCT4 in HEK-293 and 
NCCIT reporter cells, further proving KDM5A as the small molecule's target. Cells were transfected with 
the over-expression construct and were treated with O4I3 at a concentration of 100 nM for 48 h. (E) The 
combination of pharmacological inhibition of KDM5A by O4I3 or JIB-04 and KDM5A ectopic expression 
antagonizes the former's effects on inducing OCT4 expression. NCCIT-reporter cells were transfected 
with the over-expression construct and were treated with various concentrations of O4I3 for 48 h. An 
empty vector was used as the negative control (denoted as Ctrl). (F) Reprogramming efficiency was 
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found to be significantly reduced in resistant fibroblasts in the presence of KDM5A forced expression, as 
determined by TRA-1-60 staining. Error bars  SD, n = 3. Statistical significance was made in comparison 
to mock (0.1% DMSO) in (A), to the negative control in (B) and (E), and to O4I3-only treated cells in (D) 
and (F) using a two-tailed student's t-test. *, **, and *** denote a p-value less than or equal to 0.05, 0.01, 
and 0.001, respectively.       
  
Figure 18. KDM5A presents a targetable epigenetic barrier during the course of OSKM-based 
reprogramming. (A) siRNA-mediated suppression of KDM5A as well as its chemical inhibition using 
JIB-04 (5 M, 48 h) supports H3K4Me3 occupation at OCT4 promoter in reprogramming-resistant 
fibroblasts (designated as HF3), as determined by ChIP-qPCR analysis. (B) In line with the enrichment 
of methylated H3K4 at the promoter of OCT4, chemical/genetic suppression of KDM5A upregulates the 
indicated pluripotency-associated genes in HF3 cells when combined with OSKM ectopic expression, as 
detected by qRT-PCR analysis. Relative mRNA expression was determined using the  Ct method 
where the Ct values of the pluripotency genes were normalized to those of the housekeeping gene 
(actin). (C) A positive correlation was observed between KDM5A expression and reprogramming 
efficiency (assessed by the number of AP-positive colonies) in 11 human primary fibroblasts. Similar 
amount of cDNA was used for qRT-PCR analysis; Ct values are indicative of KDM5A expression. (D) 
siRNA-mediated- and pharmacological inhibition of KDM5A facilitates OSKM-based reprogramming of 
sensitive- (HF1/2) and resistant (HF3/4) fibroblasts, assessed by TRA-1-60 staining. HFs were 
transfected with the respective siRNA oligos (si) against KDM5 family members (K5A/B/C/D) for the first 
5 days of reprogramming or treated with JIB-04 (5 M) for the first 48 h. In (A) and (B) and (D), statistical 
significance was made respective to mock, which is the OSKM-only treated HFs, using a two-tailed 
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student's t-test. Data are presented as mean  SD, n = 3. ** and *** indicate a p-value less than or equal 
to 0.01 and 0.001, respectively.       
2.3. O4I3 and O4I4 combination is able to generate iPSC-like colonies in the absence of 
exogenous OCT4. 
2.3.1. O4I4 promotes OCT4-associated signaling in various cell lines.  
Having studied the mode of action of O4I3 in detail, we aimed at optimizing a chemical condition in 
which exogenous OCT4 could be completely replaced. For this, we returned to our initial hits from the 
cell-based HTS (see section 2.1.1.) and selected the most metabolically-stable derivative of the 
compound O4I2–herein O4I4–for the upcoming experiments. As described in the section 2.1.1., O4I4 
was able to induce the expression of pluripotency factors, including OCT4 and NANOG in HEK-293 and 
NCCIT reporter cells. Further experiments in O4I4-treated NCCIT cells showed that the small molecule 
increases the mRNA levels of several pluripotency-related genes, as determined by qRT-PCR (Figure 
19A) and increases cell populations with the expression of OCT4, SOX2, E-Cadherin, and NANOG, as 
indicated by FACS analysis (Figure 19B). In addition to NCCIT cells, iPSC cells deprived of bFGF, 
which is known to be essential for the maintenance of pluripotency [284], were found to rescue in the 
presence of O4I4, as indicated by comparable mRNA levels of several pluripotency genes between 
O4I4-treated iPSCs in the absence of bFGF and iPSCs cultured in standard media (Figure 19C). 
Consistently, primary HFs treated with the small molecule demonstrated an increase in the mRNA 
expression of several pluripotency genes (Figure 19D). Finally, promising data obtained from functional 
enrichment analysis of HF cells treated with O4I4 revealed high enrichment of biological processes 
associated with suppressing differentiation, on the one hand, and promoting cellular proliferation and 
adhesion, on the other hand (Figure 19E).  
2.3.2. O4I3/4 enables the generation of human iPSC-like colonies in the absence of exogenous 
OCT4. 
Based on the exciting results from O4I3's mode of action (see section 2.2.), showing a significant 
increase in the efficiency of OSKM-mediated reprogramming through inducing endogenous OCT4 
expression, we thought of combining both chemicals, O4I3 and O4I4, with episomal transfection of 
"SKML" (SOX2, KLF4, MYC, and LIN28) and without OCT4 forced expression–collectively designated 
as "CSKML"– for the generation of human iPSCs (Figure 20A). We then applied CSKML to reporter HF 
cells expressing GFP under the control of LTR7 promoter and observed few ESC-like colonies 
expressing GFP with higher intensity compared with that of "SKML" and "O4I4-SKML"-treated cells 
(Figure 20B). These cells were successfully isolated, expanded, and were used for TRA-1-60 staining, 
which revealed a comparable number of positive cells between CSKML- and OSKML-treated fibroblasts 
(Figure 20C). qRT-PCR and immunoblotting analyses showed similar mRNA and protein levels of 
several pluripotency-related markers (e.g., OCT4 and SOX2) in CSKML-iPSCs and the standard iPSCs 
(Figure 20D and 20E). Moreover, comparison of global gene expression profiles in CSKML-iPSCs, 
iPSCs, and fibroblasts revealed a similar gene expression pattern among the first two, which was distinct 
from that of HFs (Figure 20F).  




Figure 19. O4I4 induces pluripotency-related signaling molecules. (A) qRT-PCR analysis of the 
mRNA levels of several pluripotency-associated genes in NCCIT cells treated with the indicated 
concentrations of O4I4 for 24 h. (B) 10 M of O4I4 treatment for 5 days increases the number of cells 
expressing the indicated pluripotency-associated markers in NCCIT cells compared with mock (0.1% 
DMSO) treatment, as detected by flow cytometry analysis. O4I4 is denoted as compound No. 23 (see 
Figure 5). (C) O4I4 is able to protect iPSC pluripotency in the absence of bFGF, as determined by qRT-
PCR analysis of multiple pluripotency genes. Human iPSCs were cultured in the presence of 10 ng/mL 
bFGF for 24 h and were further cultivated with the indicated concentrations of O4I4 instead of bFGF for 
another 24 h. 0.1% DMSO served as mock and iPSCs cultured in standard media were used as the 
positive control. (D) 20 M of O4I4 was employed on human fibroblasts for the indicated durations (D, 
days), after which qRT-PCR was performed for the assessment of pluripotency gene expression. (E) 
Functional enrichment analysis of up- and downregulated genes upon O4I4 treatment in human 
fibroblasts. The height of the bars is directly proportional to the significance of the enrichment. Relative 
mRNA expression in (A), (C), and (D) was determined using the  Ct method where the Ct values of 
each gene were normalized to those of the housekeeping gene (actin). Error bars present the SD of 
CHAPTER [2]  [RESULTS] 
 
 104 
three independent experiments. Statistical significance was made in comparison to mock treatment in 
(A) and (C) and to the starting time point (day 0, indicated as 0D) in (D) using a two-tailed student's t-
test. *, **, and *** are indicative of a p-value less than or equal to 0.05, 0.01, and 0.001, respectively.                     
 
Figure 20. The combination of O4I3 and O4I4 is able to convert human fibroblasts to iPSC-like 
colonies in the context of transcription factor-based reprogramming and without the need for 
OCT4 ectopic expression. (A) A schematic illustrating the reprogramming process of human fibroblasts 
carrying the LTR7-EGFP promoter (denoted as HF1-LTR7) using a combination of O4I3/4 and the 
ectopic expression of "SKML" cocktail, containing SOX2, KLF4, MYC, and LIN28, without exogenous 
OCT4. HF1 cells were pre-incubated with 250 nM of O4I3 for 2 days, followed by 5 M of O4I4 for 7 days 
in combination with SKML over-expression. The small molecule-containing medium was refreshed daily. 
At day 10, the medium was replaced with E8 medium, as indicated. D, days. (B) GFP-positive colonies 
were detected to have a higher intensity in CSKML-treated HF1 and O4I4-SKML treated cells compared 
with non-transfected cells and cells over-expressing SKML alone. (C) Reprogramming efficiency was 
compared between human fibroblasts (HF1/2/3) transfected with SKML, OSKML, and CSKML cocktails, 
using TRA-1-60 staining. (D) qRT-PCR analysis of OCT4 mRNA expression using relative Ct values; 
DeltaCt = Ctgene-Ctactin. actin served as the housekeeping gene. Error bars  SD, n = 3. (E) Immunoblots 
showing comparable protein levels of pluripotency-related factors in CSKML-reprogrammed HFs to 
hiPSCs and NCCIT cells, which were used as positive controls. HF1 served as the negative control. 
actin was used as the loading control. (F) Heatmaps obtained from DNA microarray analyses of iPSCs, 
HF1, HFs reprogrammed by CSKML, OSKML, and SKML demonstrate a similar gene expression pattern 
between iPSCs and CSKML-treated HFs.                
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Given the cellular mechanism of O4I3 (see Figure 13 and Figure 14), we analyzed the global 
methylation status at the OCT4 promoter, using bisulfite sequencing, and observed a general 
hypomethylation in iPSCs generated by means of CSKML compared with HF cells, which could suggest 
reactivation of endogenous OCT4 in the former (Figure 21). 
 
2.3.3. O4I3/4-mediated activation of endogenous OCT4 involves the BMP/Smad pathway. 
2.3.3.1. "CSKML"-mediated iPSC generation is dependent on HMGA1 expression. 
To gain some mechanistic insight into the O4I3/4's effects on cellular reprogramming, we sought to 
perform RNA-sequencing (RNA-seq) on HFs, HFs treated with either O4I3 or O4I4 and the combination 
(O4I3/4), as well as HFs reprogrammed by either OSKML or CSKML. We then ranked the genes, which 
were upregulated in O4I3/4-treated fibroblasts and compared them with those of iPSCs. As shown in 
Figure 22A, high-mobility group A1 (HMGA1) was found to be one of the top hits and has also been 
previously reported to support pluripotency [285, 286]. Consistent with the RNA-seq results, ATAC-
sequencing revealed higher chromatin accessibility at HMGA1 promoter in HF cells treated with CSKML 
compared with those transfected with OSKML, hinting on the possibility that HMGA1 transcription is 
Figure 21. Hypomethylation of OCT4 gene 
promoter in iPSCs generated by means of CSKM 
compared with human fibroblasts (HF1), as 
detected by bisulfite sequencing. Each horizontal 
line is representative of the sequencing results of one 
sub-clone. Methylated- and unmethylated CpG sites 




Figure 19. Hypomethylation of OCT4 gene 
promoter in iPSCs generated by means of CSKM 
compared with human fibroblasts (HF1), as 
detected by bisulfite sequencing. Each horizontal 
line is representative of the sequencing results of one 
sub-clone. Methylated- and unmethylated CpG sites 
are depicted as solid- and open circles, respectively. 
Detailed information regarding the bisulfite 
sequencing has been provided in the method 
section.       
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Figure 19. Hypomethylation of OCT4 gene 
promoter in iPSCs generated by means of CSKM 
compared with human fibroblasts (HF1), as 
detected by bisulfite sequencing. Each horizontal 
line is representative of the sequencing results of one 
sub-clone. Methylated- and unmethylated CpG sites 
are depicted as solid- and open circles, respectively. 
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relevant to CSML-mediated reprogramming (Figure 22B). We then analyzed the timely regulation of 
OCT4 and HMGA1 protein expression in O4I3/4-treated HFs by immunoblotting and observed that 
HMGA1 accumulation occurs prior to that of OCT4 (Figure 22C). In addition to this, small molecule-
treated HF cells showed similar or slightly higher HMGA1 protein levels compared with iPSCs (Figure 
22D). In line with our expectation, fibroblasts transfected with "SKML" failed to express both HMGA1 
and OCT4, as determined by immunoblotting (Figure 22D). Furthermore, HMGA1 was not detectable 
in cells transfected with "OSKML" for 4 days, whereas it was clearly expressed in CKML-treated HFs 
(Figure 22D). 
 
 Figure 22. HMGA1 is involved in CSKML-mediated reprogramming. (A) Heatmaps obtained from 
RNA-sequencing, showing the top upregulated genes in human iPSCs as well as O4I4-treated 
fibroblasts. (B) ATAC-sequencing demonstrates chromatin accessibility of HMGA1 gene promoter in 
human fibroblasts (HF1), HF1 cells treated with either OSKML or CSKML for 7 days (D, days), as well 
as iPSCs, which were included as reference. (C) A time-dependent analysis of HMGA1 and OCT4 
protein levels in O4I3/4-treated HF1 cells reveals that HMGA1 expression precedes that of OCT4, 
detected by immunoblotting. O4I3 and O4I4 were used at a concentration of 0.5 M and 10 M for the 
indicated time points (D, days), respectively. (D) Immunoblots showing the concomitant expression of 
OCT4 and HMGA1 in HF1 treated with O4I3/4 (0.5/10 M for 4 days), CSKML, as well as in human 
iPSCs but not in OSKML- and SKML-treated cells. Vinculin was used as the loading control.  
To further support our hypothesis regarding the role of HMGA1 in CSKML-mediated activation of 
OCT4 during reprogramming, we knocked down this gene in fibroblasts using siRNA and found that 
HMGA1-deficient HF cells fail to promote OCT4 expression upon CSKML treatment, as determined by 
immunoblotting and qRT-PCR analyses (Figure 23A and 23B). Further evidence came from the ChIP-
qPCR experiment, showing the occupation of HMGA1 at the promoter of OCT4 (Figure 23C), which 
was in good agreement with a previous report [287]. Finally, we aimed at replacing O4I4 with HMGA1 
over-expression for reprogramming of primary fibroblasts towards pluripotency. As indicated in Figure 
23D, forced expression of HMGA1 from day 2 to day 9 showed the highest efficiency among other tested 
durations, as determined by TRA-1-60 staining. We then designated the new iPSCs generated by 
means of HMGA1 ectopic expression in combination with SKML as "HSKML", which were found to 
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express the iPSC marker, TRA-1-60, however to a lower extent than that of OSKML-induced iPSCs 
(Figure 23E). 
 
Figure 23. HMGA1 is involved in CSML-mediated reprogramming. (A) HMGA1 knockdown using 
siRNA (designated as siH) abolishes CSKML-induced OCT4 induction in human fibroblasts (HF1), 
detected by immunoblotting. Anti-HMGA1 siRNA was co-transfected with the SKML cocktail (see 
Figure 20 for the treatment scheme). Vinculin was used as the loading control. (B) Similar to its 
protein levels, mRNA expression of OCT4 is significantly reduced upon genetic repression of HMGA1 in 
both CSKML- and OSKML-treated HFs, assessed by qRT-PCR analysis. A non-targeting siRNA 
(designated as siControl) was used as the negative control. Relative gene expression was calculated 
using the  Ct method where the Ct values of the target genes were normalized to those of the 
housekeeping gene (actin). (C) ChIP-qPCR analysis showing the occupation of HMGA1 at the promoter 
of OCT4. (D) Reprogramming efficiency of HF cells treated with the SKML cocktail and transfected with 
the HMGA1 over-expression construct at the indicated days (D, days) was determined as the number of 
TRA-1-60-positive colonies. Transient transfection was refreshed every 2-3 days. (E) TRA-1-60 staining 
demonstrates the efficiency of the reprogramming process mediated by HMGA1 over-expression in 
combination with SKML ectopic expression (referred to as HSKML). Error bars are the SD of three 
independent experiments. In (B) multiple comparisons were performed using a two-way ANOVA test and 
post-hoc Tukey test and in (C) statistical significance was calculated using a two-tailed student's t-test. 
** and *** are representative of a p-value less than or equal to 0.01 and 0.001, respectively. 
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2.3.3.2. "CSKML"-mediated HMGA1 activation relies on the BMP/Smad pathway.  
To understand the mechanisms by which HMGA1 is activated upon CSKML treatment, we looked 
into the differentially expressed genes among fibroblasts treated with O4I4, DMSO (as mock), OSKML, 
and CSKML, using RNA-seq. As demonstrated in Figure 24A, three genes, namely PDGFRL, BMP6 
and DACT1–all of which have been previously linked to stemness signaling pathways–were found to be 
induced only in case of CSKML-treated HFs as compared to SKML-transfected cells. The BMP family 
of cytokines have been frequently shown to promote transcription factor-mediated- and chemical 
reprogramming [288, 289]. Having that in mind, we focused on the potential role of BMP signaling in 
CSKML-mediated reprogramming. As thoroughly described in the section 1.1. of chapter 1, the BMP 
pathway initiates with receptor-mediated phosphorylation of Smad1/5/8, enabling their complex 
formation with Smad4. The R-Smad-Smad4 complexes are then transferred to the nucleus where they 
regulate the transcription of various downstream genes, among others, IDs (basics of 
TGF/BMP/Smad signaling are thoroughly reviewed in [2]). In light of this, treatment of fibroblasts 
with increasing concentrations of O4I4 was found to significantly induce the mRNA levels of ID1 and 
ID2 (Figure 24B). In addition to this, immunoblotting showed a clear increase in Smad1/5/8 C-tail 
phosphorylation, as well as ID2 protein levels upon CSKML treatment (Figure 24C). In support of this, 
ectopic expression of ID1/2 appeared to activate HMGA1 and to cause a slight increase in OCT4 mRNA 
expression, an effect which was clearly enhanced in combination with O4I3/4 or CSKML (Figure 24D). 
To further support the involvement of BMP signaling in CSKML's mode of action, we sought of 
suppressing the signaling using (i) the BMP receptor inhibitor (dorsomorphin; designated as DM), (ii) 
the BMP antagonist (noggin), and (iii) siRNA-mediated knockdown of Smad4 and monitoring the effects 
of CSKML. Promising data obtained from immunoblotting showed that inhibiting the BMP pathway not 
only abrogates Smad1/5/8 receptor activation and ID2 expression but is also capable of counteracting 
CSKML-mediated HMGA1- and OCT4 induction (Figure 24C). Similarly, knocking down ID1/2 using 
siRNA resulted in the inhibition of CSKML-mediated HMGA1 and OCT4 activation, as determined by 
immunoblotting and qPCR analyses, respectively (Figure 24E and 24F). In contrast to its genetic 
inhibition, ID1/2 ectopic expression caused a profound increase in HMGA1 and OCT4 mRNA levels 
(Figure 24D).  As expected, the addition of BMP6 was found to promote OCT4 mRNA expression 
(Figure 24F). Consistent with the above data, BMP6 addition and/or ID1/2 forced expression was able 
to increase the reprogramming efficiency, as indicated by a higher number of TRA-1-60-positive 
colonies (Figure 24G). 
Moreover, we also tested the effects of other members of the BMP family, namely BMP2 and BMP9. 
The former showed similar effects to those of BMP6, as indicated by increased C-terminal 
phosphorylation of Smad1/5/8, as well as the induction of HMGA1- and OCT4 protein levels in CSKML-
treated fibroblasts (Figure 25). BMP9, on the other hand, failed to promote the expression of HMGA1 
and OCT4 (Figure 25). Altogether, the above results demonstrate the activation of endogenous 
OCT4 by CSKML through the BMP-Smad-ID-HMGA1 signaling axis. 
             




 Figure 24. HMGA1 activation by CSKML involves BMP/Smad/ID signaling. (A) RNA-seq analysis 
of up- and downregulated genes in CSKML- vs. SKML treatments, as well as in mock (0.1% DMSO) vs. 
O4I4 treatments. Human fibroblasts were transfected with SKML alone or in combination with 10 M of 
O4I4 (CSKML) for 48 h. In the other group, HFs were treated either with 0.1% DMSO or O4I4 (10 M, 
48 h). (B) O4I4 induces mRNA levels of ID genes in HFs treated with the indicated concentrations of the 
molecule for 48 h. (C) Immunoblots showing the activation of the BMP/Smad/ID pathway by CSKML 
treatment, as determined by an increase in the protein levels of receptor-phosphorylated Smad1/5/8 and 
ID2. This was found to be counteracted in the presence of 5 M of BMP receptor inhibitor (dorsomorphin; 
designated as DM) and 200 ng/mL of the BMP antagonist, noggin, as well as the siRNA-mediated 
suppression of the common Smad, Smad4. Treatment with the chemical inhibitors and siRNA 
transfection were done together with CSKML treatment for 48 h. Vinculin was used as the loading control. 
(D) Forced expression of the BMP downstream genes, ID1/2 enhances the mRNA expression of HMGA1 
and OCT4 in the absence or presence of O4I3/4 (denoted as C) and O4I3/4-SKML (CSKML) 
combination, analyzed by qRT-PCR. HF1 cells were transfected with either ID1/2 over-expression 
plasmids alone or in combination with the chemicals and the SKML cocktail for 48 h. (E) siRNA-mediated 
repression of ID1/2 abrogates CSKML-induced HMGA1, as determined by immunoblotting. A non-
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targeting siRNA (designated as siCtrl) served as the negative control. Vinculin was used as the loading 
control. (F) The addition of BMP6 (denoted as B6) in the first 72 h of CSKML treatment further increases 
CKML-induced OCT4 mRNA expression, an effect which is antagonized by genetic inhibition of ID1/2. 
Relative OCT4 gene expression was detected by qRT-PCR. (G) Reprogramming efficiency of CSKML 
is enhanced in the presence of BMP6 or by over-expressing its targets, ID1/2, as identified by TRA-1-60 
staining. In (B), (D), and (F) relative mRNA levels were determined by the  Ct method in which the Ct 
values of the target genes were normalized to those of the housekeeping gene (actin).  Error bars  
SD, n = 3. 0.1% DMSO served as mock treatment. In (B) and (D) statistical significance was made 
respective to mock using a two-tailed student's t-test and in (F) multiple comparisons were performed 
using a one-way ANOVA test followed by a post-hoc Tukey test. *, **, and *** denote a p-value less than 
or equal to 0.05, 0.01, and 0.001, respectively.                  
 
 
Figure 25. BMP2, but not BMP9, has a 
similar role to BMP6 in the context of 
CSKML-induced pluripotency. Immunoblots 
showing that BMP2 is able to promote HMGA1 
and OCT4 protein expression in a comparable 
manner to that of BMP6. BMP9, on the other 
hand, failed to activate the HMGA1/OCT4 axis. 
0.1% DMSO served as mock treatment. actin 
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3. DISCUSSION 
In parallel to the work presented in chapter 1, I had a chance to be majorly involved in the exciting 
field of "cellular reprogramming" where we focused on establishing new protocols for chemical 
conversion of human somatic cells into a pluripotent state. The ideas of this project came from previous 
reports of the group on the development of new chemicals for the induction of pluripotency factors [270, 
290], as well as the lack of strong small molecule inducers of OCT4, which has been long challenging 
the generation of human chemical iPSCs. The results presented in this chapter introduce newly 
synthesized small molecules–herein O4I3 and O4I4–as potent activators of pluripotency-associated 
markers and strong enhancers of the transcription factor-mediated reprogramming. Based on my 
interest and experience in cellular signal transduction, I was particularly intrigued by the molecular 
mechanisms underpinning the reprogramming process, which are known to be mediated by an intricate 
crosstalk between several signaling modules including those of the TGF/BMP pathway. While 
investigating the mode of action of O4I3 and O4I4, we could identify previously uncharacterized 
molecular events during the process of reprogramming at both genetic- and epigenetic levels. In this 
section, I discuss the effects of the two small molecules in the context of OSKM-mediated 
reprogramming as well as their mode of action, which unraveled the significance of the epigenetic 
modifier, KDM5A (in case of O4I3), and the HMGA1/BMP/Smad axis (in case of O4I4) in the path 
towards pluripotency. 
3.1. New chemical enhancers of transcription factor-mediated reprogramming: from inducing 
pluripotency-associated genes to a profound increase in reprogramming efficiency    
Transcription factor-mediated reprogramming–first reported by Yamanaka et al.–offers a simple 
approach, i.e., forced expression of a defined set of pluripotency factors in the somatic cell, for the 
generation of induced pluripotent stem cells (reviewed by Takahashi K. and Yamanaka S. in [291]). 
However, as thoroughly described before (also see sections 1.1. and 1.2.), this technology is 
associated with several disadvantages, such as the extremely low efficiency and safety concerns 
regarding the use of such stem cells (produced by viral transduction) for therapeutic purposes [292]. In 
view of this, many research groups have focused on the generation of iPSCs using small molecules, a 
process which is well-known as "chemical (or pharmacological) reprogramming" (reviewed in [269]). 
Looking for small molecule inducers of pluripotency, we screened a library of ~250,000 chemicals using 
cell-based assays and identified a series of OCT4 inducing compounds [270, 290]. Among these 
molecules were the analogues of imidazopyridine (we have recently reported the results in [293]), 
which were found to be particularly interesting, as they share the imidazopyridine backbone with the 
FDA-approved sedative-hypnotic drug, zolpidem. Of those, a promising candidate–herein O4I3–was 
selected and synthesized. Further investigations revealed the ability of O4I3 in the induction of 
pluripotency-associated markers (particularly OCT4), as well as in the maintenance of pluripotency 
through repressing differentiation of iPSCs (see Figure 6, Figure 7, and Figure 8). Intrigued by these 
results, we thought of testing O4I3's effects on OSKM-mediated reprogramming. Promising data 
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showed that O4I3 increases the reprogramming efficiency (from 0.01% to 0.1%) and enables the 
conversion of reprogramming-resistant fibroblasts to iPSCs when combined with ectopic expression of 
the "OSKM" cocktail (see Figure 9, Figure 10, and Figure 11).  
Although O4I3 treatment caused a profound induction of OCT4 in HEK-293 and NCCIT reporter cell 
lines as well as in fibroblasts (see Figure 6, Figure 7, and Figure 9), it failed to replace exogenous 
OCT4 in the context of OSKM-mediated reprogramming. Chemical replacement of OCT4–more than 
the rest of the pluripotency genes–has been long a challenge in establishing reprogramming cocktails 
for the generation of chemical iPSCs. This barrier was finally overcome by the work of Hou et al. who 
showed that all four exogenous "master genes", including OCT4, are dispensable for the generation of 
mouse pluripotent stem cells, using a combination of seven small molecules with forskolin (a cAMP 
agonist) as the OCT4 inducer [262]. In addition to forskolin, we and others have reported on a few 
number of molecules able to promote endogenous OCT4 expression in mouse- and human somatic 
cells, namely pyrrolo[2,3-b]pyridine based OCT4-activating compound 1 (OAC1) [294], 4-
(benzyloxy)phenyl derivatives (O4I1) [270], and 2-aminothiazoles (O4I2) [290]. Nonetheless, all these 
chemicals failed to activate OCT4 to a level sufficient for the generation of human iPSCs in the absence 
of ectopic OCT4 expression. In view of this challenge, we sought to chemically modify our previously 
identified hits [290] in order to generate new small molecules, which are capable of substituting 
exogenous OCT4. The focus was drawn to O4I2 and its analogues, which have previously shown 
promising results with regards to OCT4 activation. Although being a strong OCT4 inducer in the HEK-
293 reporter cell line, it was observed that this activity is lost in NCCIT-OCT4 cells. We have previously 
reported that O4I2 undergoes acid hydrolysis, producing a carboxylic acid product (O4I2-COOH), which 
was found to be inactive in the HEK-OCT4 reporter cells [290]. This sparked the idea of "metabolic 
instability" being responsible for abrogating the OCT4-inducing ability of O4I2, and hence the potential 
capability of "metabolically-stable" analogues to recover the small molecule's pluripotency-promoting 
effects. 
Among the enzymes catalyzing the "ester-to-acid" conversion is carboxylesterase 1, which is well-
known for metabolism and biotransformation of drugs [295]. In view of this, we sought of analyzing 
CES1-5A expression pattern, using previously published gene expression data and found high levels of 
these enzymes in PSCs and NCCIT cells. This finding not only fits with our hypothesis regarding 
metabolic instability underlying inactivation of O4I2 in NCCIT cells, but also suggests that enzymes 
produced by partially- or fully-reprogrammed cells might contribute to destabilization of chemicals, which 
in turn reduces the efficiency of chemical reprogramming. In support of this, replacing the ethyl ester 
moiety with CES1-resistant groups recovered O4I2-mediated OCT4 induction in NCCIT reporter cells 
(see Figure 5). In addition to this, the most active derivative of the stable compounds–herein O4I4–was 
found to strongly induce pluripotency-associated signaling networks in human fibroblasts, highlighting 
the significance of metabolic stability of chemicals for a successful reprogramming process. 
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In light of the promising results from O4I3, which showed a significant increase in reprogramming 
efficiency through activating endogenous OCT4, on the one hand, and the ability of O4I4 in promoting 
OCT4-associated signaling, on the other hand, we thought of using a combination of both chemicals 
(O4I3/4) in the context of OSKM-mediated reprogramming. Promising data from fibroblasts treated with 
"CSKML" (in which C stands for the combination of O4I3/4) demonstrated a clear increase in 
reprogramming efficiency when compared with that O4I4-only treated cells. Importantly, iPSCs 
generated by CSKML were found to resemble those obtained from OSKML-mediated reprogramming 
in terms of global gene expression patterns, epigenetic status, as well as their potential for differentiation 
(see Figure 20 and Figure 21). As implicated earlier, reprogramming protocols for the generation of 
chemically-induced human iPSCs are yet to be established, however, several chemical cocktails have 
been shown to successfully convert human somatic cells to iPSCs when combined with exogenous 
OCT4 expression [257]. We, however, failed to produce human chemical pluripotent stem cells using a 
combination of O4I3/4 with the previously reported chemicals, suggesting that further optimizations 
(e.g., dosages and duration of the treatment) of the chemical cocktails are necessary. 
3.2. Understanding molecular mechanisms of somatic cell reprogramming: new perspectives 
from the mode of action of OCT4-inducing compounds 
3.2.1. Is the histone demethylase enzyme KDM5A an obstacle in the path to pluripotency?   
  An exciting result in the investigations of this chapter is the identification of KDM5A as an epigenetic 
barrier during the course of reprogramming. As thoroughly described in the introduction (also see 
section 1.1.1.2.), transcription factor-induced pluripotency requires coordinated regulation of different 
epigenetic pathways (summarized in [278]). Such epigenetic events during the transition between 
differentiated- and pluripotent cells can be summarized in three main categories, (i) genomic 
demethylation (both DNA and histones), (ii) histone acetylation, and (iii) reduced levels of 
heterochromatin, altogether contributing to an "open chromatin" state. Among several epigenetic 
regulators involved in the control of chromatin landscape during the process of reprogramming are 
histone methyl transferases and their countering enzymes, histone demethylases, which determine the 
type of histone marks, and hence the access and efficiency of the transcriptional machinery (thoroughly 
discussed in two excellent reviews; [212, 296]). In view of this, some of the major histone 
modifications have been identified, with H3K4Me3 being indicative of active transcription, whereas 
H3K9Me3 and H3K27Me3 acting as repressive marks [212]. Through investigations into the molecular 
mechanism of O4I3, we observed a global increase of H3K4Me3 upon treatment with the small molecule 
as well as a significant occupation of this active histone modification at the promoter of OCT4. In support 
of this, it has been shown that at the initial phases of reprogramming, OCT4, SOX2, and KLF4–known 
as the "pioneer pluripotency factors"–bind to the nucleosomal pluripotency regions to enhance H3K4 
methylation at the enhancer and promoter sites. This will then pave the way for the activation of those 
genes that are necessary for the establishment of a pluripotent state [228, 297]. In addition to this, 
genome-wide methylation analyses have revealed the gain of H3K4Me3 at promoters of pluripotency-
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associated genes during the process of somatic cell reprogramming [254]. On the basis of these 
observations, it is easy to assume that chemicals able to protect H3K4 methylation could lift this 
epigenetic barrier and enhance the reprogramming efficiency. 
Histone methylation is a reversible process, meaning that one or more of the methyl groups existing 
on a particular lysine residue could be erased through the action of histone demethylases (HDMs), for 
example KDM5s and LSD1 in case of H3K4 (reviewed in [220]). This sparked the idea of O4I3 acting 
through the inhibition of specific HDMs, which could explain the increased levels of methylated H3K4 
upon treatment with the small molecule. Focusing on HDMs related to H3K4 demethylation, we found a 
potent inhibition of KDM5, in particular the isozyme KDM5A, using an in vitro demethylase assay, an 
effect which was also observed in case of zolpidem, however, at higher concentrations. Follow up 
experiments revealed that both pharmacological inhibition of KDM5A (using O4I3 or a known inhibitor, 
JIB-04) and siRNA-mediated knockdown are able to promote the expression of several pluripotency 
markers at the mRNA level as well as in reporter NCCIT and HEK-293 cell lines. Additionally, chemical 
and genetic repression of KDM5A increased the efficiency of OSKM-mediated reprogramming 
(assessed by TRA-1-60 staining), mimicking O4I3 treatment, whereas its over-expression abrogated 
the compound's effects. In light of our results, a number of chemical epigenetic modifiers have been 
reported to facilitate the reprogramming process of human somatic cells, for example the small molecule 
inhibitor of LSD1, parnate [260], histone deacetylase inhibitor, NaB [268], and the DNA 
methyltransferase inhibitor, RG108 [252] (also see section 1.2.1.). In particular, parnate-induced 
pluripotency could be explained through the inhibition of H3K9 demethylation, which may block the 
expression of differentiation-associated genes, on the one hand, as well as its protective effect on H3K4 
methylation, and hence activation of pluripotency genes, on the other hand [298, 299]. In case of O4I3 
(and zolpidem), we could not observe a significant inhibitory function on LSD1, a histone demethylase, 
which is–unlike KDM5s–shared between H3K4 and H3K9 marks [298]. This further supports our 
hypothesis with regards to the role of H3K4 methylation in imidazopyridine-induced pluripotency. 
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Figure 26. Imidazopyridine analogues as chemical enhancers of OSKM-based somatic cell 
reprogramming. A scheme showing the ability of OCT-4 inducing compound 3–O4I3– in converting the 
reprogramming-resistant human fibroblasts to iPSCs when combined with "OSKM" forced expression. 
We propose that inhibition of the histone demethylase enzyme, KDM5A by the small molecule increases 
the active histone mark, methylated H3K4 at OCT4 promoter, and hence lifts an important epigenetic 
barrier of cellular reprogramming. The imidazopyridine backbone has been highlighted in gray in the 
chemical structure of O4I3. The presented image is modified from [293].   
The role of enzymes regulating trimethylation of H3K4 in stem cell self-renewal and differentiation 
has been incompletely understood. A number of reports have shown the involvement of KDM5B in the 
aforementioned processes [300, 301], for example Xie et al. reported the positive regulation of self-
renewal-associated gene expression by KDM5B, which is correlated with methylated H3K36, an active 
transcriptional mark [301]. This appears to be contrasting the conventional role of KDM5B as a 
transcriptional repressor, due to its capability of removing promoter-associated H3K4Me3 (a histone 
mark normally indicative of active transcription) [298]. The example of KDM5B shows that the 
contribution of enzymes responsible for regulating histone methylation levels is highly dependent on 
their substrates, and hence could lead to various and even opposing effects in different contexts. We 
here show that KDM5A is highly expressed in fibroblasts and is decreased during the course of cellular 
reprogramming (see Figure 16). Consistent with this, suppression of KDM5A either genetically or 
pharmacologically mimicked O4I3's effects in the induction of pluripotency markers and improving 
reprogramming efficiency, whereas its forced expression was found to have an opposite outcome, 
altogether suggesting a negative role for KDM5A in the path towards pluripotency (summarized in 
Figure 26). In contrast to our results, de-repression of KDM5A using miRNA 212/132 has been reported 
to enhance reprogramming of mouse embryonic fibroblasts [302]. One way to explain this discrepancy 
could be through the differences between mouse- and human pluripotent states (reviewed in [303]). 
Additionally, the identification of epigenetic pathways (e.g., various histone marks) by which KDM5A 
leads to an increase or a decrease in the reprogramming efficiency is crucial for understanding its 
precise role in somatic cell reprogramming.       
3.2.2. The "BMP-Smad-HMGA1" axis as a positive modulator of somatic cell reprogramming      
High mobility group proteins A1–coded by HMGA1–function as architectural chromatin-binding 
proteins, promoting the expression of various genes [304, 305]. In the context of somatic cell 
reprogramming, HMGA1 is known to have high expression levels in human embryonic stem cells and 
fully-reprogrammed iPSCs, while showing low expression levels in terminally-differentiated cells and 
fibroblasts (recently reviewed in [306]). During the course of transcription factor-mediated 
reprogramming, HMGA1 has been shown to synergize with OSKM factors in enhancing the 
reprogramming efficiency through binding to the promoters of pluripotency genes, SOX2, LIN28, and c-
MYC and inducing their expression [286]. Our investigations in the mode of action of O4I3/4 revealed 
that chemically-induced HMGA1 could reactivate endogenous OCT4 to initiate the reprogramming 
process. This suggests an important role for HMGA1 as a driver of the pluripotent state via activating 
self-renewal-associated networks. 
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Further investigations comparing the differentially-expressed genes between "CSKML" and 
"OSKML"-treated fibroblasts (see Figure 24) illustrated potential upstream pathways responsible for the 
activation of HMGA1. In particular, we could show that the BMP/Smad axis is indispensable for HMGA1-
mediated OCT4 activation induced by CSKML. The BMP pathway has been previously reported to 
enhance both transcription factor- and chemically-induced reprogramming [307]. For example, BMPs 
were able to replace KLF4 in the context of OSKM-mediated reprogramming of mouse embryonic 
fibroblasts, to increase the efficiency of OCT4/SOX2-mediated reprogramming of MEFs to ~1%, and 
finally to promote OCT4-only-based reprogramming [289]. More recently, Yamanaka et al. reported that 
the BMP/Smad/ID pathway inhibits the P16-meidated senescence, and hence overcomes a major 
barrier during reprogramming [288]. Accordingly, interruption of the pathway via dorsomorphin and 
LDN1931890 or transducing inhibitory Smads (Smad6/7) was found to attenuate the positive effects on 
iPSC generation [288]. This is in line with our results, showing the countering effects of both chemical- 
and genetic inhibitors of BMP/Smad/ID signaling on HMGA1 and OCT4 activation as well as on TRA-1-
60-positive colonies (see Figure 24). On the contrary, the addition of BMP6 and forced expression of 
ID1/2 enhanced the reprogramming efficiency, as expected. In line with these data, it has been 
previously reported that adding BMP4 at early times (but not at later times) during the reprogramming 
process increases the efficiency of iPSC generation [288]. Altogether, our results further confirm the 
positive role of the BMP/Smad/ID pathway in the induction of pluripotency and suggest a previously 
unrecognized mechanism of this signaling in the context of OSKM-based reprogramming through the 
activation of HMGA1. 
3.3. Concluding remarks and future perspectives       
In this chapter, we aimed at enhancing the process of OSKM-based reprogramming using newly 
synthesized small molecules. For this, we initially performed a cell-based high throughput screen 
encompassing ~250,000 chemicals, which led to the identification of several lead structures as OCT4-
inducing compounds. Of those, more than 4000 molecules were found to be analogues of 
imidazopyridine, with a similar backbone to the FDA-approved sedative-hypnotic drug, zolpidem. A 
promising candidate, herein O4I3, was then selected and synthesized. Comprehensive analyses of 
O4I3's cellular effects revealed that the molecule is capable of (i) inducing the pluripotency-associated 
networks and (ii) supporting the generation and maintenance of iPSCs through repressing 
differentiation. Investigating the impact of O4I3 on OSKM-mediated reprogramming, we observed (iii) a 
significant increase in reprogramming efficiency upon the addition of O4I3 to the OSKM cocktail. Of 
note, the above effects were found to be reproducible with zolpidem, further supporting our hypothesis 
with regards to the use of imidazopyridines as enhancers of somatic cell reprogramming.  
Through investigations into the molecular mode of action of O4I3 using comparative gene expression 
analyses, we found that more than 30% of the similarly regulated genes between O4I3-treated HFs, 
OSKM-treated HFs and PSCs are involved in epigenetic modifications. This sparked the idea of O4I3 
acting through the epigenetic pathways in order to promote the generation of iPSCs. Focusing on the 
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most well-known histone modifications, we observed a profound increase in trimethylated H3K4 levels 
at the promoter of OCT4 and globally in response to O4I3. The methylation status of specific histone 
marks is determined via the countering action of histone methyl transferases and histone demethylases, 
for example KDM5s and LSD1 in case of H3K4. In light of this, we found a (iv) potent inhibition of the 
histone demethylase enzyme, KDM5A upon O4I3 treatment in vitro and in cells, an effect which was 
also observed in case of zolpidem. Additional experiments further confirmed (v) the role of KDM5A as 
an epigenetic barrier of reprogramming, as its genetic/chemical suppression mimicked O4I3's effects in 
inducing pluripotency genes and increasing the OSKM-based reprogramming efficiency. Despite this, 
there are several questions remaining to be addressed with regards to the impact of O4I3 on 
KDM5A and its relevance to the induction of pluripotency. For example, has O4I3 any significant 
effect on epigenetic marks other than H3K4 as well as their regulating enzymes? and what is the 
precise mode of interaction of O4I3 with KDM5 demethylases? These issues, among others, 
present interesting topics for future projects.  
Although inducing OCT4 expression significantly, O4I3 was not able to substitute exogenous OCT4 
during the course of reprogramming, a long-lasting challenge in the generation of chemically-induced 
human iPSCs. This encouraged us to test different combinations of small molecules by which 
exogenous OCT4 could be replaced. After several attempts with our initial hits from the screen, we 
selected the most potent metabolically-active derivative of O4I2, herein O4I4, for additional experiments. 
(vi) Using a combination of O4I3, O4I4 (designated as O4I3/4), and the ectopic expression of "SKML" 
(altogether referred to as "CSKML"), we were able to generate partially-reprogrammed iPSCs without 
the need of OCT4 transduction. This finding, although promising, requires further experimental 
support, particularly with regards to the characterization of the newly-reprogrammed iPSCs, 
including the long-term expansion capacity, clone formation assay after passaging, colony 
morphology, and teratoma assays. 
Our mechanistic analyses of the O4I3/4's mode of action in human somatic cell reprogramming 
revealed (vii) the involvement of BMP/Smad signaling upstream of HMGA1, which in turn activates 
endogenous OCT4 and initiates the reprogramming process. We could show that over-expression of 
HMGA1 together with "SKML" (herein referred to as "HSMKL" iPSCs) or the addition of BMP6 and the 
downstream signaling molecules, ID1/2 increases the reprogramming efficiency in a similar manner to 
that of "CSKML" treatment. There remained unanswered questions related to the signaling 
program triggered by O4I3/4, for example if the BMP/Smad/HMGA1 axis can replace the full role 
of the small molecules in the generation of iPSCs. Nonetheless, our findings provide new insights 
into the molecular events during reprogramming and present new chemical tools able to enhance the 
transcription factor-based reprogramming of human somatic cells.
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4. MATERIALS AND METHODS 
4.1. Materials 
4.1.1. Consumables 
Table 1. List of the general consumables used in the described experiments of chapter 1 and 
chapter 2. 
Item Supplier 
96-well plates (round bottom) Greiner Bio-One, Germany 
Accutase® Sigma-Aldrich, Germany 
BD FACSFlowTM Becton Dickinson, Germany 
BDTM FACSclean Becton Dickinson, Germany 
Cell culture flasks (T-25, -75, -175) Greiner Bio-One, Germany 
Cell culture petri-dishes Greiner Bio-One, Germany 
Cell culture plates (6-, 12-, 24-, 48-, and 96- 
well plates) 
Greiner Bio-One, Germany 
DMEM-F12 Knockout medium Gibco, Germany 
Dulbecco’s Modified Eagle Medium 
GlutaMAXTM 
Gibco, Germany 
Dulbecco’s Phosphate-Buffered Saline (D-
PBS) 
Gibco, Germany 
Eppendorf tubes (1.5 and 2.0 mL) Greiner Bio-One, Germany 
Essential® 8 medium Thermo Fisher Scientific, Germany 
FACS tubes Becton Dickinson, Germany 
Falcon/Centrifuge tubes Greiner Bio-One, Germany 
Fetal Calf Serum (FCS) Gibco, Germany 
Opti-MEM Reduced Serum Medium Gibco, Germany 
PageRulerTM Prestained Protein Ladder Nippon Genetics Europe GmbH, Germany 
Parafilm® M Sigma-Aldrich, Germany 
Penicillin-streptomycin Gibco, Germany 
Polyvinylidene fluoride (PVDF) membranes GE Healthcare, Germany 
Ponceau S Sigma-Aldrich, Germany 
RPMI 1640-GlutaMAXTM Gibco, Germany 
Serological pipettes (2.0, 5.0, 10.0, 25.0 mL) Costar corning incorporated 
Syringe filters (0.2 μm pore size) GE Healthcare, Germany 
Syringes (50 mL) Becton Dickinson, Germany 
TrypLETM Express Gibco, Germany 
WhatmanTM 3mm CHR (45x57 cm) GE Healthcare, Germany 
White 96-well microplate (clear bottom) Costar corning incorporated 
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4.1.2. Chemicals, drugs, and cytokines 
Table 2. List of chemicals, growth factors, and drugs used in the described experiments of 
chapter 1 and chapter 2. 
Chemical Supplier 
1,4-Dithioththeriotol (DTT) Carl Roth GmbH, Germany 
4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid (HEPES) 
Carl Roth GmbH, Germany 
Activin Thermo Fisher Scientific, Germany 
Alvocidib (Flavopiridol) Selleckchem, Germany 
Aprotinin AppliChem, Germany 
bFGF Thermo Fisher Scientific, Germany 
BMP4 Thermo Fisher Scientific, Germany 
Bovine Serum Albumin (BSA) Carl Roth GmbH, Germany 
Bromophenol blue AppliChem, Germany 
CaCl2 AppliChem, Germany 
CHIR99021 Sigma-Aldrich, Germany 
Chloroform 
Zentralbereich Theoretikum Chemikalienlager, 
Heidelberg University. 
CPI-455 Selleckchem, Germany 
Cycloheximide (CHX) Sigma-Aldrich, Germany 
Daminozide Selleckchem, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Germany 
Ethanol VWR Chemicals, Germany 
Ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid (EGTA) 
Sigma-Aldrich, Germany 
Ethylenediaminetetraacetic acid (EDTA) Merck, Germany 
Glycerol Sigma-Aldrich, Germany 
Glycine Sigma-Aldrich, Germany 
GSK-J4 Selleckchem, Germany 
IGEPAL-CA630 Sigma-Aldrich, Germany 
Isopropanol 
Zentralbereich Theoretikum Chemikalienlager, 
Heidelberg University. 
JIB-04 Selleckchem, Germany 
KCl AppliChem, Germany 
LY294002 Selleckchem, Germany 
Methanol Sigma-Aldrich, Germany 
MG-132 Sigma-Aldrich, Germany 
MgCl2 Sigma-Aldrich, Germany 
Milk Carl Roth GmbH, Germany 
Na3VO4 AppliChem, Germany 
Na4P2O7 AppliChem, Germany 
NaCl AppliChem, Germany 
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NaF AppliChem, Germany 
Paraformaldehyde (PFA) Sigma-Aldrich, Germany 
PD0325901 Selleckchem, Germany 
Pepstatin AppliChem, Germany 
Phenylmethane sulfonyl fluoride (PMSF) AppliChem, Germany 
Rotiphorese® Gel 30/ Acrylamide mix Carl Roth GmbH, Germany 
SB-431542 Selleckchem, Germany 
SB203580 Selleckchem, Germany 
Sodium dodecyl sulfate (SDS) Merck, Germany 
SP600125 Selleckchem, Germany 
ß-mercaptoethanol Merck, Germany 
Tetramethylethylenediamine (TEMED) Carl Roth GmbH, Germany 
TGF1 Biomol, Germany 
Trichloroacetic acid VWR Chemicals, Germany 
Tris Carl Roth GmbH, Germany 
Tris-HCl Carl Roth GmbH, Germany 
Triton X-100 Carl Roth GmbH, Germany 
Tween 20 Carl Roth GmbH, Germany 
U0126 Selleckchem, Germany 
Urea Carl Roth GmbH, Germany 
Y-27632 (ROCK inhibitor) Sigma-Aldrich, Germany 
Zolpidem Selleckchem, Germany 
4.1.3. Commercially-available reagents and kits 
Table 3. List of the commercially-available reagents and kits used in the described 
experiments of chapter 1 and chapter 2. 
Reagent/Kit Supplier 
Annexin V/propidium iodide BD Biosciences, Germany 
Beetle juice kit PJK, Germany 
Bradford reagent Sigma-Aldrich, Germany 
Cellartis iPSC differentiation kit Takara, Germany 
Epigenase jarid demethylase 
activity/inhibition assay kit 
Epigentek, Biocat, Germany 
Epigenase LSD1 demethylase 
activity/inhibition assay kit 
Epigentek, Biocat, Germany 
EpiQuik histone demethylase (H3K4 specific) 
activity/inhibition assay kit 
Epigentek, Biocat, Germany 
Episomal OSKM (Epi5) expression kit Thermo Fisher Scientific, Germany 
EpiTect Bisulfite Kit Qiagen, Germany 
Geltrex Thermo Fisher Scientific, Germany 
Hoechst 33342 Sigma-Aldrich, Germany 
LightCycler® 480 SYBR Green I Master Roche, Germany 
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Lipofectamine® 3000 Thermo Fisher Scientific, Germany 
Matrigel Thermo Fisher Scientific, Germany 
NucleoSpin® RNA plus  
Protein A/G magnetic beads Thermo Fisher Scientific, Germany 
ProtoScript® First Strand cDNA Synthesis 
Kit 
New England Biolabs, Germany 
QIAzol lysis reagent Qiagen, Germany 
SimpleChIP Plus Enzymatic Chromatin IP Kit Cell Signaling Technology, Germany 
SRB sodium salt Santa Cruz Biotechnology, Germany 
StemDiff differentiation kit Stemcell Technologies, Germany 
Streptavidin magnetic beads Thermo Fisher Scientific, Germany 
Thiazolyl blue tetrazolium bromide dye (MTT) Sigma-Aldrich, Germany 
TransNGS® Tn5 DNA library pre-Kit for 
Illumina 
 
Western lightningTM plus-ECL Perkin Elmer, Germany 
4.1.4. Antibodies 
Table 4. List of the primary/secondary antibodies used for immunoblotting, 
immunoprecipitation, flow cytometry, immunocytochemistry, and immunohistochemistry 
experiments described in chapter 1 and chapter 2.  
Target protein Catalogue No. Supplier 
E-Cadherin #3195 
Cell Signaling Technology, 
Germany 
Erk1/2 SC-135900 
Santa Cruz Biotechnology, 
Germany 
Flag #8146 
Cell Signaling Technology, 
Germany 
Goat anti-mouse Alexa Flor 
594 
#115-585-003 Dianova, Germany 
Goat anti-rabbit Alexa Flor 488 #005-540-003 Dianova, Germany 
H3K27Me3 #9733 
Cell Signaling Technology, 
Germany 
H3K4Me3 #9751 
Cell Signaling Technology, 
Germany 
H3K9Me3 #13969 
Cell Signaling Technology, 
Germany 
HMGA1 ab4078 Abcam, Germany 
Horse reddish peroxidase 
(HRP)-linked anti-mouse IgG 
#7076 
Cell Signaling Technology, 
Germany 
HRP-linked anti-rabbit IgG #7074 
Cell Signaling Technology, 
Germany 
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ID2 SC-398104 
Santa Cruz Biotechnology, 
Germany 
KDM5A #3876 
Cell Signaling Technology, 
Germany 
KDM5B #3273 
Cell Signaling Technology, 
Germany 
KDM5C #5361 
Cell Signaling Technology, 
Germany 
KDM5D PA5‐40120 
Thermo Fisher Scientific, 
Germany 
LIN28 #3334‐1 Epitomics, Germany 
MDM2 #86934 
Cell Signaling Technology, 
Germany 
NANOG #4893 
Cell Signaling Technology, 
Germany 
OCT4 #2840 
Cell Signaling Technology, 
Germany 
p53 SC-126 
Santa Cruz Biotechnology, 
Germany 
Phospho-Erk1/2 (T202/Y204) #5683 
Cell Signaling Technology, 
Germany 
Phospho-Smad1/5/8 #9511 




(Smad2/3 antibody sampler 
kit) 
Cell Signaling Technology, 
Germany 
Phospho-Smad3 (S204) PA5-36877 
Thermo Fisher Scientific, 
Germany 
Phospho-Smad3 (S213) ab63403 Abcam, Germany 
Phospho-Smad3 (S423/425) 
#12747 














(Smad2/3 antibody sampler 
kit) 








Cell Signaling Technology, 
Germany 
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Thermo Fisher Scientific, 
Germany 
Smad4 #9515 
Cell Signaling Technology, 
Germany 
SOX2 #4900 
Cell Signaling Technology, 
Germany 
ßactin SC-47778 Santa Cruz Biotechnology 
ßcatenin #8480 
Cell Signaling Technology, 
Germany 
TRA-1-60 #4746 
Cell Signaling Technology, 
Germany 
TRA-1-81 #4745 
Cell Signaling Technology, 
Germany 
VHL ab140989 Abcam, Germany 
Vinculin SC-73614 Santa Cruz Biotechnology 
4.1.5. Primers 
Table 5. List of primer pairs used for qRT-PCR experiments of chapter 1 and chapter 2. All 
sequences were synthesized by Eurofins Genomics (Germany). Lyophilized primers were dissolved 
in nuclease-free water to a final concentration of 100 pmol/L and were further diluted (1:20) for 
qRT-PCR analysis.   
Target gene 
Primer sequence 
 (forward; 5'→3') 
Primer sequence 
 (reverse; 5'→3') 
ACTB (Actin) TGCTCCAGCAGGTCCTAAGT TGGTAGCTGAGGGCAGAACT 
AFP CTGACAGAGGCACCACTGAA ATCTCCAGAGTCCAGCACA 
BMPR1A (ALK3) ATCTAGCCACATCTTGGAGGA ACTGGACTACACACCAAGGG 
ACVR1B (ALK4) ATGCTGCGCCATGAAAACAT CCCCTTCCTCCCTTGTATTGG 
RNF111 (Arkadia) ACTTATAAAGGTCCCAGGATCAC AATTTGTGCCTCACAGTATCTGC 
c-Myc TTCGGGTAGTGGAAAACCAG CAGCAGCTCGAA TTTCTTCC 
Cbl-b CAGTGCCTGGAAGGATTTGTG AGTTAAAACTGTGCCGCCTG 




CDKN1A (p21) GACACCACTGGAGGGTGACT CAGGTCCACATGGTCTTCCT 
STUB1 (CHIP) GGCCGCGCGATCACC GAAGTGCGCCTTCACAGACT 
CCN2 (CTGF) CTATGAGTGGGACAGGAACACTGC TAAGGGAAGATCAAACGCGAACGGC 
DUSP14 CATGGCCCCTCGGATGATTT AATGCAGGTGATGCCACGA 
ESRR CCTTCCAATCAGCTGCCTTC GATCTGCCTGCCTCTCTCAT 
FGF2 AGGAGTGTGTGCTAACCGTT CAGTTCGTTTCAGTGCCACA 
FGF4 TGAGTGCACGTTCAAGGAGA GACACTCGGTTCCCCTTCTT 
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FGF5 AGTGGTATGTGGCCCTGAAT CTGCTCCGACTGCTTGAATC 
FoxA2 CTACTCCTCCGTGAGCAACA GACGACATGTTCATGGAGCC 
FOXH1 GGATATCCAGCCCCCATAGT CTTCCCTGGTCAGGTTTCAGG 
GATA4 TCCAAACCAGAAAATGGAAG CTGTGCCCGTAGTGAGATGA 
GATA6 CCACAACACAACCTACAGCC ACGCCTATGTAGAGCCCATC 
HMGA1 GAAAAGGACGGCACTGAGAA CTTCCTGGAGTTGTGGTGGT 
ID1 CATGAACGGCTGTTACTCAC GTTCCAACTTCGGATTCCGAG 
ID2 GACTGCTACTCCAAGCTCAAG GTGATGCAGGCGACAATAGTG 
ID3 CAGCTTAGCCAGGTGGAAATC GTCGTTGGAGATGACAAGTTC 
KDM5A GCTCTGCAAAGACTGGTTCC AGTCTCTAGCCTGGGCCTTC 
KDM5B TTTTGAGCTGTTGCCAGATG TGATGCAGGCAAACAAGAAG 
KLF4 CGCCGCTCCATTACCAAGA GCGAATTTCCATCCACAGCC 
LIN28A GTGGATGTCTTTGTGCACCAG GACACGGATGGATTCCAGAC 
NANOG AATACCTCAGCCTCCAGCAGATG TGCGTCACACCATTGCTATTCTTC 
NEDD4L TCTCGGGCACCCTCACC GTTCTCCCCTCTGCCTCCA 
NES (Nestin) TCCAGGAACGGAAAATCAAG GCCTCCTCATCCCCTACTTC 
NODAL GTCGACATCACTTGCCAGAC TGGTCGGATGAAACTCCTCC 







PAX6 GACTTCAGCTGAAGCGGAAG GGTAGATCTATTTTGGCTGC 
ZFP42 (REX1) TGGACACGTCTGTGCTCTTC GTCTTGGCGTCTTCTCGAAC 
Runx2 CCACATGATTCTGCCTCTCC GGAGAAAGTTTGCACCGCAC 
SALL4 ATTTGTGGGACCCTCGACAT GGTAAAAGCTCGCCCACAAA 
SKIL (SnoN) GTGCTGTTTTCCATTTTCATGCC AGCTCACACACGATACTGAAA 
Smad1 GTGCTGGTTCCAAGACACAG ATTGGGAGAGTGAGGAAACG 
Smad2 AGAAGTCAGCTGGTGGGTCT TGAGTGGTGAGGCTTTCTC 
Smad3 GGGCTTTGAGGCTGTCTACC CAGAGTCACCTGGAGTTGGG 
Smad4 TGCCATAGACAAGGTGGAG AGCCTCCCATCCAATGTTC 
Smad5 TTGTCAAGGTGAGTTGTGACC CCTGCCGGTGATATTCTGCT 
Smad7 CAGTTGAGTTGGCGTCTTCC CAAGAAGGAGGGATGTCTGGG 
Smurf1 GATACCGGATACCAGCGTTTG GGTTCCTATTCTGTCTCGTG 
Smurf2 ACAGAGGACAACGCAACAAG ATTACGGATCTCCCATCAG 
SNAI1 (SNAIL1) CCTCTACTTCAGTCTCTTCC CTTTCGAGCCTGGAGAATTCCTTG 
SNAI2 (Slug) CTCCTCTTTCCGGATACTCCTC GTAGTCTTTCCTCTGAGCCAC 
SOX17 CAGAATCCAGACCTGCACAA GCGGCCGGTACTTGTAGTT 
SOX2 AACCCCAAGATGCACAACTC GCTTAGCCTCGTCGATGAAC 
SOX7 ACCCCAACTACAAGTACCGG TACTCACCCCTGTCCTCCTT 
STAT3 GGCCATCTTGAGCACTAAGC CGGACTGGATCTGGGTCTTA 
TBXT (T) ACCCAGTTCATAGCGGTGAC GGATTGGGAGTACCCAGGTT 
TBX3 CATCGCTGTGACTGCATACC TCTCTTCGGCCATTTCCAGT 
TP53 AATCTCAGAGCTTCCCGTCA TGCCTCTGCCAGTTTTTCTT 
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TRIMM33 AGTGGCCATTTTCACCCTTATC GCCTGTGATGTCATTCTGCTG 
TUBB3 (-tubulin) CAGATGTTCGATGCCAAGAA GGGATCCACTCCACGAAGTA 
TWIST1 CAGATGTTCGATGCCAAGAA GGGATCCACTCCACGAAGTA 
USP34 GCCGAACGATGTGCGAGA GCCTCTGTGTCCAGGAATTGAT 
USP4 TGGGCTATACCAGGGTCAGG GCTAGGCGCAGTGCTTGATT 
USP9x CCAGGACCGTGATACACAAA GGCGCTTCACCAAACAAACT 
VCL (vinculin) CAGTCAGACCCTTACTCAGTG CAGCCTCATCGAAGGTAAGGA 
ZNF534 GGGGAAGCATTGTTCAGAAA TGGGATGGGGGTATTACAGA 
4.1.6.   Cell lines 
Table 6. List of cell lines used in the described experiments of chapter 1 and chapter 2. 
Cell line Supplier 
CCC5 
Generated from patient tissue by the group of Prof. 
Dr. Steven Dooley (Heidelberg University, Germany). 
CCSW1 
Generated from patient tissue by the group of Prof. 
Dr. Steven Dooley (Heidelberg University, Germany). 
DU-145 ATCC, USA 
GBC 
Generated from patient tissue by the group of Prof. 
Dr. Steven Dooley (Heidelberg University, Germany). 
HCT116 p53-/- 
Kind gift from Prof. Dr. Thomas G. Hofmann (DKFZ, 
Heidelberg, Germany), originally introduced by Bunz 
et al. [308]. 
HCT116 wt ATCC, USA 
HEK-293 ATCC, USA 
HEK-293/NCCIT reporter cell lines 
Established by the group of Prof. Dr. James Adjaye 
(Heinrich Heine University Düsseldorf, Düsseldorf, 
Germany). 
HeLa ATCC, USA 
HEP3B 
Kind gift from Prof. Dr. med. Thomas Longerich 
(Heidelberg University, Germany). 
HEPG2 ATCC, USA 
HL-60 ATCC, USA 
HT-29 ATCC, USA 
HUCCT1 
Generated from patient tissue by the group of Prof. 
Dr. Steven Dooley (Heidelberg University, Germany). 
Human foreskin fibroblasts (HFs) 
Patient-derived HFs were provided by Prof. Dr. med. 
Jochen Utikal (DKFZ, Heidelberg, Germany). 
Human pluripotent stem cells 
(hPSCs) 
Human iPSCs were provided by Prof. Andreas Kurtz 
(Charité-Universitätsmedizin Berlin, Berlin, Germany) 
Jurkat ATCC, USA 
K-562 ATCC, USA 
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LX-2 
Kind gift from Prof. Dr. Steven Dooley (Heidelberg 
University, Germany). 
MCF-7 ATCC, USA 
MMNK1 
Generated from patient tissue by the group of Prof. 
Dr. Steven Dooley (Heidelberg University, Germany). 
NCCIT ATCC, USA 
PC3 ATCC, USA 
SUPT1 ATCC, USA 
U-937 ATCC, USA 
4.1.7.   Instruments 
Table 7. List of the instruments utilized to perform the described experiments of chapter 1 
and chapter 2. 
Instrument Supplier 
AccuBlock Tm Digital Dry Bath Labnet International, Inc., USA 
Analytical balance 440-33N Kern und Sohn, Germany 
Biorevo fluorescence microscope BZ9000 Keyence, USA 
BlueFlash-L SERVA Electrophoresis, Germany 
Centrifuge 5415R Eppendorf, Germany 
Centrifuge 5702 Eppendorf, Germany 
Centrifuge 5804 Eppendorf, Germany 
EnduroTM Power Supplies Labnet International, Inc., USA 
FACS Calibur Becton Dickinson, Germany 
Guava easyCyte HT sampling flow 
cytometer 
Guava Technologies, USA 
Hemocytometer Brand, Germany 
HERA cell 150i incubator Thermo Fisher Scientific, Germany 
LAS3000 Imaging System Fujifilm, Germany 
Magnetic rack Nippon Genetics Europe GmbH, Germany 
Micropipettes (10, 20, 100, 200, 1000 μL) Eppendorf, Germany 
Microscope CKX41 Olympus Life Science, Germany 
Miltidrop Combi Thermo Fisher Scientific, Germany 
Mixer mill MM 300 Retsch, Germany 
Multichannel pipettes (100 and 200 μL) Eppendorf, Germany 
NanoDrop 2000 spectrophotometer Thermo Fisher Scientific, Germany 
Orbital shaker/Belly Dancer Stovall Life Science Inc., USA 
Pipetboy Integra Biosciences, Germany 
Power Station 200 Labnet International, Inc., USA 
Problot hybridization oven Labnet International, Inc., USA 
Real-time thermal cycler qTower Analytik Jena AG, Germany 
Roller mixer SRT6 Stuart, Germany 
Spectrafuge Mini Labnet International, Inc., USA 
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Tecan Infinite F200 Pro Tecan, Germany 
Tecan Ultra plate reader Tecan, Germany 
Thermomixer comfort Eppendorf, Germany 
Vacuum pump ZM Engineering, Germany 
VIAFLO ASSIST automated multi-channel 
pipettes 
Integra Biosciences, Germany 
Vortex-Genie®2 Scientific Industries, Inc., USA 
Water bath GFL, Germany 
4.1.8.   Buffers and solutions 
Table 8. List of buffers/solutions and the corresponding recipes used in the described 
experiments of chapter 1 and chapter 2. If not listed in the presented table, the recipe has been 
indicated in the respective method section (also see section 4.2.).  
Buffer/solution Component Concentration 
3x Gel loading buffer 











5x Gel loading buffer 
Tris HCl (pH = 6.8, 25°C) 
SDS 
Glycerol 
Bromophenol blue  
ß-mercaptoethanol 






Annexin v binding buffer 
HEPES (pH = 7.4) 
NaCl 
CaCl2 






















(in distilled water) 
10% (w/v) 
25 mM 









(Filtered through 0.45 M 
sterile filter) 


















Stacking gel for Tris- 
glycine SDS- 
polyacrylamide gel (5%) 
30% Acrylamide mix  
1.0 M Tris (pH = 6.8)  
10% SDS 
10% Ammonium persulfate  
TEMED  











Tween 20  







Polyacrylamide gel (10%) 
30% Acrylamide mix 
1.5 M Tris (pH = 8.8) 
10% SDS 










Table 9. List of siRNA oligonucleotide sequences used for transient knockdown experiments 
of chapter 1 and chapter 2. All small interfering RNA sequences were purchased from Thermo 
Fisher Scientific (Germany), unless otherwise stated in the text (for more details regarding the 
oligo IDs, suppliers, as well as the transfection protocol refer to section 4.2.3.).   
Target gene Sense sequence (5'→3') Antisense sequence (5'→3') 
HMGA1 AAUGUUCAUCCUCAUUGCCTT GGCAAUGAGGAUGAACAUUTG 
ID1 GGUAAACGUGCUGCUCUACTT GUAGAGCAGCACGUUUACCTG 
KDM5A GGUCACCCGAAGACGAAAATT UUUUCGUCUUCGGGUGACCTC 
KDM5B GGGCAUUAUGAACGAAUUCTT GAAUUCGUUCAUAAUGCCCTC 
KDM5C GGUGGUUAUGAAGCUAUCUTT AGAUAGCUUCAUAACCACCTT 
KDM5D GGUGGGAACGUGUCAUCAATT UUGAUGACACGUUCCCACCTC 
MDM2 GCCAUUGCUUUUGAAGUUATT UAACUUCAAAAGCAAUGGCTT 
PSMA3 GCUAUUGGAAUCAGAUGCATT UGCAUCUGAUUCCAAUAGCTG 
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PSMA6 GGUCUACACACAGAAUGCUTT AGCAUUCUGUGUGUAGACCTG 
PSMD4 GGAUGCUGUCAACAUAGUUTT AACUAUGUUGACAGCAUCCTG 
RBBP6 GCGAUGGCAACUACAAAAGTT CUUUUGUAGUUGCCAUCGCTG 
VHL GGAGCGCAUUGCACAUCAATT UUGAUGUGCAAUGCGCUCCTG 
4.1.10. Computer software 
Table 10. List of the computer software used in preforming the described experiments of 
chapter 1 and chapter 2 and analyzing the associated data. 
Software Supplier 
CellQuest Pro analysis software Becton Dickinson, Germany 
GraphPad PRISM GraphPad Software Inc., USA 
Image Reader LAS-3000 Fujifilm, Germany 
ImageJ National Institutes of Health, USA 
Microsoft Excel Microsoft, USA 
NanoDrop 2000 software Thermo Fisher Scientific, Germany 
Inkscape https://inkscape.org 
Adobe Illustrator Adobe Inc., USA 
Photoshop Adobe Inc., USA 
GuavaSoft 3.1.1 software Guava Technologies, USA 
R 3.3.2 computing environment R Core Team, Austria 
qPCRsoft 3.1 Analytik Jena, Germany 
4.2. Methods 
4.2.1. Cell culture  
Cell lines listed in Table 6 were cultured in DMEM GlutaMAXTM supplemented with 10% (v/v) 
FCS and 1% (v/v) penicillin/streptomycin, with the exception of hPSCs and suspension cell lines, 
HL-60, U-937, K-562, and SUPT1. The latter were maintained in RPMI GlutaMAXTM containing 10% 
(v/v) and 1% (v/v) FCS and penicillin/streptomycin, respectively. The former as well as the induced 
pluripotent stem cells were cultivated in Essential® 8 medium or in DMEM-F12 Knockout medium 
with 20% knockout serum and 10 ng/mL bFGF in cell culture plates coated with Geltrex or Matrigel. 
All cells were kept in a standard cell culture incubator at 37°C under 5% CO2 in a humidified 
atmosphere. Cells were passaged at 70-80% confluency. Adherent cell lines were sub-cultured by 
aspirating the old medium, washing once with D-PBS, then incubating with TrypLETM Express for 3-
8 mins depending on the cell line. For example, human primary cholangiocarcinoma cells (CCC5, 
CCSW1, HUCCT1, GBC, and MMNK1) require longer incubation periods (~8 mins) with TrypLETM 
Express. Detached cells were then collected in standard DMEM and were centrifuged for 3 mins at 
200-300 g. Medium on top of the cellular pellet was aspirated, and the cellular pellet was 
resuspended in fresh media. Medium containing a known cell number, depending on the culture 
flask used as well as the growth rate of each cell line, was then transferred back to the flask 
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containing fresh medium. Suspension cells were sub-cultured by collecting them from the flask and 
transferring them to a 15 mL falcon tube, after which the same protocol described above for the 
adherent cells was used. With regards to hPSCs, a similar protocol as the adherent cells was 
applied, however Accutase® was replaced with TrypLETM Express for detaching the cells and D-
PBS (instead of fresh medium) was used to harvest the detached cells. Additionally, the small 
molecule ROCK inhibitor was used in the first 24 h after passaging in order to support hPSC 
proliferation and viability [276]. After seeding at the desired density in designated culture plates, 
cells were maintained in the incubator overnight prior to treatments. All treatments were carried out 
in standard media with 10% FCS and 1% antibiotics or Essential® 8 medium supplemented with 10 
ng/mL bFGF (in case of hPSCs), with the exception of TGF1 treatment, which was performed in 
the presence of 1% FCS. The concentrations of cytokines, small molecules, and drugs as well as 
the duration of treatments are indicated in the corresponding results' section.            
4.2.2. Cell viability assays 
MTT- and SRB cytotoxicity assays were employed to assess the impact of various treatments on 
cellular proliferation. Cells were seeded in 96-well- 24-well- or 12-well plates at a density of 10,000- 
50,000 or 150,000, in 150 L- 500 L- and 1 mL medium/well, respectively. On the following day, 
cells were treated as indicated in the respective results' section. For SRB assay, cells were fixed at 
the end of the treatment periods using 10% ice-cold trichloroacetic acid, followed by incubation at 4 
°C for at least one hour. Plates were then washed three times and were dried using a hybridization 
oven set at 60°C for 30 mins. SRB solution (0.054 % (w/v) SRB in 1 % (v/v) acetic acid in water) 
was then added to the wells and incubated for 30 mins in dark at room temperature. Plates were 
then washed three times with 1 % acetic acid and were dried at 60 °C for 30 mins. Finally, the SRB 
dye was solubilized using 10 mM Tris buffer (pH = 10.5) and measurements were performed at 535 
nm absorbance wavelength using the Tecan Ultra plate reader. For MTT assay, treatment medium 
was replaced with DMEM (1% FCS), containing 0.5 mg/mL of the MTT dye, followed by 1-2 h 
incubation at 37°C. Intracellular formazan pellets were then dissolved in DMSO, and absorbance 
was measured at 595 nm wavelength using the Tecan Ultra plate reader.   
4.2.3. Transient transfection studies: ectopic gene expression and RNA interference 
Small interfering RNA oligos against KDM5A (oligo ID: 107607), KDM5B, (oligo ID: 108065), 
KDM5C (oligo ID: 14315), KDM5D (oligo ID: 107493),  HMGA1 (oligo ID: 217139), ID1 (oligo ID: 
11072), PSMA3 (oligo ID: 105604), PSMA6 (oligo ID: 105047), PSMD4 (oligo ID: 12139), RBBP6 
(oligo ID: 143012), VHL (oligo ID: 138745), MDM2 (oligo ID: 122296) as well as the non-targeting 
siRNA were obtained from Thermo Fisher Scientific (Darmstadt, Germany). For more information 
regarding the siRNA sequences refer to Table 9. Anti-Smad4 oligos were synthesized using 
previously published sequences [65] and riboxx siRNA-design (Riboxx, Radebeul, Germany). To 
knockdown the aforementioned genes, 40 pmol of the respective siRNA were diluted in 100 μL/well 
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Opti-MEM reduced serum medium in a 24-well plate. 1.5 μL/well Lipofectamine® 3000 were added, 
and the plate was left to incubate at room temperature for 10-20 mins (not more than 30 mins). 
60,000 cells suspended in DMEM containing 10% FCS and no antibiotics were then added to each 
well and cells were maintained in the incubator overnight. Medium was changed to fresh DMEM 
(containing 10% FCS and 1% PS) on the following day and small molecule treatments were 
performed at 48 h post-transfection, otherwise cells were used directly for the described 
experiments. For transient over-expression experiments, the following constructs were used; Smad2 
(Addgene plasmid #14042), Smad2 N (#14929), Smad2 C (#12624), Smad2 EPSM (#14933), 
Smad3 (#14052), Smad3 SSV (#12639) Smad3 N (#14827), Smad3 C (#14830), Smad3 LC 
(#14829), Smad3 EPSM (#14963), KDM5A (#14799), ID1 (#16061), and ID2 (#98394). HMGA1 was 
a kind gift from the group of Prof. Robert Hock (University of Würzburg, Germany) [309]. DNA-lipid 
complexes were prepared in 200/100 μL/well Opti-MEM reduced serum in a 6-well/24-well plate 
using 2.5/0.5 g/well plasmid DNA and 5/1.5 L/well of the transfection reagents, Lipofectamine® 
3000 and P3000. Similar to siRNA-mediated knockdown, the mixture was left at room temperature 
for 10-20 mins (not more than 30 mins), after which cell suspension was added at a density of 
800,000 cells/well (in case of 6-well plates) and 60,000 cells/well (in case of 24-well plates). 24 h 
later, medium was refreshed and at 48 h post-transfection, cells were either treated with small 
molecules or used directly for the respective experiments. In all plasmid transfections, the 
corresponding empty vector served as the negative control.  
4.2.4. RNA extraction, reverse transcription, and qRT-PCR 
As previously reported [310], after the described treatments, cells were harvested from 6-well 
plates in Eppendorf tubes using the QIAzol lysis reagent (150 L for 5 mins at room temperature), 
followed by the addition of 30 L chloroform, mixing for 15 secs, and placing on ice for 15 mins. 
Cells were then centrifuged at 13,000 g for 15 mins at a temperature of 4°C. The aqueous phase on 
top was then transferred to fresh tubes and RNA was precipitated by adding 75 L isopropanol per 
tube and incubation for 10 mins at room temperature, followed by centrifugation under the same 
conditions. The RNA pellet was then washed twice with 70% (v/v) ethanol in water. After 
centrifugation (7500 g for 5 mins; at 4°C), RNA pellets were left to dry at room temperature, and 
were dissolved in 20-50 L of RNAase-free water. Alternatively, total RNA was extracted using 
NulceoSpin®RNA Plus, according to the manufacturer's instruction. The quality of the resulting RNA 
samples was then determined by NanoDrop 2000 UV-Vis spectrophotometer.   
cDNA synthesis was performed by reverse transcription of 500-1000 ng of total RNA using 
ProtoScript II first strand cDNA synthesis kit. The mRNA expression of the genes listed in Table 5 
was determined using real-time thermal cycler q-Tower. The amplification reaction solutions (5 μL) 
were prepared with 2.5× of ready to use master mix LightCycler® 480 SYBR Green I, 1× of nuclease-
free H2O and cDNA templates, as well as 1× of primer mixtures listed in Table 5. The thermal cycler 
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conditions used are as follows; an initial denaturation step at 95°C for 5 mins, 45 cycles of 
denaturation (95°C, 10 secs/cycle), annealing at 60°C for 10 secs, and a final elongation step at 
72°C for 20 secs. Melting curve analysis was performed after each cycle in order to exclude wells 
with false positive results. 
4.2.5. Immunoblotting 
As we have thoroughly described [311], cells were lysed at the end of the respective treatments 
by 40-100 L (depending on the cell number and desired protein concentration) of a urea-based 
lysis buffer (6M urea, 1 mM EDTA, 5 mM NaF, and 0.5% Triton X-100) supplemented with the 
following protease- and phosphatase inhibitors; 10 μg/mL pepstatin, 0.1 mM PMSF, 10 μg/mL 
aprotinin, 1 mM sodium orthovanadate, and 2.5 mM sodium pyrophosphate. Eppendorf tubes 
containing cellular lysates were then placed on ice for 10-20 mins, followed by centrifugation at 4°C 
for 20-30 mins at maximum speed. The supernatant was then transferred to fresh tubes and protein 
concentration was determined with Bradford reagent. Sample preparation was performed by mixing 
5x gel loading buffer (see Table 8) with volumes of cell lysates corresponding to equal amounts of 
protein (~20-50 μg of total protein depending on the investigated target protein), which were 
normalized by diluting with 6M urea buffer. Samples were then denatured at 95°C for 5 mins, and 
were loaded equally on SDS-PAGE gels, followed by gel electrophoresis (~80-100 V for ~2 h). 
Protein transfer was carried out using the semi-dry blotting and the sequential placing of the 
following layers on the anode plate of the transfer machine; 3 layers of filter papers soaked in anode 
buffer (see Table 8), then the methanol-activated PVDF membrane soaked in anode buffer, the 
SDS-PAGE gel soaked in cathode buffer (see Table 8), and finally 3 layers of cathode-soaked filter 
papers. The trapped air bubbles were carefully removed upon the addition of each layer for efficient 
transferring and an electrical current of 2.5 mA/cm2 was applied for 30-40 mins. The membrane was 
then washed once with 1x Tris-buffered saline (TBS)/Tween (see Table 8) for 5 mins on an orbital 
shaker, followed by incubation with the Ponceau S solution for 5 mins and moderate washing with 
TBS/Tween, thereafter transfer efficiency was documented by imaging. After thorough washing with 
TBS/Tween for the removal of Ponceau S, membrane was blocked with 5% (w/v) non-fat dry milk in 
TBS/Tween for at least 2 h at room temperature or overnight at 4°C. Membrane was then washed 
shortly with TBS/Tween prior to overnight incubation at 4°C with the desired primary antibody 
solution prepared with 5% (w/v) BSA (or milk) in TBS/Tween at dilutions recommended by the 
supplier (also see Table 4). After washing once for 5 mins with TBS/Tween, membrane was 
incubated for 1 h at room temperature with the corresponding anti-rabbit or -mouse HRP-conjugated 
secondary antibody dissolved in 5% (w/v) milk in TBS/Tween. The membrane was then washed at 
least three time (each time for 5 mins) with TBS/Tween, and the target protein was finally visualized 
using the HRP-substrate, Western Lightning Plus-EClTM (Perkin Elmer) and imaged by the LAS3000 
imaging system.  
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4.2.6. Immunoprecipitation: streptavidin-biotin pull-down assays     
HCT116 cells were seeded in 10 cm-culture dishes until they reach 70-80% confluency. For in 
vitro pull-down assay, cells were harvested with 500 μL of a lysis buffer containing 20 mM Tris HCl 
(pH = 8), 150 mM NaCl, 1% Nonidet P-40 (NP-40), and 2 mM EDTA and supplemented with the 
aforementioned protease- and phosphatase inhibitors (see section 4.2.5.). Upon the addition of ice-
cold lysis buffer, petri dishes were left on ice for 30 mins, after which cells were scraped off the dish 
using a plastic cell scraper. Cell lysates were then transferred to pre-cold Eppendorf tubes, and were 
centrifuged at 4°C for 30 mins at maximum speed. The supernatant was then transferred to fresh 
tubes and was pre-washed by a 20 min-incubation with 0.25 mg of streptavidin magnetic beads at 
room temperature, followed by separation on a magnetic rack. Pre-cleaned lysates were then 
incubated with 100 M of biotin for 30 mins at 4°C with rotation. Streptavidin beads were then added 
to the samples at a dilution of 1:10 for 30 mins at 4°C with gentle agitation and were separated from 
the supernatant using a magnetic rack. The supernatant was subsequently transferred to fresh tubes 
and was incubated with biotin (as the negative control) and the biotin-conjugated small molecule 
(herein E738 B) at a final concentration of 100 M at 4°C overnight. This was followed by the addition 
of the streptavidin beads (at 1:10 dilution) and incubation with rotation at 4°C for 1-3 h, then 
separation on a magnetic rack. The supernatant was then discarded and the pellets (beads) were 
washed at least three times with 500 μL of the aforementioned lysis buffer containing 
protease/phosphatase inhibitors. To elute the protein from the beads, we mixed the beads with 150 
L 3x SDS gel loading buffer (see Table 8) and heated the mixture for 3-5 mins at 96°C. The beads 
were then precipitated using a magnetic rack and the supernatant was transferred to fresh tubes 
and was run on SDS-PAGE. Samples were analyzed in collaboration with Dr. Thomas Ruppert at 
the ZMBH core facility for mass spectrometry and proteomics (Heidelberg, Germany) using the in-
gel digestion by trypsin method, followed by MALDI TOF MS analysis. The pull-down assays in cells 
were carried out using a similar protocol, with the only difference of incubating HCT116 cells with 
biotinylated small molecule (E738 B, 10 M for 24 h), biotin (10 M for 24 h) or 0.1% DMSO; the 
last two were included as the negative controls of the experiment. Briefly, treated cells were then 
used for immunoprecipitation by adding the beads (at 1:10 dilution for 30 mins at 4°C), followed by 
separation on a magnetic rack, three times washing with the lysis buffer, and elution as described 
earlier.  
4.2.7. Luciferase reporter assay 
NCCIT-OCT4 and -NANOG, as well as HEK-OCT4 reporter cells were seeded in 24-well plates 
at a density of 100,000 cells/well. On the following day, cells were treated with the indicated small 
molecules, and at the end of the respective treatment, luciferase assay was performed using the 
Beetle juice kit according to the manufacturer's protocol. Briefly, cells were harvested by adding 80 
L/well of the luciferase lysis buffer (see Table 8). After incubation with the lysis buffer at 37°C for 
15-30 mins, cells were shortly kept on ice and the contents were transferred to Eppendorf tubes, 
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thereafter centrifuged for 10 mins at 4°C at maximum speed to separate cell debris. 20 L of the 
supernatant was then loaded onto a white 96-well plate with transparent bottom and the plate was 
centrifuged at 2000 rpm for 1 min. Immediately after this, 100 L of the Beetle juice reaction mixture 
containing luciferin and ATP were added to each well pre-loaded with samples. The plate was then 
incubated in dark for 5 mins at room temperature, followed by luminescence measurement using 
the Tecan Ultra plate reader. In addition to this, protein concentration was measured using the 
Bradford reagent. Luciferase values were normalized to those of the respective Bradford values, 
and finally to the respective mock treatment, resulting in the fold change of luciferase activity. 
Bradford ratios below 0.1 (compared to blank) were considered as toxic conditions, and hence were 
excluded from further analysis.  
4.2.8. Immunocytochemistry  
Human fibroblasts and PSCs were seeded in 96-well plates at a density of 10,000 cells/well. At 
the end of the respective treatment, cells were fixed using 50 L/well of 4% PFA in D-PBS for 10-
15 mins (not more than 20 mins) at room temperature, after which washed at least two time (each 
time for 5 mins) with 200 L/well D-PBS. Fixed permeable cells were then incubated for 30 mins 
with 50 L/well of the blocking buffer (see Table 8) with rotation at room temperature, followed by 
overnight incubation with rotation at 4°C with 20-30 L/well of the desired primary antibody solution 
(also see Table 4) prepared in the blocking buffer at dilutions recommended by the manufacturer. 
The primary antibodies were then replaced with a 100 L/well mixture, containing the matching 
Alexa Flor 488 goat anti-rabbit or Alexa Flor 594 anti-mouse secondary antibodies, as well as 1 
g/mL of the Hoechst dye in order to visualize nuclei. After 1 h of incubation with rotation in dark at 
room temperature, cells were sufficiently washed with D-PBS (at least three time for 5 mins), and 
fluorescence signals were detected using the BIOREVO fluorescence microscope.  
 4.2.9. Flow cytometric analysis of cell death: annexin V and propidium iodide staining                            
As previously described [312], 200,000 cells/well were seeded in 12-well plates and kept in the 
incubator overnight. On the following day, cells were treated for the indicated durations, after which 
250,000 cells/well were harvested by trypsinization (using TrypLETM Express) in Eppendorf tubes. 
Cells were then washed once with 0.5-1 mL of the annexin V binding buffer (see Table 8), 
centrifuged at 200 g for 3 mins, thereafter the pellets were incubated with 50 L/sample of the 
binding buffer containing 5 L of both FITC-conjugated annexin V and propidium iodide. After 10-
15 mins incubation with rotation in dark at room temperature, each sample was resuspended in 
binding buffer or phenol red-free DMEM up to a final volume of 200-500 L. This was followed by 
loading the samples on round-bottom 96-well plates for FACS analysis, which was performed by the 
Guava easyCyte HT sampling flow cytometer. Data were analyzed using the GuavaSoft 3.1.1 
software.  
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4.2.10. Flow cytometric analysis of pluripotency-associated markers 
For analyzing the expression of pluripotency-related markers by FACS, NCCIT reporter cells or 
iPSCs were seeded in 6-well plates (in case of iPSCs coated with Geltrex) at a density of 300,000-
500,000 cells/well and were left in the incubator overnight. On the following day, they were treated 
for the indicated periods, otherwise harvested directly. A similar protocol to that of 
immunocytochemistry was used to fix and permeabilize the cells, followed by incubation with 
primary- and secondary antibody solutions (for more details refer to section 4.2.8.). Fluorescence 
signals were then measured by FACSCalibur and data were analyzed using the software, CellQuest 
Pro. 
4.2.11. Analysis of reprogramming efficiency: TRA-1-60+/AP+ colony counting 
To determine the number of TRA-1-60- and AP-positive colonies (as a measure of 
reprogramming efficiency), iPSCs generated by means of episomal OSKM transfection in the 
absence or presence of OCT4-inducing small molecules and/or forced expression of KDM5A, 
HMGA1, and ID1/2, we performed immunostaining using the respective antibodies in living cells 
after 32 days (for a detailed protocol on immunocytochemistry refer to section 4.2.8.). 
Transfection efficiency was determined by quantifying the fluorescence signal resulting from the 
simultaneous over-expression of the pCXLE-EGFP (Addgene plasmid #27082).     
4.2.12. iPSCs differentiation into the three germ layers 
Mono-layer iPSCs seeded in Geltrex-coated 24-well plates and at a confluency of 60-80% were 
used for differentiation using the following kits, according to the manufacturer's instructions (also 
see Table 3); (i) Cellartis iPSC to hepatocyte differentiation system was utilized to differentiate 
iPSCs to endoderm, and (ii) StemDiff neuron differentiation kit was used for differentiation into the 
ectoderm germ layer. For mesoderm generation, iPSCs were seeded in Geltrex-coated plates as 
single cells till they reach 80% confluency, after which Essential® 8 medium was replaced with 
N2B27 containing freshly-added 100 ng/mL of Activin, 20 ng/mL of bFGF, 10 ng/mL of BMP4, 10 
µM of LY294002 and 5 µM of CHIR99021. The medium was refreshed every 2-3 days until 14 days.    
4.2.13. Chromatin-immunoprecipitation assay 
SimpleChIP Plus Enzymatic Chromatin IP Kit (see Table 3) was used for DNA isolation 
precipitated with H3K4M3 and H3K27Me3 antibodies, according to the manufacturer's protocol. 
Non-targeting rabbit IgG served as the negative control and total histone H3 antibodies (provided 
by the manufacturer) were used as reference. Recruited DNA was then subjected to qRT-PCR using 
ChIP primer sets, and human RPL30 exon 3 primer pairs were used as positive control.    
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4.2.14. In vitro measurements of H3K4 methylation and demethylase activity of the histone 
demethylases, KDM4, KDM5s, and LSD1 
For the in vitro measurement of H3K4 methylation status in response to O4I3 and zolpidem, the 
Epiquik histone demethylase (H3K4 specific) activity/inhibition assay kit (see Table 3) was used, 
according to the manufacturer's instructions. The in vitro inhibitory activity of the small molecules on 
KDM5s, KDM4 (also known as JMJD2), and LSD1 was determined using the following kits, 
respectively; (i) Epigenase JARID demethylase activity/inhibition assay kit, (ii) Epigenase JMJD2 
demethylase activity/inhibition assay kit, and (iii) EpiQuik histone demethylase LSD1 
activity/inhibition assay kit (see Table 3 for detailed information of the suppliers).     
4.2.15. Bisulfate sequencing 
The bisulfite conversion of DNA was performed using the EpiTect Bisulfite Kit (see Table 3), 
according to the manufacturer's instructions. 5 µL of bisulfite-treated genomic DNA was used to 
amplify the OCT4 promoter region in human iPSCs and the parental fibroblasts. PCR products were 
cloned into pGEM-T vectors (Promega) and sequenced using the M13 forward primer. Primers used 
to amplify the OCT4 promoter region have been previously described [313] (also see Table 5 for 
the forward- and reverse primer sequences).   
4.2.16. ATAC-sequencing 
After lysing cells with a lysis buffer containing 10 mM Tris HCL (pH = 7.4), 10 mM NaCl, 3 mM 
MgCl2, and 0.1% IGEPAL-CA630, DNA library was prepared by the TransNGS® Tn5 DNA library 
pre-Kit for Illumina, according to the manufacturer’s instructions.  
4.2.17. Gene expression profiling and associated data analyses 
Gene expression profiling was conducted on the Illumina Human Sentrix-12v4 BeadChip array 
by the genomics and proteomics core facility at the German cancer research center (DKFZ). Gene 
expression analyses were performed in collaboration with the group of Prof. Miguel A. Andrade-
Navarro (University of Mainz, Germany), using R.3.3.2. computing environment and packages from 
the open-source software development project Bioconductor 3.4. [314]. In addition, we used the 
standalone tool STEM 1.3.11 for clustering of gene profiles and functional enrichment analysis. 
Quality assessment and preprocessing of raw data were done with the package beadarray 2.24.2. 
[315]. Preprocessing involved default image processing (with median-based local background), 
default Illumina removal for outlying observations, mean summarization of bead-level observations 
into probe-level data, quantile normalization of probe-level data and log2 transformation. The 
resulting probes were matched to genes using annotations from the package illuminaHumanv4.db 
1.26.0. We filtered probes, that poorly matched the annotated genes (quality status of ‘no-match’ 
and ‘bad’) as well as low-expression probes (detection score > 0.05) across all samples. 
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Dose experiment data analysis; 14108 probes were available for clustering analysis with STEM, 
a tool for clustering short-time series data, that can differentiate between real- and random temporal 
expression patterns. For this purpose, we selected one probe per gene (the one with highest 
variance, if multiple probes matched to single gene) and converted the data into fold changes with 
respect to the not-treated cells. We analyzed the data as short-time series of length three 
(corresponding to dose levels) by treating the dose level as a time factor. We applied STEM in 
default mode, except for the following settings; at least one measurement with absolute fold change 
of 0.65; significance of model profiles corrected by false discovery rate (FDR) method; cellular 
component terms, terms with evidence code IEA and NAS or terms that had less than 10 genes in 
common with the identified model profiles (or clusters of similar model profiles) were excluded from 
the Gene Ontology (GO) enrichment analysis [316]; multiple testing correction of GO term significant 
values was determined by the randomization test, with 5000 randomly sampled gene sets per term. 
Expression profiles of selected gene sets (related to significantly enriched GO terms) were 
visualized by heatmaps with the packages heatmap 1.0.8. 
Fibroblast/iPSC experiment data analysis; approximately 18,000 probes, after filtering, were 
available for differential expression analysis. The latter was based on fold changes i.e., the probes 
with at least two-fold expression relative to the untreated fibroblast were selected as differentially 
expressed; since single biological replicates per treatment were used, statistical tests were not 
applicable. Global gene expression comparison between pairs of samples was visualized by scatter 
plots, plotted with the package ggplot2 2.2.1, while the heatmaps of gene expressions were 
visualized with the package ComplexHeatmap 1.12.0. In addition, columns and rows in the 
heatmaps were reordered with hierarchical clustering based on average linkage and Euclidean 
distance or Pearson correlation. Functional enrichment analysis on differentially expressed probes 
was performed with gProfileR version r1732_e89_eg36 via the R interface in the package gProfileR 
version 0.6.1. More specifically, the query lists were treated as unordered human gene lists, and the 
set of probes retained after filtering was supplied as a background. Multiple testing correction was 
done by the FDR method according to Benjamini and Hochberg et al. [317] with 0.05 FDR cut-off, 
including biological processes and molecular functions from the Gene Ontology database, KEGG 
and REACTOME pathway databases with a size of 5 up to 500 genes (all database references 
could be found in [318].).   
4.2.18. Statistics 
statistical analyses were performed using Microsoft Excel, GraphPad Prism, and the R software. 
Densitometric quantifications were done by the ImageJ software. Statistical significance was 
calculated using a two-tailed student's t-test, as indicated in the respective figure legend. Multiple 
comparisons were employed either by one-way- or two-way ANOVA, followed by a post-hoc Tukey 
test, as determined in figure legends. p-values less than or equal to 0.05, 0.01, 0.001, and 0.0001 
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are denoted as *, **, ***, and **** on the figures, respectively. Error bars represent either the SD or 
SEM, as indicated in the corresponding figure legends.   
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